WO2007113385A1 - Diagnostic and therapeutic agents - Google Patents
Diagnostic and therapeutic agents Download PDFInfo
- Publication number
- WO2007113385A1 WO2007113385A1 PCT/FI2007/050176 FI2007050176W WO2007113385A1 WO 2007113385 A1 WO2007113385 A1 WO 2007113385A1 FI 2007050176 W FI2007050176 W FI 2007050176W WO 2007113385 A1 WO2007113385 A1 WO 2007113385A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amino
- acid
- targeting
- seq
- units
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940124597 therapeutic agent Drugs 0.000 title description 3
- 239000000032 diagnostic agent Substances 0.000 title description 2
- 229940039227 diagnostic agent Drugs 0.000 title description 2
- 230000008685 targeting Effects 0.000 claims abstract description 279
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 179
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 148
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 119
- 239000012636 effector Substances 0.000 claims abstract description 69
- 201000011510 cancer Diseases 0.000 claims abstract description 52
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 37
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 206010027476 Metastases Diseases 0.000 claims abstract description 33
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 201000010099 disease Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 15
- 210000001072 colon Anatomy 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims description 64
- 238000000034 method Methods 0.000 claims description 50
- 230000027455 binding Effects 0.000 claims description 38
- 238000009739 binding Methods 0.000 claims description 38
- 125000004122 cyclic group Chemical group 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 30
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 125000006850 spacer group Chemical group 0.000 claims description 20
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 18
- 235000013922 glutamic acid Nutrition 0.000 claims description 18
- 239000004220 glutamic acid Substances 0.000 claims description 18
- 241000282414 Homo sapiens Species 0.000 claims description 17
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 17
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 16
- 235000002374 tyrosine Nutrition 0.000 claims description 16
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 13
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 12
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Chemical group CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Chemical group CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004472 Lysine Substances 0.000 claims description 11
- 206010027458 Metastases to lung Diseases 0.000 claims description 11
- 230000002708 enhancing effect Effects 0.000 claims description 11
- 235000014705 isoleucine Nutrition 0.000 claims description 11
- 229960000310 isoleucine Drugs 0.000 claims description 11
- 235000005772 leucine Nutrition 0.000 claims description 11
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 10
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 10
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 10
- 229960003104 ornithine Drugs 0.000 claims description 10
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical group CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 238000002560 therapeutic procedure Methods 0.000 claims description 9
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical group C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 8
- 239000004474 valine Chemical group 0.000 claims description 8
- 235000014393 valine Nutrition 0.000 claims description 8
- 150000008574 D-amino acids Chemical group 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 230000001472 cytotoxic effect Effects 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 150000003951 lactams Chemical class 0.000 claims description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 230000005298 paramagnetic effect Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 239000002738 chelating agent Substances 0.000 claims description 4
- 230000001085 cytostatic effect Effects 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 4
- 239000000824 cytostatic agent Substances 0.000 claims description 3
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 3
- 239000007801 affinity label Substances 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims description 2
- 239000012857 radioactive material Substances 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 90
- 229940024606 amino acid Drugs 0.000 description 65
- 102000004196 processed proteins & peptides Human genes 0.000 description 55
- 235000001014 amino acid Nutrition 0.000 description 54
- 150000001413 amino acids Chemical class 0.000 description 50
- 230000015572 biosynthetic process Effects 0.000 description 49
- 238000003786 synthesis reaction Methods 0.000 description 44
- 150000001875 compounds Chemical class 0.000 description 43
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- 239000011347 resin Substances 0.000 description 34
- 229920005989 resin Polymers 0.000 description 34
- -1 amino, hydrazino, carboxyl Chemical group 0.000 description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 31
- 239000000047 product Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 26
- 210000001519 tissue Anatomy 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 23
- 125000003118 aryl group Chemical group 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 229960000250 adipic acid Drugs 0.000 description 20
- 150000002500 ions Chemical class 0.000 description 20
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 20
- 230000006870 function Effects 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 19
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 18
- 229910052693 Europium Inorganic materials 0.000 description 18
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 18
- 125000003277 amino group Chemical group 0.000 description 17
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 16
- 239000002253 acid Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 15
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 230000003278 mimic effect Effects 0.000 description 12
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 230000000155 isotopic effect Effects 0.000 description 11
- 239000003607 modifier Substances 0.000 description 11
- 229910052757 nitrogen Inorganic materials 0.000 description 11
- 230000003287 optical effect Effects 0.000 description 11
- 239000000816 peptidomimetic Substances 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 10
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- 238000005755 formation reaction Methods 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 10
- 238000001254 matrix assisted laser desorption--ionisation time-of-flight mass spectrum Methods 0.000 description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 description 10
- 238000004007 reversed phase HPLC Methods 0.000 description 10
- 239000007790 solid phase Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 235000013350 formula milk Nutrition 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 230000004224 protection Effects 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N Histidine Chemical compound OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 8
- 239000013522 chelant Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000004091 panning Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methyl-2-butanol Substances CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 7
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 7
- 239000005695 Ammonium acetate Substances 0.000 description 7
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 229940043376 ammonium acetate Drugs 0.000 description 7
- 235000019257 ammonium acetate Nutrition 0.000 description 7
- 230000003321 amplification Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000003199 nucleic acid amplification method Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 7
- 125000003396 thiol group Chemical group [H]S* 0.000 description 7
- 229960004799 tryptophan Drugs 0.000 description 7
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 125000002619 bicyclic group Chemical group 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002744 extracellular matrix Anatomy 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 229960002949 fluorouracil Drugs 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000001072 heteroaryl group Chemical group 0.000 description 6
- 235000014304 histidine Nutrition 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 238000010647 peptide synthesis reaction Methods 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 150000003668 tyrosines Chemical class 0.000 description 6
- CSFFOBGGUBKCFN-UHFFFAOYSA-N 2,4-diamino-2-methylbutanoic acid Chemical compound OC(=O)C(N)(C)CCN CSFFOBGGUBKCFN-UHFFFAOYSA-N 0.000 description 5
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
- 229910052796 boron Inorganic materials 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 210000002889 endothelial cell Anatomy 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 229940042795 hydrazides for tuberculosis treatment Drugs 0.000 description 5
- 230000003301 hydrolyzing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 description 4
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- DQLDJYFGVBVMIU-UHFFFAOYSA-N 2,7-diamino-2-methylheptanoic acid Chemical compound OC(=O)C(N)(C)CCCCCN DQLDJYFGVBVMIU-UHFFFAOYSA-N 0.000 description 4
- ZSOMLUKLVIXWFO-UHFFFAOYSA-N 2,8-diamino-2-methyloctanoic acid Chemical compound OC(=O)C(N)(C)CCCCCCN ZSOMLUKLVIXWFO-UHFFFAOYSA-N 0.000 description 4
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
- KPKVOFCBXIWXHF-UHFFFAOYSA-N 2-amino-3-phenylhexanoic acid Chemical compound CCCC(C(N)C(O)=O)C1=CC=CC=C1 KPKVOFCBXIWXHF-UHFFFAOYSA-N 0.000 description 4
- FOOIMJUGVGZOLD-UHFFFAOYSA-N 2-amino-4-phenylhexanoic acid Chemical compound OC(=O)C(N)CC(CC)C1=CC=CC=C1 FOOIMJUGVGZOLD-UHFFFAOYSA-N 0.000 description 4
- IRZQDMYEJPNDEN-UHFFFAOYSA-N 2-azaniumyl-3-phenylbutanoate Chemical compound OC(=O)C(N)C(C)C1=CC=CC=C1 IRZQDMYEJPNDEN-UHFFFAOYSA-N 0.000 description 4
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- 102000001189 Cyclic Peptides Human genes 0.000 description 4
- 108010069514 Cyclic Peptides Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- 108091093037 Peptide nucleic acid Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 4
- 150000001576 beta-amino acids Chemical class 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 4
- 235000008191 folinic acid Nutrition 0.000 description 4
- 239000011672 folinic acid Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 150000002308 glutamine derivatives Chemical class 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 229960001691 leucovorin Drugs 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
- 238000010532 solid phase synthesis reaction Methods 0.000 description 4
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- QWXZOFZKSQXPDC-LLVKDONJSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-LLVKDONJSA-N 0.000 description 3
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 3
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- SXGMVGOVILIERA-UHFFFAOYSA-N 2,3-diaminobutanoic acid Chemical compound CC(N)C(N)C(O)=O SXGMVGOVILIERA-UHFFFAOYSA-N 0.000 description 3
- UWNBABFZOWPLEC-UHFFFAOYSA-N 2,4-diamino-3-methylbutanoic acid Chemical compound NCC(C)C(N)C(O)=O UWNBABFZOWPLEC-UHFFFAOYSA-N 0.000 description 3
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 description 3
- SDMNFUKYUGGKNV-UHFFFAOYSA-N 2-amino-3-(1h-pyrrol-3-yl)propanoic acid Chemical compound OC(=O)C(N)CC=1C=CNC=1 SDMNFUKYUGGKNV-UHFFFAOYSA-N 0.000 description 3
- CQNKZTQJMLGAHJ-UHFFFAOYSA-N 2-amino-4-(1h-pyrrol-3-yl)butanoic acid Chemical compound OC(=O)C(N)CCC=1C=CNC=1 CQNKZTQJMLGAHJ-UHFFFAOYSA-N 0.000 description 3
- 108090001008 Avidin Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 150000001414 amino alcohols Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 230000009920 chelation Effects 0.000 description 3
- 229940044683 chemotherapy drug Drugs 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 150000001923 cyclic compounds Chemical class 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000002333 glycines Chemical class 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229960003151 mercaptamine Drugs 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 125000001151 peptidyl group Chemical group 0.000 description 3
- 150000002994 phenylalanines Chemical class 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 150000003679 valine derivatives Chemical class 0.000 description 3
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 2
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 description 2
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 description 2
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 description 2
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 description 2
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- FZENGILVLUJGJX-NSCUHMNNSA-N (E)-acetaldehyde oxime Chemical group C\C=N\O FZENGILVLUJGJX-NSCUHMNNSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 2
- PMLUYTNKEAJUHH-UHFFFAOYSA-N 2,4-diamino-2-ethylbutanoic acid Chemical compound CCC(N)(C(O)=O)CCN PMLUYTNKEAJUHH-UHFFFAOYSA-N 0.000 description 2
- QVYHIBSIPZDXFJ-UHFFFAOYSA-N 2,7-diamino-2-ethylheptanoic acid Chemical compound CCC(N)(C(O)=O)CCCCCN QVYHIBSIPZDXFJ-UHFFFAOYSA-N 0.000 description 2
- BKYKOLNPPZRJKZ-UHFFFAOYSA-N 2,7-diamino-3-ethylheptanoic acid Chemical compound OC(=O)C(N)C(CC)CCCCN BKYKOLNPPZRJKZ-UHFFFAOYSA-N 0.000 description 2
- NRYGUZPDBUSVBJ-UHFFFAOYSA-N 2,7-diamino-3-methylheptanoic acid Chemical compound OC(=O)C(N)C(C)CCCCN NRYGUZPDBUSVBJ-UHFFFAOYSA-N 0.000 description 2
- VQBKXWRJYCMNOS-UHFFFAOYSA-N 2,8-diamino-2-ethyloctanoic acid Chemical compound CCC(N)(C(O)=O)CCCCCCN VQBKXWRJYCMNOS-UHFFFAOYSA-N 0.000 description 2
- IGEPDWOOKADGMT-UHFFFAOYSA-N 2,8-diamino-3-ethyloctanoic acid Chemical compound OC(=O)C(N)C(CC)CCCCCN IGEPDWOOKADGMT-UHFFFAOYSA-N 0.000 description 2
- SUWJHRYOQRBPNH-UHFFFAOYSA-N 2,8-diamino-3-methyloctanoic acid Chemical compound OC(=O)C(N)C(C)CCCCCN SUWJHRYOQRBPNH-UHFFFAOYSA-N 0.000 description 2
- VOWKMMDXKYIBPG-UHFFFAOYSA-N 2-amino-3-(1h-pyrazol-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=NN1 VOWKMMDXKYIBPG-UHFFFAOYSA-N 0.000 description 2
- REBWUCRWJNKVLL-UHFFFAOYSA-N 2-amino-3-(1h-pyrrol-2-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CN1 REBWUCRWJNKVLL-UHFFFAOYSA-N 0.000 description 2
- XMMHIZQFGKMBIE-UHFFFAOYSA-N 2-amino-3-(2-methylphenyl)hexanoic acid Chemical compound CCCC(C(N)C(O)=O)C1=CC=CC=C1C XMMHIZQFGKMBIE-UHFFFAOYSA-N 0.000 description 2
- ZWHICQNVEWBZEB-UHFFFAOYSA-N 2-amino-3-(3-methylphenyl)hexanoic acid Chemical compound CCCC(C(N)C(O)=O)C1=CC=CC(C)=C1 ZWHICQNVEWBZEB-UHFFFAOYSA-N 0.000 description 2
- IYEPWXAPHDCHBS-UHFFFAOYSA-N 2-amino-3-(3h-benzimidazol-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2N=CNC2=C1 IYEPWXAPHDCHBS-UHFFFAOYSA-N 0.000 description 2
- NAKLBXVLJBZSIP-UHFFFAOYSA-N 2-amino-3-cyclopropylbutanoic acid Chemical compound OC(=O)C(N)C(C)C1CC1 NAKLBXVLJBZSIP-UHFFFAOYSA-N 0.000 description 2
- VGHSTKSUXOSXQU-UHFFFAOYSA-N 2-amino-3-phenylpentanoic acid Chemical compound OC(=O)C(N)C(CC)C1=CC=CC=C1 VGHSTKSUXOSXQU-UHFFFAOYSA-N 0.000 description 2
- XUPMNWTYMSKXLG-UHFFFAOYSA-N 2-amino-3-pyrazolidin-1-ylpropanoic acid Chemical compound OC(=O)C(N)CN1CCCN1 XUPMNWTYMSKXLG-UHFFFAOYSA-N 0.000 description 2
- SNFZTHNFWXKRGA-UHFFFAOYSA-N 2-amino-3-pyrazolidin-3-ylpropanoic acid Chemical compound OC(=O)C(N)CC1CCNN1 SNFZTHNFWXKRGA-UHFFFAOYSA-N 0.000 description 2
- VPAWHCGYWCVBBF-UHFFFAOYSA-N 2-amino-3-pyrimidin-4-ylpropanoic acid Chemical compound OC(=O)C(N)CC1=CC=NC=N1 VPAWHCGYWCVBBF-UHFFFAOYSA-N 0.000 description 2
- VDHXLTBUWWQUPL-UHFFFAOYSA-N 2-amino-3-pyrrol-1-ylpropanoic acid Chemical compound OC(=O)C(N)CN1C=CC=C1 VDHXLTBUWWQUPL-UHFFFAOYSA-N 0.000 description 2
- ZZLHMMKDKOYMAR-UHFFFAOYSA-N 2-amino-4-(1h-benzimidazol-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1NC=N2 ZZLHMMKDKOYMAR-UHFFFAOYSA-N 0.000 description 2
- VJFXOUKPXBUIJY-UHFFFAOYSA-N 2-amino-4-(1h-pyrazol-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC=1C=CNN=1 VJFXOUKPXBUIJY-UHFFFAOYSA-N 0.000 description 2
- AKOINERHKFEQLT-UHFFFAOYSA-N 2-amino-4-(1h-pyrrol-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CN1 AKOINERHKFEQLT-UHFFFAOYSA-N 0.000 description 2
- DJNSPJACSSHESV-UHFFFAOYSA-N 2-amino-4-(2-methylphenyl)hexanoic acid Chemical compound OC(=O)C(N)CC(CC)C1=CC=CC=C1C DJNSPJACSSHESV-UHFFFAOYSA-N 0.000 description 2
- IRLPRVMUEFCSRP-UHFFFAOYSA-N 2-amino-4-(3-methylphenyl)hexanoic acid Chemical compound OC(=O)C(N)CC(CC)C1=CC=CC(C)=C1 IRLPRVMUEFCSRP-UHFFFAOYSA-N 0.000 description 2
- OSOQHFMFXOFZDU-UHFFFAOYSA-N 2-amino-4-(3h-benzimidazol-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2N=CNC2=C1 OSOQHFMFXOFZDU-UHFFFAOYSA-N 0.000 description 2
- SXZQYVMIXUCMTL-UHFFFAOYSA-N 2-amino-4-pyrazolidin-1-ylbutanoic acid Chemical compound OC(=O)C(N)CCN1CCCN1 SXZQYVMIXUCMTL-UHFFFAOYSA-N 0.000 description 2
- LIOVDQDUUUMDMJ-UHFFFAOYSA-N 2-amino-4-pyrazolidin-3-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1CCNN1 LIOVDQDUUUMDMJ-UHFFFAOYSA-N 0.000 description 2
- DKDFDEKVGHBVIX-UHFFFAOYSA-N 2-amino-4-pyridin-3-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CN=C1 DKDFDEKVGHBVIX-UHFFFAOYSA-N 0.000 description 2
- OUVVNKJDSQAXCO-UHFFFAOYSA-N 2-amino-4-pyrimidin-4-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CC=NC=N1 OUVVNKJDSQAXCO-UHFFFAOYSA-N 0.000 description 2
- JQWDMUAOESFACC-UHFFFAOYSA-N 2-amino-4-pyrrol-1-ylbutanoic acid Chemical compound OC(=O)C(N)CCN1C=CC=C1 JQWDMUAOESFACC-UHFFFAOYSA-N 0.000 description 2
- KOKZYBZLSNQSJP-UHFFFAOYSA-N 2-amino-5-phenylhexanoic acid Chemical compound OC(=O)C(N)CCC(C)C1=CC=CC=C1 KOKZYBZLSNQSJP-UHFFFAOYSA-N 0.000 description 2
- MARPOZVUYLUPEA-UHFFFAOYSA-N 2-azaniumyl-3-(1h-benzimidazol-4-yl)propanoate Chemical compound OC(=O)C(N)CC1=CC=CC2=C1NC=N2 MARPOZVUYLUPEA-UHFFFAOYSA-N 0.000 description 2
- XGUXJMWPVJQIHI-UHFFFAOYSA-N 2-azaniumyl-3-cyclopropylpropanoate Chemical compound OC(=O)C(N)CC1CC1 XGUXJMWPVJQIHI-UHFFFAOYSA-N 0.000 description 2
- UYTSRQMXRROFPU-UHFFFAOYSA-N 2-azaniumyl-3-fluoropropanoate Chemical compound FCC(N)C(O)=O UYTSRQMXRROFPU-UHFFFAOYSA-N 0.000 description 2
- PDRJLZDUOULRHE-UHFFFAOYSA-N 2-azaniumyl-3-pyridin-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CC=N1 PDRJLZDUOULRHE-UHFFFAOYSA-N 0.000 description 2
- DFZVZEMNPGABKO-UHFFFAOYSA-N 2-azaniumyl-3-pyridin-3-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CN=C1 DFZVZEMNPGABKO-UHFFFAOYSA-N 0.000 description 2
- FQFVANSXYKWQOT-UHFFFAOYSA-N 2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=NC=C1 FQFVANSXYKWQOT-UHFFFAOYSA-N 0.000 description 2
- LPBSHGLDBQBSPI-UHFFFAOYSA-N 2-azaniumyl-4,4-dimethylpentanoate Chemical compound CC(C)(C)CC(N)C(O)=O LPBSHGLDBQBSPI-UHFFFAOYSA-N 0.000 description 2
- MSECZMWQBBVGEN-UHFFFAOYSA-N 2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)C(N)CCC1=CN=CN1 MSECZMWQBBVGEN-UHFFFAOYSA-N 0.000 description 2
- JTTHKOPSMAVJFE-UHFFFAOYSA-N 2-azaniumyl-4-phenylbutanoate Chemical compound OC(=O)C(N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-UHFFFAOYSA-N 0.000 description 2
- ZZHGQIHRAUVHOE-UHFFFAOYSA-N 2-azaniumyl-4-phenylpentanoate Chemical compound OC(=O)C(N)CC(C)C1=CC=CC=C1 ZZHGQIHRAUVHOE-UHFFFAOYSA-N 0.000 description 2
- SJRUMPBLRJLYRM-UHFFFAOYSA-N 2-azaniumyl-4-pyridin-2-ylbutanoate Chemical compound OC(=O)C(N)CCC1=CC=CC=N1 SJRUMPBLRJLYRM-UHFFFAOYSA-N 0.000 description 2
- XOQZTHUXZWQXOK-UHFFFAOYSA-N 2-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)C(N)CCCC1=CC=CC=C1 XOQZTHUXZWQXOK-UHFFFAOYSA-N 0.000 description 2
- UGWULZWUXSCWPX-UHFFFAOYSA-N 2-sulfanylideneimidazolidin-4-one Chemical compound O=C1CNC(=S)N1 UGWULZWUXSCWPX-UHFFFAOYSA-N 0.000 description 2
- CHIDDYZONKDHLG-UHFFFAOYSA-N 3-[2-[2-[2-(9h-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]ethoxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCOCCOCCOCCC(=O)O)C3=CC=CC=C3C2=C1 CHIDDYZONKDHLG-UHFFFAOYSA-N 0.000 description 2
- AQAKDXPQJWVYRG-UHFFFAOYSA-N 3-amino-4-phenylpentanoic acid Chemical compound OC(=O)CC(N)C(C)C1=CC=CC=C1 AQAKDXPQJWVYRG-UHFFFAOYSA-N 0.000 description 2
- KPJNDHVABVUHPG-UHFFFAOYSA-N 3-amino-6-phenylhexanoic acid Chemical compound OC(=O)CC(N)CCCC1=CC=CC=C1 KPJNDHVABVUHPG-UHFFFAOYSA-N 0.000 description 2
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 2
- OQEBBZSWEGYTPG-UHFFFAOYSA-N 3-aminobutanoic acid Chemical compound CC(N)CC(O)=O OQEBBZSWEGYTPG-UHFFFAOYSA-N 0.000 description 2
- QCHPKSFMDHPSNR-UHFFFAOYSA-N 3-aminoisobutyric acid Chemical compound NCC(C)C(O)=O QCHPKSFMDHPSNR-UHFFFAOYSA-N 0.000 description 2
- CJJYCYZKUNRKFP-UHFFFAOYSA-N 3-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)CC(N)CCC1=CC=CC=C1 CJJYCYZKUNRKFP-UHFFFAOYSA-N 0.000 description 2
- ASBJGPTTYPEMLP-UHFFFAOYSA-N 3-chloroalanine Chemical compound ClCC(N)C(O)=O ASBJGPTTYPEMLP-UHFFFAOYSA-N 0.000 description 2
- FXXGGVGRDTUZDT-UHFFFAOYSA-N 4-amino-6-phenylhexanoic acid Chemical compound OC(=O)CCC(N)CCC1=CC=CC=C1 FXXGGVGRDTUZDT-UHFFFAOYSA-N 0.000 description 2
- URBAOHLJWLYLQE-UHFFFAOYSA-N 4-azaniumyl-5-phenylpentanoate Chemical compound OC(=O)CCC(N)CC1=CC=CC=C1 URBAOHLJWLYLQE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- OFVBLKINTLPEGH-UHFFFAOYSA-N DL-beta-Homophenylalanine Chemical compound OC(=O)CC(N)CC1=CC=CC=C1 OFVBLKINTLPEGH-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229910052688 Gadolinium Inorganic materials 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N Heptanedioic acid Natural products OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229910052689 Holmium Inorganic materials 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 2
- 239000006142 Luria-Bertani Agar Substances 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 239000007825 activation reagent Substances 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940045985 antineoplastic platinum compound Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- PMLJIHNCYNOQEQ-UHFFFAOYSA-N aspartic 1-amide Chemical compound NC(=O)C(N)CC(O)=O PMLJIHNCYNOQEQ-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000011717 athymic nude mouse Methods 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 2
- 238000006664 bond formation reaction Methods 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 238000009109 curative therapy Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- TXCDCPKCNAJMEE-UHFFFAOYSA-N dibenzofuran Chemical compound C1=CC=C2C3=CC=CC=C3OC2=C1 TXCDCPKCNAJMEE-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 2
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- GCHPUFAZSONQIV-UHFFFAOYSA-N isovaline Chemical compound CCC(C)(N)C(O)=O GCHPUFAZSONQIV-UHFFFAOYSA-N 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000003058 platinum compounds Chemical class 0.000 description 2
- 229920003055 poly(ester-imide) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000006340 racemization Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940054269 sodium pyruvate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- BCIPGSZQUDLGSY-INIZCTEOSA-N tert-butyl (4s)-4-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxopentanoate Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C=O)C3=CC=CC=C3C2=C1 BCIPGSZQUDLGSY-INIZCTEOSA-N 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NHTGHBARYWONDQ-UHFFFAOYSA-N (+-)-α-methyl-tyrosine Chemical compound OC(=O)C(N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-UHFFFAOYSA-N 0.000 description 1
- RBNSZWOCWHGHMR-UHFFFAOYSA-N (2-iodoacetyl) 2-iodoacetate Chemical compound ICC(=O)OC(=O)CI RBNSZWOCWHGHMR-UHFFFAOYSA-N 0.000 description 1
- PPCCENJMUXTBEV-QMMMGPOBSA-N (2R)-2-anilino-2,3,3,3-tetrahydroxypropanoic acid Chemical class OC([C@](NC1=CC=CC=C1)(C(=O)O)O)(O)O PPCCENJMUXTBEV-QMMMGPOBSA-N 0.000 description 1
- SWBJHBWDAUDXMI-SSDOTTSWSA-N (2S)-2-anilino-3,3,3-trihydroxypropanoic acid Chemical class OC([C@H](NC1=CC=CC=C1)C(=O)O)(O)O SWBJHBWDAUDXMI-SSDOTTSWSA-N 0.000 description 1
- ONJAYABUUXNZOY-QMMMGPOBSA-N (2r)-2,3,3,3-tetrahydroxy-2-(n-hydroxyanilino)propanoic acid Chemical class OC(=O)[C@](O)(C(O)(O)O)N(O)C1=CC=CC=C1 ONJAYABUUXNZOY-QMMMGPOBSA-N 0.000 description 1
- IFXHSYYADKQNAP-AKGZTFGVSA-N (2s)-2,4-diamino-3-cyclopropyl-4-oxobutanoic acid Chemical compound OC(=O)[C@@H](N)C(C(N)=O)C1CC1 IFXHSYYADKQNAP-AKGZTFGVSA-N 0.000 description 1
- BDTHUVJWFWEPPV-AOIFVJIMSA-N (2s)-2,5-diamino-3-(difluoromethyl)-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)C(C(F)F)CC(N)=O BDTHUVJWFWEPPV-AOIFVJIMSA-N 0.000 description 1
- ZLLBMVVNYMURTO-MSZQBOFLSA-N (2s)-2,5-diamino-3-cyclopropyl-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)C(CC(N)=O)C1CC1 ZLLBMVVNYMURTO-MSZQBOFLSA-N 0.000 description 1
- CTSYQHQZVZGFAT-RZKHNPSRSA-N (2s)-2,5-diamino-3-ethyl-5-oxopentanoic acid Chemical compound NC(=O)CC(CC)[C@H](N)C(O)=O CTSYQHQZVZGFAT-RZKHNPSRSA-N 0.000 description 1
- JNFVXFXEIGUSBZ-AOIFVJIMSA-N (2s)-2,5-diamino-3-hydroxy-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)C(O)CC(N)=O JNFVXFXEIGUSBZ-AOIFVJIMSA-N 0.000 description 1
- XNKMSCUMMWLUPG-YFKPBYRVSA-N (2s)-2,5-diamino-3-methylidene-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)C(=C)CC(N)=O XNKMSCUMMWLUPG-YFKPBYRVSA-N 0.000 description 1
- VJXJSVSUWVSVDG-YFKPBYRVSA-N (2s)-2-(2,3-dihydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC=CC(O)=C1O VJXJSVSUWVSVDG-YFKPBYRVSA-N 0.000 description 1
- YHNZPUXSHLCCSQ-YFKPBYRVSA-N (2s)-2-(2,4-dihydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC=C(O)C=C1O YHNZPUXSHLCCSQ-YFKPBYRVSA-N 0.000 description 1
- ONLJZBLCDCWZEK-YFKPBYRVSA-N (2s)-2-(2,5-dihydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC(O)=CC=C1O ONLJZBLCDCWZEK-YFKPBYRVSA-N 0.000 description 1
- QBCHVCPIXHKVAP-YFKPBYRVSA-N (2s)-2-(2,6-dihydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=C(O)C=CC=C1O QBCHVCPIXHKVAP-YFKPBYRVSA-N 0.000 description 1
- ACTNTGXKWRIUIM-LURJTMIESA-N (2s)-2-(2-hydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC=CC=C1O ACTNTGXKWRIUIM-LURJTMIESA-N 0.000 description 1
- STRLORFSHRJIES-YFKPBYRVSA-N (2s)-2-(3,5-dihydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC(O)=CC(O)=C1 STRLORFSHRJIES-YFKPBYRVSA-N 0.000 description 1
- QYWQUVZKQYRLDZ-LURJTMIESA-N (2s)-2-(3-hydroxyanilino)propanoic acid Chemical class OC(=O)[C@H](C)NC1=CC=CC(O)=C1 QYWQUVZKQYRLDZ-LURJTMIESA-N 0.000 description 1
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- KEFQVZYLTYLBRA-NSHDSACASA-N (2s)-2-amino-2-[(4-hydroxyphenyl)methyl]butanoic acid Chemical compound CC[C@@](N)(C(O)=O)CC1=CC=C(O)C=C1 KEFQVZYLTYLBRA-NSHDSACASA-N 0.000 description 1
- LOAXHSWOVHEPGC-LBPRGKRZSA-N (2s)-2-amino-2-[(4-hydroxyphenyl)methyl]pentanoic acid Chemical compound CCC[C@@](N)(C(O)=O)CC1=CC=C(O)C=C1 LOAXHSWOVHEPGC-LBPRGKRZSA-N 0.000 description 1
- SEZWJSBQTSPTTK-VKHMYHEASA-N (2s)-2-amino-3-(2,3,5,6-tetrabromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(Br)C(Br)=C(O)C(Br)=C1Br SEZWJSBQTSPTTK-VKHMYHEASA-N 0.000 description 1
- KOHJJJIJWDKTGK-VKHMYHEASA-N (2s)-2-amino-3-(2,3,5,6-tetrachloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(Cl)C(Cl)=C(O)C(Cl)=C1Cl KOHJJJIJWDKTGK-VKHMYHEASA-N 0.000 description 1
- KFUSMUNGVKVABM-VKHMYHEASA-N (2s)-2-amino-3-(2,3,5,6-tetrafluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C(F)=C(O)C(F)=C1F KFUSMUNGVKVABM-VKHMYHEASA-N 0.000 description 1
- RZTCXNSXFYZDTL-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,5-tribromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(Br)=C(O)C(Br)=C1Br RZTCXNSXFYZDTL-YFKPBYRVSA-N 0.000 description 1
- HTLMKFDITXPDNG-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,5-trichloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(Cl)=C(O)C(Cl)=C1Cl HTLMKFDITXPDNG-YFKPBYRVSA-N 0.000 description 1
- AUJOGVIKYBGMRE-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,5-trifluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=C(O)C(F)=C1F AUJOGVIKYBGMRE-YFKPBYRVSA-N 0.000 description 1
- OZKLKOUDIDDESS-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,6-tribromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(Br)C=C(O)C(Br)=C1Br OZKLKOUDIDDESS-YFKPBYRVSA-N 0.000 description 1
- RSYALYWQKYRLRH-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,6-trichloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(Cl)C=C(O)C(Cl)=C1Cl RSYALYWQKYRLRH-YFKPBYRVSA-N 0.000 description 1
- LVKGBSFEYFVENX-YFKPBYRVSA-N (2s)-2-amino-3-(2,3,6-trifluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C=C(O)C(F)=C1F LVKGBSFEYFVENX-YFKPBYRVSA-N 0.000 description 1
- NKLMLRIOJDRBCZ-YFKPBYRVSA-N (2s)-2-amino-3-(2,3-dibromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Br)=C1Br NKLMLRIOJDRBCZ-YFKPBYRVSA-N 0.000 description 1
- ZRUVMHGZAQLATN-NSHDSACASA-N (2s)-2-amino-3-(2,3-diethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=C(O)C=CC(C[C@H](N)C(O)=O)=C1CC ZRUVMHGZAQLATN-NSHDSACASA-N 0.000 description 1
- XWNMQLVJIYFCFZ-YFKPBYRVSA-N (2s)-2-amino-3-(2,3-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1F XWNMQLVJIYFCFZ-YFKPBYRVSA-N 0.000 description 1
- CVLYJBHDGGDQSE-ZETCQYMHSA-N (2s)-2-amino-3-(2,5-dibromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(Br)=C(O)C=C1Br CVLYJBHDGGDQSE-ZETCQYMHSA-N 0.000 description 1
- VMFMISHZRGKGGK-ZETCQYMHSA-N (2s)-2-amino-3-(2,5-dichloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(Cl)=C(O)C=C1Cl VMFMISHZRGKGGK-ZETCQYMHSA-N 0.000 description 1
- OSEBOUAPUQUKMV-NSHDSACASA-N (2s)-2-amino-3-(2,5-diethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=CC(C[C@H](N)C(O)=O)=C(CC)C=C1O OSEBOUAPUQUKMV-NSHDSACASA-N 0.000 description 1
- HEYMKHHKRTUJHU-ZETCQYMHSA-N (2s)-2-amino-3-(2,5-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(F)=C(O)C=C1F HEYMKHHKRTUJHU-ZETCQYMHSA-N 0.000 description 1
- VNCFKQCZXPKSGB-QMMMGPOBSA-N (2s)-2-amino-3-(2,6-dichloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(Cl)C=C(O)C=C1Cl VNCFKQCZXPKSGB-QMMMGPOBSA-N 0.000 description 1
- BSZAKSZIVUNKRK-LBPRGKRZSA-N (2s)-2-amino-3-(2,6-diethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=CC(O)=CC(CC)=C1C[C@H](N)C(O)=O BSZAKSZIVUNKRK-LBPRGKRZSA-N 0.000 description 1
- GXXSRPQBOBZVBN-QMMMGPOBSA-N (2s)-2-amino-3-(2,6-difluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(F)C=C(O)C=C1F GXXSRPQBOBZVBN-QMMMGPOBSA-N 0.000 description 1
- HKDPKZJZEIOKTD-MSZQBOFLSA-N (2s)-2-amino-3-(2-amino-2-oxoethyl)hexanoic acid Chemical compound CCCC(CC(N)=O)[C@H](N)C(O)=O HKDPKZJZEIOKTD-MSZQBOFLSA-N 0.000 description 1
- QGFVUADZXXJSDI-QMMMGPOBSA-N (2s)-2-amino-3-(2-chloro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1Cl QGFVUADZXXJSDI-QMMMGPOBSA-N 0.000 description 1
- BOLUZPBFHZSEQD-JTQLQIEISA-N (2s)-2-amino-3-(2-ethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=CC(O)=CC=C1C[C@H](N)C(O)=O BOLUZPBFHZSEQD-JTQLQIEISA-N 0.000 description 1
- WEJIXBMNLWITCR-QMMMGPOBSA-N (2s)-2-amino-3-(2-fluoro-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1F WEJIXBMNLWITCR-QMMMGPOBSA-N 0.000 description 1
- OXENBAZVGYOXAH-VIFPVBQESA-N (2s)-2-amino-3-(3-ethyl-4-hydroxyphenyl)propanoic acid Chemical compound CCC1=CC(C[C@H](N)C(O)=O)=CC=C1O OXENBAZVGYOXAH-VIFPVBQESA-N 0.000 description 1
- NCOXUOLLPWDGFR-VKHMYHEASA-N (2s)-2-amino-3-(4-hydroxy-2,3,5,6-tetraiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(I)C(I)=C(O)C(I)=C1I NCOXUOLLPWDGFR-VKHMYHEASA-N 0.000 description 1
- OTWWHLKFLQSOPI-YFKPBYRVSA-N (2s)-2-amino-3-(4-hydroxy-2,3,5-triiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C(I)=C1I OTWWHLKFLQSOPI-YFKPBYRVSA-N 0.000 description 1
- YKMWEGAUSYBGDO-YFKPBYRVSA-N (2s)-2-amino-3-(4-hydroxy-2,3,6-triiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(I)C=C(O)C(I)=C1I YKMWEGAUSYBGDO-YFKPBYRVSA-N 0.000 description 1
- TVLVIPIAVQSKLB-YFKPBYRVSA-N (2s)-2-amino-3-(4-hydroxy-2,3-diiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1I TVLVIPIAVQSKLB-YFKPBYRVSA-N 0.000 description 1
- PEZDVOIXEPGGDR-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2,3-dimethylphenyl)propanoic acid Chemical compound CC1=C(O)C=CC(C[C@H](N)C(O)=O)=C1C PEZDVOIXEPGGDR-VIFPVBQESA-N 0.000 description 1
- ZKRGJDADKBVHGU-ZETCQYMHSA-N (2s)-2-amino-3-(4-hydroxy-2,5-diiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC(I)=C(O)C=C1I ZKRGJDADKBVHGU-ZETCQYMHSA-N 0.000 description 1
- LTLXBLYXTNZJFT-VIFPVBQESA-N (2s)-2-amino-3-(4-hydroxy-2,5-dimethylphenyl)propanoic acid Chemical compound CC1=CC(C[C@H](N)C(O)=O)=C(C)C=C1O LTLXBLYXTNZJFT-VIFPVBQESA-N 0.000 description 1
- WDADJLQLOHRBIQ-QMMMGPOBSA-N (2s)-2-amino-3-(4-hydroxy-2,6-diiodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=C(I)C=C(O)C=C1I WDADJLQLOHRBIQ-QMMMGPOBSA-N 0.000 description 1
- BMBZSHPNHVPCNG-QMMMGPOBSA-N (2s)-2-amino-3-(4-hydroxy-2-iodophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1I BMBZSHPNHVPCNG-QMMMGPOBSA-N 0.000 description 1
- RFUREPLFJWAIAH-ASHVXDOASA-N (2s)-2-amino-3-carbamoyl-4,4-difluorobutanoic acid Chemical compound OC(=O)[C@@H](N)C(C(F)F)C(N)=O RFUREPLFJWAIAH-ASHVXDOASA-N 0.000 description 1
- GFQKEKUFTSJNBA-VKHMYHEASA-N (2s)-2-amino-3-carbamoylbut-3-enoic acid Chemical compound OC(=O)[C@@H](N)C(=C)C(N)=O GFQKEKUFTSJNBA-VKHMYHEASA-N 0.000 description 1
- WQRMSVPHHCAVSR-AKGZTFGVSA-N (2s)-2-amino-3-carbamoylhexanoic acid Chemical compound CCCC(C(N)=O)[C@H](N)C(O)=O WQRMSVPHHCAVSR-AKGZTFGVSA-N 0.000 description 1
- PIEVRPLNBFDAFP-BKLSDQPFSA-N (2s)-2-amino-3-carbamoylpentanoic acid Chemical compound CCC(C(N)=O)[C@H](N)C(O)=O PIEVRPLNBFDAFP-BKLSDQPFSA-N 0.000 description 1
- LXRUAYBIUSUULX-NFJMKROFSA-N (2s)-2-amino-3-methylbutanedioic acid Chemical compound OC(=O)C(C)[C@H](N)C(O)=O LXRUAYBIUSUULX-NFJMKROFSA-N 0.000 description 1
- FXYGZLPVPNAWMW-AWEZNQCLSA-N (2s)-2-azaniumyl-3,3-dicyclohexylpropanoate Chemical compound C1CCCCC1C([C@H]([NH3+])C([O-])=O)C1CCCCC1 FXYGZLPVPNAWMW-AWEZNQCLSA-N 0.000 description 1
- CZMZPVRJCFFMGI-YFKPBYRVSA-N (2s)-2-azaniumyl-3-(2,3-dichloro-4-hydroxyphenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1Cl CZMZPVRJCFFMGI-YFKPBYRVSA-N 0.000 description 1
- LSNDLIKCFHLFKO-JTQLQIEISA-N (2s)-2-azaniumyl-3-(4-hydroxy-2,6-dimethylphenyl)propanoate Chemical compound CC1=CC(O)=CC(C)=C1C[C@H](N)C(O)=O LSNDLIKCFHLFKO-JTQLQIEISA-N 0.000 description 1
- XGUXJMWPVJQIHI-YFKPBYRVSA-N (2s)-2-azaniumyl-3-cyclopropylpropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1CC1 XGUXJMWPVJQIHI-YFKPBYRVSA-N 0.000 description 1
- XWNYVTGUCSJNQO-VKHMYHEASA-N (2s)-5-amino-2-(difluoromethylamino)-5-oxopentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(F)F XWNYVTGUCSJNQO-VKHMYHEASA-N 0.000 description 1
- RWBLYSWJMSKZAL-UCORVYFPSA-N (2s,3s)-2,5-diamino-3-methyl-5-oxopentanoic acid Chemical compound NC(=O)C[C@H](C)[C@H](N)C(O)=O RWBLYSWJMSKZAL-UCORVYFPSA-N 0.000 description 1
- VQTLPSCRBFYDNX-LWMBPPNESA-N (3S)-3-hydroxy-L-asparagine Chemical compound OC(=O)[C@@H](N)[C@H](O)C(N)=O VQTLPSCRBFYDNX-LWMBPPNESA-N 0.000 description 1
- UQWNNUPJBDWRHC-UWVGGRQHSA-N (3s,4s)-4-amino-5-cyclohexyl-3-hydroxypentanoic acid Chemical compound OC(=O)C[C@H](O)[C@@H](N)CC1CCCCC1 UQWNNUPJBDWRHC-UWVGGRQHSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical group C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- XHAOODLHQQVQAR-UHFFFAOYSA-N 2,3-diamino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound CC(N)C(N)(C(O)=O)C1(F)CC1 XHAOODLHQQVQAR-UHFFFAOYSA-N 0.000 description 1
- KLHNTFGZBFRVIA-UHFFFAOYSA-N 2,3-diamino-2-(1-fluorocyclopropyl)propanoic acid Chemical compound NCC(N)(C(O)=O)C1(F)CC1 KLHNTFGZBFRVIA-UHFFFAOYSA-N 0.000 description 1
- BUMWSYZBBSSHBW-UHFFFAOYSA-N 2,3-diamino-2-cyclopropylpropanoic acid Chemical compound NCC(N)(C(O)=O)C1CC1 BUMWSYZBBSSHBW-UHFFFAOYSA-N 0.000 description 1
- ODOYGHUPIHCNMT-UHFFFAOYSA-N 2,3-diamino-2-ethylbutanoic acid Chemical compound CCC(N)(C(C)N)C(O)=O ODOYGHUPIHCNMT-UHFFFAOYSA-N 0.000 description 1
- KIJVTYCTTULCBX-UHFFFAOYSA-N 2,3-diamino-2-methylbutanoic acid Chemical compound CC(N)C(C)(N)C(O)=O KIJVTYCTTULCBX-UHFFFAOYSA-N 0.000 description 1
- BJVNVLORPOBATD-UHFFFAOYSA-N 2,3-diamino-2-methylpropanoic acid Chemical compound NCC(N)(C)C(O)=O BJVNVLORPOBATD-UHFFFAOYSA-N 0.000 description 1
- XUKLJJOJKUELBZ-UHFFFAOYSA-N 2,3-diamino-3-(1-fluorocyclopropyl)butanoic acid Chemical compound OC(=O)C(N)C(N)(C)C1(F)CC1 XUKLJJOJKUELBZ-UHFFFAOYSA-N 0.000 description 1
- OJQPNKPZJOVVGA-UHFFFAOYSA-N 2,3-diamino-3-cyclopropylbutanoic acid Chemical compound OC(=O)C(N)C(N)(C)C1CC1 OJQPNKPZJOVVGA-UHFFFAOYSA-N 0.000 description 1
- GVTKGCGMUSNHKW-UHFFFAOYSA-N 2,3-diamino-3-cyclopropylpropanoic acid Chemical compound OC(=O)C(N)C(N)C1CC1 GVTKGCGMUSNHKW-UHFFFAOYSA-N 0.000 description 1
- KAWLHBPCRLENDL-UHFFFAOYSA-N 2,3-diamino-3-methylbutanoic acid Chemical compound CC(C)(N)C(N)C(O)=O KAWLHBPCRLENDL-UHFFFAOYSA-N 0.000 description 1
- PMDSASKBGWNSNY-UHFFFAOYSA-N 2,3-diamino-3-methylpentanoic acid Chemical compound CCC(C)(N)C(N)C(O)=O PMDSASKBGWNSNY-UHFFFAOYSA-N 0.000 description 1
- HZIHVNNCKFUSJN-UHFFFAOYSA-N 2,3-diaminopentanoic acid Chemical compound CCC(N)C(N)C(O)=O HZIHVNNCKFUSJN-UHFFFAOYSA-N 0.000 description 1
- NSTLZJGTTTXAFZ-UHFFFAOYSA-N 2,4-diamino-2,3-dimethylbutanoic acid Chemical compound NCC(C)C(C)(N)C(O)=O NSTLZJGTTTXAFZ-UHFFFAOYSA-N 0.000 description 1
- SXIIUMGDCWKWED-UHFFFAOYSA-N 2,4-diamino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound NCCC(N)(C(O)=O)C1(F)CC1 SXIIUMGDCWKWED-UHFFFAOYSA-N 0.000 description 1
- IVPXYLTVOUEJAE-UHFFFAOYSA-N 2,4-diamino-2-cyclopropylbutanoic acid Chemical compound NCCC(N)(C(O)=O)C1CC1 IVPXYLTVOUEJAE-UHFFFAOYSA-N 0.000 description 1
- VXBKQIHBFPYKSG-UHFFFAOYSA-N 2,4-diamino-3-cyclopropylbutanoic acid Chemical compound OC(=O)C(N)C(CN)C1CC1 VXBKQIHBFPYKSG-UHFFFAOYSA-N 0.000 description 1
- GGARNRUDCFBAFO-UHFFFAOYSA-N 2,4-diamino-3-ethylcycloheptane-1-carboxylic acid Chemical compound CCC1C(N)CCCC(C(O)=O)C1N GGARNRUDCFBAFO-UHFFFAOYSA-N 0.000 description 1
- CHLXMSIPUOLEMV-UHFFFAOYSA-N 2,4-diamino-3-ethylcyclohexane-1-carboxylic acid Chemical compound CCC1C(N)CCC(C(O)=O)C1N CHLXMSIPUOLEMV-UHFFFAOYSA-N 0.000 description 1
- VQVHCAXHYBLRIF-UHFFFAOYSA-N 2,4-diamino-3-methyl-4-oxobutanoic acid Chemical compound NC(=O)C(C)C(N)C(O)=O VQVHCAXHYBLRIF-UHFFFAOYSA-N 0.000 description 1
- GWIOWLACKTWWNC-UHFFFAOYSA-N 2,5-diaminocyclohexane-1-carboxylic acid Chemical compound NC1CCC(N)C(C(O)=O)C1 GWIOWLACKTWWNC-UHFFFAOYSA-N 0.000 description 1
- SNSKAZSDDBTRDW-UHFFFAOYSA-N 2,5-diaminocyclononane-1-carboxylic acid Chemical compound NC1CCCCC(C(O)=O)C(N)CC1 SNSKAZSDDBTRDW-UHFFFAOYSA-N 0.000 description 1
- RJVWYCIKOGRRHX-UHFFFAOYSA-N 2,6-diamino-3-cyclopropyl-6-oxohexanoic acid Chemical compound NC(=O)CCC(C(N)C(O)=O)C1CC1 RJVWYCIKOGRRHX-UHFFFAOYSA-N 0.000 description 1
- HRWJZDHGTOZAAS-UHFFFAOYSA-N 2,6-diamino-3-ethyl-6-oxohexanoic acid Chemical compound OC(=O)C(N)C(CC)CCC(N)=O HRWJZDHGTOZAAS-UHFFFAOYSA-N 0.000 description 1
- XZNNTSAEXIYFHO-UHFFFAOYSA-N 2,6-diamino-3-hydroxy-6-oxohexanoic acid Chemical compound OC(=O)C(N)C(O)CCC(N)=O XZNNTSAEXIYFHO-UHFFFAOYSA-N 0.000 description 1
- YYDCNJXJEQVSTD-UHFFFAOYSA-N 2,6-diamino-3-methyl-6-oxohexanoic acid Chemical compound OC(=O)C(N)C(C)CCC(N)=O YYDCNJXJEQVSTD-UHFFFAOYSA-N 0.000 description 1
- OPNQUOSFLSXQEL-UHFFFAOYSA-N 2,6-diamino-4-cyclopropyl-6-oxohexanoic acid Chemical compound OC(=O)C(N)CC(CC(N)=O)C1CC1 OPNQUOSFLSXQEL-UHFFFAOYSA-N 0.000 description 1
- XTWJYNJDBPETML-UHFFFAOYSA-N 2,6-diamino-4-ethyl-6-oxohexanoic acid Chemical compound NC(=O)CC(CC)CC(N)C(O)=O XTWJYNJDBPETML-UHFFFAOYSA-N 0.000 description 1
- WDBKLBREFXMUHM-UHFFFAOYSA-N 2,6-diamino-4-hydroxy-6-oxohexanoic acid Chemical compound OC(=O)C(N)CC(O)CC(N)=O WDBKLBREFXMUHM-UHFFFAOYSA-N 0.000 description 1
- DTKZPAKZHWUSHD-UHFFFAOYSA-N 2,6-diamino-4-methyl-6-oxohexanoic acid Chemical compound NC(=O)CC(C)CC(N)C(O)=O DTKZPAKZHWUSHD-UHFFFAOYSA-N 0.000 description 1
- GRTWLOSOXQQNQC-UHFFFAOYSA-N 2,6-diamino-5-cyclopropyl-6-oxohexanoic acid Chemical compound OC(=O)C(N)CCC(C(N)=O)C1CC1 GRTWLOSOXQQNQC-UHFFFAOYSA-N 0.000 description 1
- NTHMHNWQLMWRHF-UHFFFAOYSA-N 2,6-diamino-5-hydroxy-6-oxohexanoic acid Chemical compound OC(=O)C(N)CCC(O)C(N)=O NTHMHNWQLMWRHF-UHFFFAOYSA-N 0.000 description 1
- MGLKMUXPWQEQGI-UHFFFAOYSA-N 2,6-diamino-5-methyl-6-oxohexanoic acid Chemical compound NC(=O)C(C)CCC(N)C(O)=O MGLKMUXPWQEQGI-UHFFFAOYSA-N 0.000 description 1
- CHEPITLQOXULOT-UHFFFAOYSA-N 2,6-diamino-6-oxo-3-propylhexanoic acid Chemical compound CCCC(C(N)C(O)=O)CCC(N)=O CHEPITLQOXULOT-UHFFFAOYSA-N 0.000 description 1
- HJABLCYESROEJG-UHFFFAOYSA-N 2,7-diamino-3-cyclopropyl-7-oxoheptanoic acid Chemical compound NC(=O)CCCC(C(N)C(O)=O)C1CC1 HJABLCYESROEJG-UHFFFAOYSA-N 0.000 description 1
- ZRVONQMLPVUULG-UHFFFAOYSA-N 2,7-diamino-3-ethyl-7-oxoheptanoic acid Chemical compound OC(=O)C(N)C(CC)CCCC(N)=O ZRVONQMLPVUULG-UHFFFAOYSA-N 0.000 description 1
- GKSBYCLTVRSNBY-UHFFFAOYSA-N 2,7-diamino-3-hydroxy-7-oxoheptanoic acid Chemical compound OC(=O)C(N)C(O)CCCC(N)=O GKSBYCLTVRSNBY-UHFFFAOYSA-N 0.000 description 1
- YRHRIVASYIEJNB-UHFFFAOYSA-N 2,7-diamino-3-methyl-7-oxoheptanoic acid Chemical compound OC(=O)C(N)C(C)CCCC(N)=O YRHRIVASYIEJNB-UHFFFAOYSA-N 0.000 description 1
- DIKMHINYVHHZCS-UHFFFAOYSA-N 2,7-diamino-4-cyclopropyl-7-oxoheptanoic acid Chemical compound OC(=O)C(N)CC(CCC(N)=O)C1CC1 DIKMHINYVHHZCS-UHFFFAOYSA-N 0.000 description 1
- RHKLOTREICIIKT-UHFFFAOYSA-N 2,7-diamino-4-ethyl-7-oxoheptanoic acid Chemical compound NC(=O)CCC(CC)CC(N)C(O)=O RHKLOTREICIIKT-UHFFFAOYSA-N 0.000 description 1
- HMFOVAIMBLMOOZ-UHFFFAOYSA-N 2,7-diamino-4-hydroxy-7-oxoheptanoic acid Chemical compound OC(=O)C(N)CC(O)CCC(N)=O HMFOVAIMBLMOOZ-UHFFFAOYSA-N 0.000 description 1
- KHQXDGWTODEQPQ-UHFFFAOYSA-N 2,7-diamino-4-methyl-7-oxoheptanoic acid Chemical compound NC(=O)CCC(C)CC(N)C(O)=O KHQXDGWTODEQPQ-UHFFFAOYSA-N 0.000 description 1
- BEQSUTHQKMHPOR-UHFFFAOYSA-N 2,7-diamino-5-cyclopropyl-7-oxoheptanoic acid Chemical compound OC(=O)C(N)CCC(CC(N)=O)C1CC1 BEQSUTHQKMHPOR-UHFFFAOYSA-N 0.000 description 1
- JCSWRVRXDAGUSA-UHFFFAOYSA-N 2,7-diamino-5-ethyl-7-oxoheptanoic acid Chemical compound NC(=O)CC(CC)CCC(N)C(O)=O JCSWRVRXDAGUSA-UHFFFAOYSA-N 0.000 description 1
- NLFGSXITURYVMM-UHFFFAOYSA-N 2,7-diamino-5-hydroxy-7-oxoheptanoic acid Chemical compound OC(=O)C(N)CCC(O)CC(N)=O NLFGSXITURYVMM-UHFFFAOYSA-N 0.000 description 1
- IWVFDDIZXBVAQO-UHFFFAOYSA-N 2,7-diamino-5-methyl-7-oxoheptanoic acid Chemical compound NC(=O)CC(C)CCC(N)C(O)=O IWVFDDIZXBVAQO-UHFFFAOYSA-N 0.000 description 1
- WSLZZXLDKZCBIO-UHFFFAOYSA-N 2,7-diamino-7-oxo-3-propylheptanoic acid Chemical compound CCCC(C(N)C(O)=O)CCCC(N)=O WSLZZXLDKZCBIO-UHFFFAOYSA-N 0.000 description 1
- ZJQVXFYXBWAASL-UHFFFAOYSA-N 2,7-diamino-7-oxo-4-propylheptanoic acid Chemical compound NC(=O)CCC(CCC)CC(N)C(O)=O ZJQVXFYXBWAASL-UHFFFAOYSA-N 0.000 description 1
- QTNACZLPTBPOOG-UHFFFAOYSA-N 2,7-diamino-7-oxoheptanoic acid Chemical compound OC(=O)C(N)CCCCC(N)=O QTNACZLPTBPOOG-UHFFFAOYSA-N 0.000 description 1
- NMDDZEVVQDPECF-UHFFFAOYSA-N 2,7-diaminoheptanoic acid Chemical compound NCCCCCC(N)C(O)=O NMDDZEVVQDPECF-UHFFFAOYSA-N 0.000 description 1
- VCJYILZEBHIANJ-UHFFFAOYSA-N 2,8-diamino-3-ethylcyclooctane-1-carboxylic acid Chemical compound CCC1CCCCC(N)C(C(O)=O)C1N VCJYILZEBHIANJ-UHFFFAOYSA-N 0.000 description 1
- KMPBBRFCAYFTMR-UHFFFAOYSA-N 2,8-diaminooctanoic acid Chemical compound NCCCCCCC(N)C(O)=O KMPBBRFCAYFTMR-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- VAOYPHGXHKUTHC-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-[2-[bis(carboxymethyl)amino]-3-(4-isothiocyanatophenyl)propyl]amino]acetic acid Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CC(N(CC(O)=O)CC(O)=O)CC1=CC=C(N=C=S)C=C1 VAOYPHGXHKUTHC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BPMMAHFODYSUGM-UHFFFAOYSA-N 2-amino-2-(1-fluorocyclopropyl)acetic acid Chemical compound OC(=O)C(N)C1(F)CC1 BPMMAHFODYSUGM-UHFFFAOYSA-N 0.000 description 1
- SAALIVCOKCBULY-UHFFFAOYSA-N 2-amino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound CCC(N)(C(O)=O)C1(F)CC1 SAALIVCOKCBULY-UHFFFAOYSA-N 0.000 description 1
- BKHKZAZORNZRQU-UHFFFAOYSA-N 2-amino-2-(1-fluorocyclopropyl)propanoic acid Chemical compound OC(=O)C(N)(C)C1(F)CC1 BKHKZAZORNZRQU-UHFFFAOYSA-N 0.000 description 1
- PZUHOEXADUBYCE-UHFFFAOYSA-N 2-amino-2-(aminomethyl)butanoic acid Chemical compound CCC(N)(CN)C(O)=O PZUHOEXADUBYCE-UHFFFAOYSA-N 0.000 description 1
- WQMWQPSZTDYVNB-UHFFFAOYSA-N 2-amino-2-cyclopropylbutanoic acid Chemical compound CCC(N)(C(O)=O)C1CC1 WQMWQPSZTDYVNB-UHFFFAOYSA-N 0.000 description 1
- ZVWLOELKXCXZCT-UHFFFAOYSA-N 2-amino-2-sulfanylpentanoic acid Chemical compound CCCC(N)(S)C(O)=O ZVWLOELKXCXZCT-UHFFFAOYSA-N 0.000 description 1
- JAFOKWHCRSAYAA-UHFFFAOYSA-N 2-amino-3-(1,3-dihydropyrazol-2-yl)propanoic acid Chemical compound OC(=O)C(N)CN1CC=CN1 JAFOKWHCRSAYAA-UHFFFAOYSA-N 0.000 description 1
- ZUQNGYBTOKRKBJ-UHFFFAOYSA-N 2-amino-3-(1,5-dihydropyrazol-2-yl)propanoic acid Chemical compound OC(=O)C(N)CN1NCC=C1 ZUQNGYBTOKRKBJ-UHFFFAOYSA-N 0.000 description 1
- QCWLUAFEDNNDJL-UHFFFAOYSA-N 2-amino-3-(1-benzothiophen-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1C=CS2 QCWLUAFEDNNDJL-UHFFFAOYSA-N 0.000 description 1
- MWIJOUKBVWNDBA-UHFFFAOYSA-N 2-amino-3-(1-benzothiophen-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2SC=CC2=C1 MWIJOUKBVWNDBA-UHFFFAOYSA-N 0.000 description 1
- ZMEQBUUMQCKEBP-UHFFFAOYSA-N 2-amino-3-(1-benzothiophen-6-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2C=CSC2=C1 ZMEQBUUMQCKEBP-UHFFFAOYSA-N 0.000 description 1
- AQRCHORVCBGJPG-UHFFFAOYSA-N 2-amino-3-(1-benzothiophen-7-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1SC=C2 AQRCHORVCBGJPG-UHFFFAOYSA-N 0.000 description 1
- FGGPWDJPMFHYTE-UHFFFAOYSA-N 2-amino-3-(1-fluorocyclopropyl)butanoic acid Chemical compound OC(=O)C(N)C(C)C1(F)CC1 FGGPWDJPMFHYTE-UHFFFAOYSA-N 0.000 description 1
- MYFWUKZYURBPHI-UHFFFAOYSA-N 2-amino-3-(1h-imidazol-2-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=NC=CN1 MYFWUKZYURBPHI-UHFFFAOYSA-N 0.000 description 1
- QRQIQGUIEJQCKU-UHFFFAOYSA-N 2-amino-3-(1h-inden-1-yl)propanoic acid Chemical compound C1=CC=C2C(CC(N)C(O)=O)C=CC2=C1 QRQIQGUIEJQCKU-UHFFFAOYSA-N 0.000 description 1
- SHMNFTNLPZMSSC-UHFFFAOYSA-N 2-amino-3-(1h-inden-2-yl)propanoic acid Chemical compound C1=CC=C2CC(CC(N)C(O)=O)=CC2=C1 SHMNFTNLPZMSSC-UHFFFAOYSA-N 0.000 description 1
- LTNXGTOXJVWQIB-UHFFFAOYSA-N 2-amino-3-(1h-inden-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1C=CC2 LTNXGTOXJVWQIB-UHFFFAOYSA-N 0.000 description 1
- PZAIIOLEODEAFH-UHFFFAOYSA-N 2-amino-3-(1h-inden-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2CC=CC2=C1 PZAIIOLEODEAFH-UHFFFAOYSA-N 0.000 description 1
- KYNMONSTYCGIDJ-UHFFFAOYSA-N 2-amino-3-(1h-indol-2-yl)propanoic acid Chemical compound C1=CC=C2NC(CC(N)C(O)=O)=CC2=C1 KYNMONSTYCGIDJ-UHFFFAOYSA-N 0.000 description 1
- DSEIRMIVNPCUSR-UHFFFAOYSA-N 2-amino-3-(1h-indol-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1C=CN2 DSEIRMIVNPCUSR-UHFFFAOYSA-N 0.000 description 1
- AYNAZYTXSBGFDA-UHFFFAOYSA-N 2-amino-3-(1h-indol-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2NC=CC2=C1 AYNAZYTXSBGFDA-UHFFFAOYSA-N 0.000 description 1
- LFCGLYKVUKDXRB-UHFFFAOYSA-N 2-amino-3-(1h-indol-6-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2C=CNC2=C1 LFCGLYKVUKDXRB-UHFFFAOYSA-N 0.000 description 1
- PQDAIODTDQJFBL-UHFFFAOYSA-N 2-amino-3-(1h-indol-7-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1NC=C2 PQDAIODTDQJFBL-UHFFFAOYSA-N 0.000 description 1
- CRANRHDFXPQPHR-UHFFFAOYSA-N 2-amino-3-(1h-pyrazol-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC=1C=NNC=1 CRANRHDFXPQPHR-UHFFFAOYSA-N 0.000 description 1
- FKUWYXIMABQGMF-UHFFFAOYSA-N 2-amino-3-(2,3-dihydropyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(N)CN1CCC=C1 FKUWYXIMABQGMF-UHFFFAOYSA-N 0.000 description 1
- UMWQSCXOOZSRBV-UHFFFAOYSA-N 2-amino-3-(2,5-dihydropyrrol-1-yl)propanoic acid Chemical compound OC(=O)C(N)CN1CC=CC1 UMWQSCXOOZSRBV-UHFFFAOYSA-N 0.000 description 1
- RFLNCUQAJCTEPH-UHFFFAOYSA-N 2-amino-3-(2,6-dibromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)C(N)CC1=C(Br)C=C(O)C=C1Br RFLNCUQAJCTEPH-UHFFFAOYSA-N 0.000 description 1
- UBPJIGYYLTZEDD-UHFFFAOYSA-N 2-amino-3-(2-bromo-4-hydroxyphenyl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1Br UBPJIGYYLTZEDD-UHFFFAOYSA-N 0.000 description 1
- WLKQYWCVYKPBNI-UHFFFAOYSA-N 2-amino-3-(2-methylphenyl)butanoic acid Chemical compound OC(=O)C(N)C(C)C1=CC=CC=C1C WLKQYWCVYKPBNI-UHFFFAOYSA-N 0.000 description 1
- KJEPNWSIRGXVJW-UHFFFAOYSA-N 2-amino-3-(2-methylphenyl)pentanoic acid Chemical compound OC(=O)C(N)C(CC)C1=CC=CC=C1C KJEPNWSIRGXVJW-UHFFFAOYSA-N 0.000 description 1
- XNSBFNWYYMCJQK-UHFFFAOYSA-N 2-amino-3-(3,4-dihydro-2h-pyrrol-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=NCCC1 XNSBFNWYYMCJQK-UHFFFAOYSA-N 0.000 description 1
- VBGFOTANPCSLFG-UHFFFAOYSA-N 2-amino-3-(3,4-dihydropyrazol-2-yl)propanoic acid Chemical compound OC(=O)C(N)CN1CCC=N1 VBGFOTANPCSLFG-UHFFFAOYSA-N 0.000 description 1
- OQQBKJSFHLREQY-UHFFFAOYSA-N 2-amino-3-(3-methylphenyl)butanoic acid Chemical compound OC(=O)C(N)C(C)C1=CC=CC(C)=C1 OQQBKJSFHLREQY-UHFFFAOYSA-N 0.000 description 1
- JRPQYEOGMZHGQB-UHFFFAOYSA-N 2-amino-3-(3-methylphenyl)pentanoic acid Chemical compound OC(=O)C(N)C(CC)C1=CC=CC(C)=C1 JRPQYEOGMZHGQB-UHFFFAOYSA-N 0.000 description 1
- VSGNAKWQBBNZBC-UHFFFAOYSA-N 2-amino-3-(3h-inden-1-yl)propanoic acid Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CCC2=C1 VSGNAKWQBBNZBC-UHFFFAOYSA-N 0.000 description 1
- CFIDLQROYKTLLT-UHFFFAOYSA-N 2-amino-3-(3h-inden-4-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC2=C1CC=C2 CFIDLQROYKTLLT-UHFFFAOYSA-N 0.000 description 1
- WUHMURZAALSAGM-UHFFFAOYSA-N 2-amino-3-(3h-inden-5-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=CC=C2C=CCC2=C1 WUHMURZAALSAGM-UHFFFAOYSA-N 0.000 description 1
- OTWWSNSXZPBHHT-UHFFFAOYSA-N 2-amino-3-(4,5-dihydro-3h-pyrazol-3-yl)propanoic acid Chemical compound OC(=O)C(N)CC1CCN=N1 OTWWSNSXZPBHHT-UHFFFAOYSA-N 0.000 description 1
- HUGAWXCWXHSPBW-UHFFFAOYSA-N 2-amino-3-(4-hydroxycyclohexyl)propanoic acid Chemical compound OC(=O)C(N)CC1CCC(O)CC1 HUGAWXCWXHSPBW-UHFFFAOYSA-N 0.000 description 1
- GPGTWVGYQOTGDY-UHFFFAOYSA-N 2-amino-3-(7h-purin-2-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=NC=C2NC=NC2=N1 GPGTWVGYQOTGDY-UHFFFAOYSA-N 0.000 description 1
- IIWHRHDINDTBLI-UHFFFAOYSA-N 2-amino-3-(7h-purin-6-yl)propanoic acid Chemical compound OC(=O)C(N)CC1=NC=NC2=C1NC=N2 IIWHRHDINDTBLI-UHFFFAOYSA-N 0.000 description 1
- SSQHOESYULAMQS-UHFFFAOYSA-N 2-amino-3-(7h-purin-8-yl)propanoic acid Chemical compound C1=NC=C2NC(CC(N)C(O)=O)=NC2=N1 SSQHOESYULAMQS-UHFFFAOYSA-N 0.000 description 1
- AYAXJTKSICHTNF-UHFFFAOYSA-N 2-amino-3-(aminomethyl)pentanoic acid Chemical compound CCC(CN)C(N)C(O)=O AYAXJTKSICHTNF-UHFFFAOYSA-N 0.000 description 1
- JIZBYCXGVFKHFF-UHFFFAOYSA-N 2-amino-3-(benzimidazol-1-yl)propanoic acid Chemical compound C1=CC=C2N(CC(N)C(O)=O)C=NC2=C1 JIZBYCXGVFKHFF-UHFFFAOYSA-N 0.000 description 1
- SRGOJUDAJKUDAZ-UHFFFAOYSA-N 2-amino-3-cyclobutylpropanoic acid Chemical compound OC(=O)C(N)CC1CCC1 SRGOJUDAJKUDAZ-UHFFFAOYSA-N 0.000 description 1
- FWBXNMSLCRNZOV-UHFFFAOYSA-N 2-amino-3-imidazol-1-ylpropanoic acid Chemical compound OC(=O)C(N)CN1C=CN=C1 FWBXNMSLCRNZOV-UHFFFAOYSA-N 0.000 description 1
- FHJNAFIJPFGZRI-UHFFFAOYSA-N 2-amino-3-methylpentanedioic acid Chemical compound OC(=O)CC(C)C(N)C(O)=O FHJNAFIJPFGZRI-UHFFFAOYSA-N 0.000 description 1
- RDGVMNXEKUTFQK-UHFFFAOYSA-N 2-amino-3-purin-9-ylpropanoic acid Chemical compound N1=CN=C2N(CC(N)C(O)=O)C=NC2=C1 RDGVMNXEKUTFQK-UHFFFAOYSA-N 0.000 description 1
- NOOACUGMFYWDFI-UHFFFAOYSA-N 2-amino-3-pyrazolidin-4-ylpropanoic acid Chemical compound OC(=O)C(N)CC1CNNC1 NOOACUGMFYWDFI-UHFFFAOYSA-N 0.000 description 1
- BGMINVIHGGTWEC-UHFFFAOYSA-N 2-amino-3-pyridazin-3-ylpropanoic acid Chemical compound OC(=O)C(N)CC1=CC=CN=N1 BGMINVIHGGTWEC-UHFFFAOYSA-N 0.000 description 1
- IOIQFYKCCUDSQT-UHFFFAOYSA-N 2-amino-3-pyridazin-4-ylpropanoic acid Chemical compound OC(=O)C(N)CC1=CC=NN=C1 IOIQFYKCCUDSQT-UHFFFAOYSA-N 0.000 description 1
- XCNOBDDQOATTBY-UHFFFAOYSA-N 2-amino-3-pyrimidin-2-ylpropanoic acid Chemical compound OC(=O)C(N)CC1=NC=CC=N1 XCNOBDDQOATTBY-UHFFFAOYSA-N 0.000 description 1
- UFURPNJIXOBVRS-UHFFFAOYSA-N 2-amino-3-pyrimidin-5-ylpropanoic acid Chemical compound OC(=O)C(N)CC1=CN=CN=C1 UFURPNJIXOBVRS-UHFFFAOYSA-N 0.000 description 1
- RVCJHIIAIHAVIP-UHFFFAOYSA-N 2-amino-3-pyrrolidin-1-ylpropanoic acid Chemical compound OC(=O)C(N)CN1CCCC1 RVCJHIIAIHAVIP-UHFFFAOYSA-N 0.000 description 1
- CNSSCDOMOBISKK-UHFFFAOYSA-N 2-amino-3-pyrrolidin-2-ylpropanoic acid Chemical compound OC(=O)C(N)CC1CCCN1 CNSSCDOMOBISKK-UHFFFAOYSA-N 0.000 description 1
- UJGNCYAOIKEUNK-UHFFFAOYSA-N 2-amino-3-pyrrolidin-3-ylpropanoic acid Chemical compound OC(=O)C(N)CC1CCNC1 UJGNCYAOIKEUNK-UHFFFAOYSA-N 0.000 description 1
- JHQMBIHFFZPIBF-UHFFFAOYSA-N 2-amino-4-(1,3-dihydropyrazol-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCN1CC=CN1 JHQMBIHFFZPIBF-UHFFFAOYSA-N 0.000 description 1
- OYPYALDLHJXFOC-UHFFFAOYSA-N 2-amino-4-(1,5-dihydropyrazol-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCN1NCC=C1 OYPYALDLHJXFOC-UHFFFAOYSA-N 0.000 description 1
- SFYRVTIJGYHIJW-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-2-yl)butanoic acid Chemical compound C1=CC=C2SC(CCC(N)C(O)=O)=CC2=C1 SFYRVTIJGYHIJW-UHFFFAOYSA-N 0.000 description 1
- OPHZMYNHCQNOHH-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-3-yl)butanoic acid Chemical compound C1=CC=C2C(CCC(N)C(O)=O)=CSC2=C1 OPHZMYNHCQNOHH-UHFFFAOYSA-N 0.000 description 1
- FXDFUEIQNSVMPV-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1C=CS2 FXDFUEIQNSVMPV-UHFFFAOYSA-N 0.000 description 1
- ABNZWCJDXPVMJA-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2SC=CC2=C1 ABNZWCJDXPVMJA-UHFFFAOYSA-N 0.000 description 1
- MDXKGLMMDZXCMV-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-6-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2C=CSC2=C1 MDXKGLMMDZXCMV-UHFFFAOYSA-N 0.000 description 1
- CKOWTADGDRGFJP-UHFFFAOYSA-N 2-amino-4-(1-benzothiophen-7-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1SC=C2 CKOWTADGDRGFJP-UHFFFAOYSA-N 0.000 description 1
- ULRAOHIYUQZJKV-UHFFFAOYSA-N 2-amino-4-(1h-benzimidazol-2-yl)butanoic acid Chemical compound C1=CC=C2NC(CCC(N)C(O)=O)=NC2=C1 ULRAOHIYUQZJKV-UHFFFAOYSA-N 0.000 description 1
- AOYWNLYMEZIHOZ-UHFFFAOYSA-N 2-amino-4-(1h-imidazol-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=NC=CN1 AOYWNLYMEZIHOZ-UHFFFAOYSA-N 0.000 description 1
- REHFLKQWKZJSGN-UHFFFAOYSA-N 2-amino-4-(1h-inden-1-yl)butanoic acid Chemical compound C1=CC=C2C(CCC(N)C(O)=O)C=CC2=C1 REHFLKQWKZJSGN-UHFFFAOYSA-N 0.000 description 1
- KHJAXNJUNSKIPT-UHFFFAOYSA-N 2-amino-4-(1h-inden-2-yl)butanoic acid Chemical compound C1=CC=C2CC(CCC(N)C(O)=O)=CC2=C1 KHJAXNJUNSKIPT-UHFFFAOYSA-N 0.000 description 1
- PITBZKKAWYFKTI-UHFFFAOYSA-N 2-amino-4-(1h-inden-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1C=CC2 PITBZKKAWYFKTI-UHFFFAOYSA-N 0.000 description 1
- QUGFDAGMGLFSSJ-UHFFFAOYSA-N 2-amino-4-(1h-inden-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2CC=CC2=C1 QUGFDAGMGLFSSJ-UHFFFAOYSA-N 0.000 description 1
- ZSRIVBKUDGBDCZ-UHFFFAOYSA-N 2-amino-4-(1h-indol-2-yl)butanoic acid Chemical compound C1=CC=C2NC(CCC(N)C(O)=O)=CC2=C1 ZSRIVBKUDGBDCZ-UHFFFAOYSA-N 0.000 description 1
- GHKKIXUJIVFRRC-UHFFFAOYSA-N 2-amino-4-(1h-indol-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1C=CN2 GHKKIXUJIVFRRC-UHFFFAOYSA-N 0.000 description 1
- CEASKZFGMRUDHU-UHFFFAOYSA-N 2-amino-4-(1h-indol-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2NC=CC2=C1 CEASKZFGMRUDHU-UHFFFAOYSA-N 0.000 description 1
- KTVFKTJFBZWTCV-UHFFFAOYSA-N 2-amino-4-(1h-indol-6-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2C=CNC2=C1 KTVFKTJFBZWTCV-UHFFFAOYSA-N 0.000 description 1
- RGGSCAILNZCIDO-UHFFFAOYSA-N 2-amino-4-(1h-indol-7-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1NC=C2 RGGSCAILNZCIDO-UHFFFAOYSA-N 0.000 description 1
- RKOFPYXMTLRKKH-UHFFFAOYSA-N 2-amino-4-(1h-pyrazol-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC=1C=NNC=1 RKOFPYXMTLRKKH-UHFFFAOYSA-N 0.000 description 1
- XZGJMWOPNONOGZ-UHFFFAOYSA-N 2-amino-4-(2,3-dihydropyrrol-1-yl)butanoic acid Chemical compound OC(=O)C(N)CCN1CCC=C1 XZGJMWOPNONOGZ-UHFFFAOYSA-N 0.000 description 1
- CFESAJKRMAVFAY-UHFFFAOYSA-N 2-amino-4-(2,5-dihydropyrrol-1-yl)butanoic acid Chemical compound OC(=O)C(N)CCN1CC=CC1 CFESAJKRMAVFAY-UHFFFAOYSA-N 0.000 description 1
- AJCKYATVTAPOSH-UHFFFAOYSA-N 2-amino-4-(2-amino-2-oxoethyl)heptanoic acid Chemical compound CCCC(CC(N)=O)CC(N)C(O)=O AJCKYATVTAPOSH-UHFFFAOYSA-N 0.000 description 1
- UIINSJBTFLRMLY-UHFFFAOYSA-N 2-amino-4-(2-methylphenyl)butanoic acid Chemical compound CC1=CC=CC=C1CCC(N)C(O)=O UIINSJBTFLRMLY-UHFFFAOYSA-N 0.000 description 1
- DWFGDRDSDIAUHZ-UHFFFAOYSA-N 2-amino-4-(2-methylphenyl)pentanoic acid Chemical compound OC(=O)C(N)CC(C)C1=CC=CC=C1C DWFGDRDSDIAUHZ-UHFFFAOYSA-N 0.000 description 1
- XIZWSXXTFSGOIZ-UHFFFAOYSA-N 2-amino-4-(3,4-dihydro-2h-pyrrol-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=NCCC1 XIZWSXXTFSGOIZ-UHFFFAOYSA-N 0.000 description 1
- WNMFLJHPTJAHGR-UHFFFAOYSA-N 2-amino-4-(3,4-dihydropyrazol-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCN1CCC=N1 WNMFLJHPTJAHGR-UHFFFAOYSA-N 0.000 description 1
- KBLBWKYPVDWDJL-UHFFFAOYSA-N 2-amino-4-(3-methylphenyl)pentanoic acid Chemical compound OC(=O)C(N)CC(C)C1=CC=CC(C)=C1 KBLBWKYPVDWDJL-UHFFFAOYSA-N 0.000 description 1
- HOORMYFKMJGXTQ-UHFFFAOYSA-N 2-amino-4-(3h-inden-1-yl)butanoic acid Chemical compound C1=CC=C2C(CCC(N)C(O)=O)=CCC2=C1 HOORMYFKMJGXTQ-UHFFFAOYSA-N 0.000 description 1
- GCBPVUIXTRNOGP-UHFFFAOYSA-N 2-amino-4-(3h-inden-4-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CC2=C1CC=C2 GCBPVUIXTRNOGP-UHFFFAOYSA-N 0.000 description 1
- YDBHDXPGYKQYKJ-UHFFFAOYSA-N 2-amino-4-(3h-inden-5-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CC=C2C=CCC2=C1 YDBHDXPGYKQYKJ-UHFFFAOYSA-N 0.000 description 1
- MTGAHVUSOJQRAX-UHFFFAOYSA-N 2-amino-4-(4,5-dihydro-3h-pyrazol-3-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1CCN=N1 MTGAHVUSOJQRAX-UHFFFAOYSA-N 0.000 description 1
- NBOHLKADVKDEFR-UHFFFAOYSA-N 2-amino-4-(7h-purin-2-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=NC=C2NC=NC2=N1 NBOHLKADVKDEFR-UHFFFAOYSA-N 0.000 description 1
- VCOLSTQVXBJPIX-UHFFFAOYSA-N 2-amino-4-(7h-purin-6-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=NC=NC2=C1NC=N2 VCOLSTQVXBJPIX-UHFFFAOYSA-N 0.000 description 1
- SMSCDFWPGQOYPK-UHFFFAOYSA-N 2-amino-4-(7h-purin-8-yl)butanoic acid Chemical compound C1=NC=C2NC(CCC(N)C(O)=O)=NC2=N1 SMSCDFWPGQOYPK-UHFFFAOYSA-N 0.000 description 1
- CQVUDPOAHFIFAF-UHFFFAOYSA-N 2-amino-4-(benzimidazol-1-yl)butanoic acid Chemical compound C1=CC=C2N(CCC(N)C(O)=O)C=NC2=C1 CQVUDPOAHFIFAF-UHFFFAOYSA-N 0.000 description 1
- ZOPDGQCODFPDAQ-UHFFFAOYSA-N 2-amino-4-(cyclopenten-1-yl)butanoic acid Chemical compound OC(=O)C(N)CCC1=CCCC1 ZOPDGQCODFPDAQ-UHFFFAOYSA-N 0.000 description 1
- JIUHDQRXTPIQSV-UHFFFAOYSA-N 2-amino-4-chlorobutanoic acid Chemical compound OC(=O)C(N)CCCl JIUHDQRXTPIQSV-UHFFFAOYSA-N 0.000 description 1
- IHESYJFOPIMOGO-UHFFFAOYSA-N 2-amino-4-cyclobutylbutanoic acid Chemical compound OC(=O)C(N)CCC1CCC1 IHESYJFOPIMOGO-UHFFFAOYSA-N 0.000 description 1
- LKXHGSLJBHXRFI-UHFFFAOYSA-N 2-amino-4-cyclopentylbutanoic acid Chemical compound OC(=O)C(N)CCC1CCCC1 LKXHGSLJBHXRFI-UHFFFAOYSA-N 0.000 description 1
- XQBROTNHOLWMJR-UHFFFAOYSA-N 2-amino-4-cyclopropylbutanoic acid Chemical compound OC(=O)C(N)CCC1CC1 XQBROTNHOLWMJR-UHFFFAOYSA-N 0.000 description 1
- RNDKANKZXDNZKY-UHFFFAOYSA-N 2-amino-4-imidazol-1-ylbutanoic acid Chemical compound OC(=O)C(N)CCN1C=CN=C1 RNDKANKZXDNZKY-UHFFFAOYSA-N 0.000 description 1
- UVYOZWOEKOMIPR-UHFFFAOYSA-N 2-amino-4-indol-1-ylbutanoic acid Chemical compound C1=CC=C2N(CCC(N)C(O)=O)C=CC2=C1 UVYOZWOEKOMIPR-UHFFFAOYSA-N 0.000 description 1
- KJMNIAISRUFCAM-UHFFFAOYSA-N 2-amino-4-purin-9-ylbutanoic acid Chemical compound N1=CN=C2N(CCC(N)C(O)=O)C=NC2=C1 KJMNIAISRUFCAM-UHFFFAOYSA-N 0.000 description 1
- KWAMNEICFOVNJI-UHFFFAOYSA-N 2-amino-4-pyrazol-1-ylbutanoic acid Chemical compound OC(=O)C(N)CCN1C=CC=N1 KWAMNEICFOVNJI-UHFFFAOYSA-N 0.000 description 1
- PQRAYVHILUICJR-UHFFFAOYSA-N 2-amino-4-pyrazolidin-4-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1CNNC1 PQRAYVHILUICJR-UHFFFAOYSA-N 0.000 description 1
- VAYGUGGKWYCVKM-UHFFFAOYSA-N 2-amino-4-pyridazin-3-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CC=CN=N1 VAYGUGGKWYCVKM-UHFFFAOYSA-N 0.000 description 1
- JUKASKRPYDFOIR-UHFFFAOYSA-N 2-amino-4-pyridazin-4-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CC=NN=C1 JUKASKRPYDFOIR-UHFFFAOYSA-N 0.000 description 1
- WHCQVPISOOTNON-UHFFFAOYSA-N 2-amino-4-pyridin-4-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CC=NC=C1 WHCQVPISOOTNON-UHFFFAOYSA-N 0.000 description 1
- SKIUFGYQPSYKLF-UHFFFAOYSA-N 2-amino-4-pyrimidin-2-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=NC=CC=N1 SKIUFGYQPSYKLF-UHFFFAOYSA-N 0.000 description 1
- CLFJLLMVFMNLQJ-UHFFFAOYSA-N 2-amino-4-pyrimidin-5-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1=CN=CN=C1 CLFJLLMVFMNLQJ-UHFFFAOYSA-N 0.000 description 1
- KHMINASOVGHESH-UHFFFAOYSA-N 2-amino-4-pyrrolidin-1-ylbutanoic acid Chemical compound OC(=O)C(N)CCN1CCCC1 KHMINASOVGHESH-UHFFFAOYSA-N 0.000 description 1
- FBFZLYZNUOPKLY-UHFFFAOYSA-N 2-amino-4-pyrrolidin-2-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1CCCN1 FBFZLYZNUOPKLY-UHFFFAOYSA-N 0.000 description 1
- PXRNBVDSALFNSS-UHFFFAOYSA-N 2-amino-4-pyrrolidin-3-ylbutanoic acid Chemical compound OC(=O)C(N)CCC1CCNC1 PXRNBVDSALFNSS-UHFFFAOYSA-N 0.000 description 1
- AFNWNZIDMQCYFS-UHFFFAOYSA-N 2-amino-5-(2-amino-2-oxoethyl)octanoic acid Chemical compound CCCC(CC(N)=O)CCC(N)C(O)=O AFNWNZIDMQCYFS-UHFFFAOYSA-N 0.000 description 1
- LRESZXOPCNUUHN-UHFFFAOYSA-N 2-amino-5-(2-methylphenyl)hexanoic acid Chemical compound OC(=O)C(N)CCC(C)C1=CC=CC=C1C LRESZXOPCNUUHN-UHFFFAOYSA-N 0.000 description 1
- PZMHBFICRGDBNW-UHFFFAOYSA-N 2-amino-5-(2-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC=C1CCCC(N)C(O)=O PZMHBFICRGDBNW-UHFFFAOYSA-N 0.000 description 1
- NGXJROYMSDVUMO-UHFFFAOYSA-N 2-amino-5-(3-methylphenyl)hexanoic acid Chemical compound OC(=O)C(N)CCC(C)C1=CC=CC(C)=C1 NGXJROYMSDVUMO-UHFFFAOYSA-N 0.000 description 1
- GWKPQPNDWDPPQD-UHFFFAOYSA-N 2-amino-5-(3-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC(CCCC(N)C(O)=O)=C1 GWKPQPNDWDPPQD-UHFFFAOYSA-N 0.000 description 1
- FLLAQJKZHFRXEQ-UHFFFAOYSA-N 2-amino-5-carbamoylheptanoic acid Chemical compound CCC(C(N)=O)CCC(N)C(O)=O FLLAQJKZHFRXEQ-UHFFFAOYSA-N 0.000 description 1
- FPJGDMJAIRYLBP-UHFFFAOYSA-N 2-amino-5-carbamoyloctanoic acid Chemical compound CCCC(C(N)=O)CCC(N)C(O)=O FPJGDMJAIRYLBP-UHFFFAOYSA-N 0.000 description 1
- FYMRPJYQCOSYAQ-UHFFFAOYSA-N 2-amino-6-(2-methylphenyl)hexanoic acid Chemical compound CC1=CC=CC=C1CCCCC(N)C(O)=O FYMRPJYQCOSYAQ-UHFFFAOYSA-N 0.000 description 1
- KGVWKKLWONQKOG-UHFFFAOYSA-N 2-amino-6-(3-methylphenyl)hexanoic acid Chemical compound CC1=CC=CC(CCCCC(N)C(O)=O)=C1 KGVWKKLWONQKOG-UHFFFAOYSA-N 0.000 description 1
- CBAWNLIZBXJSFS-UHFFFAOYSA-N 2-amino-6-(propan-2-ylamino)hexanoic acid Chemical compound CC(C)NCCCCC(N)C(O)=O CBAWNLIZBXJSFS-UHFFFAOYSA-N 0.000 description 1
- HDIIAKZNFLPDPT-UHFFFAOYSA-N 2-amino-6-methylheptanoic acid Chemical compound CC(C)CCCC(N)C(O)=O HDIIAKZNFLPDPT-UHFFFAOYSA-N 0.000 description 1
- PZXDKILRPSNHBC-UHFFFAOYSA-N 2-amino-6-phenylhexanoic acid Chemical compound OC(=O)C(N)CCCCC1=CC=CC=C1 PZXDKILRPSNHBC-UHFFFAOYSA-N 0.000 description 1
- DSUAJFIEKRKPEE-UHFFFAOYSA-N 2-aminobut-3-ynoic acid Chemical compound C#CC(N)C(O)=O DSUAJFIEKRKPEE-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- WAMWSIDTKSNDCU-UHFFFAOYSA-N 2-azaniumyl-2-cyclohexylacetate Chemical compound OC(=O)C(N)C1CCCCC1 WAMWSIDTKSNDCU-UHFFFAOYSA-N 0.000 description 1
- BUSBCPMSNBMUMT-UHFFFAOYSA-N 2-azaniumyl-2-cyclopropylacetate Chemical compound OC(=O)C(N)C1CC1 BUSBCPMSNBMUMT-UHFFFAOYSA-N 0.000 description 1
- VRFYYCFVOBCXDL-UHFFFAOYSA-N 2-azaniumyl-2-cyclopropylpropanoate Chemical compound OC(=O)C(N)(C)C1CC1 VRFYYCFVOBCXDL-UHFFFAOYSA-N 0.000 description 1
- KWOMLHIFHFWBSB-UHFFFAOYSA-N 2-azaniumyl-2-ethylbutanoate Chemical compound CCC(N)(CC)C(O)=O KWOMLHIFHFWBSB-UHFFFAOYSA-N 0.000 description 1
- XRYMBDSTGWVPBC-UHFFFAOYSA-N 2-azaniumyl-3-(1-benzothiophen-2-yl)propanoate Chemical compound C1=CC=C2SC(CC(N)C(O)=O)=CC2=C1 XRYMBDSTGWVPBC-UHFFFAOYSA-N 0.000 description 1
- GAUUPDQWKHTCAX-UHFFFAOYSA-N 2-azaniumyl-3-(1-benzothiophen-3-yl)propanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CSC2=C1 GAUUPDQWKHTCAX-UHFFFAOYSA-N 0.000 description 1
- UERIWNMZWSIKSK-UHFFFAOYSA-N 2-azaniumyl-3-(1h-benzimidazol-2-yl)propanoate Chemical compound C1=CC=C2NC(CC(N)C(O)=O)=NC2=C1 UERIWNMZWSIKSK-UHFFFAOYSA-N 0.000 description 1
- MNHWYCRCODAGAH-UHFFFAOYSA-N 2-azaniumyl-3-(cyclopenten-1-yl)propanoate Chemical compound OC(=O)C(N)CC1=CCCC1 MNHWYCRCODAGAH-UHFFFAOYSA-N 0.000 description 1
- ORQXBVXKBGUSBA-UHFFFAOYSA-N 2-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)C(N)CC1CCCCC1 ORQXBVXKBGUSBA-UHFFFAOYSA-N 0.000 description 1
- KDYAKYRBGLKMAK-UHFFFAOYSA-N 2-azaniumyl-3-cyclopentylpropanoate Chemical compound OC(=O)C(N)CC1CCCC1 KDYAKYRBGLKMAK-UHFFFAOYSA-N 0.000 description 1
- PZMGYYOIDASHPT-UHFFFAOYSA-N 2-azaniumyl-3-indol-1-ylpropanoate Chemical compound C1=CC=C2N(CC(N)C(O)=O)C=CC2=C1 PZMGYYOIDASHPT-UHFFFAOYSA-N 0.000 description 1
- IDIDJDIHTAOVLG-UHFFFAOYSA-N 2-azaniumyl-3-methylsulfanylpropanoate Chemical compound CSCC(N)C(O)=O IDIDJDIHTAOVLG-UHFFFAOYSA-N 0.000 description 1
- ADJZXDVMJPTFKT-UHFFFAOYSA-N 2-azaniumyl-4-(1h-indol-3-yl)butanoate Chemical compound C1=CC=C2C(CCC(N)C(O)=O)=CNC2=C1 ADJZXDVMJPTFKT-UHFFFAOYSA-N 0.000 description 1
- LOOZZTFGSTZNRX-UHFFFAOYSA-N 2-azaniumyl-4-(4-hydroxyphenyl)butanoate Chemical compound OC(=O)C(N)CCC1=CC=C(O)C=C1 LOOZZTFGSTZNRX-UHFFFAOYSA-N 0.000 description 1
- MXHKOHWUQAULOV-UHFFFAOYSA-N 2-azaniumyl-4-cyclohexylbutanoate Chemical compound OC(=O)C(N)CCC1CCCCC1 MXHKOHWUQAULOV-UHFFFAOYSA-N 0.000 description 1
- LJYFXGDRJCHELF-UHFFFAOYSA-N 2-azaniumyl-4-fluorobutanoate Chemical compound OC(=O)C(N)CCF LJYFXGDRJCHELF-UHFFFAOYSA-N 0.000 description 1
- PABWDKROPVYJBH-UHFFFAOYSA-N 2-azaniumyl-4-methylpent-4-enoate Chemical compound CC(=C)CC(N)C(O)=O PABWDKROPVYJBH-UHFFFAOYSA-N 0.000 description 1
- YQORMSBFOZKIPW-UHFFFAOYSA-N 2-pyridin-1-ium-4-ylbutanoate Chemical compound CCC(C(O)=O)C1=CC=NC=C1 YQORMSBFOZKIPW-UHFFFAOYSA-N 0.000 description 1
- MBMKGIRTTXAGCM-YFKPBYRVSA-N 3, 4 Dihydroxy phenyl alanine Chemical class OC(=O)[C@H](C)NC1=CC=C(O)C(O)=C1 MBMKGIRTTXAGCM-YFKPBYRVSA-N 0.000 description 1
- IDLBQMQTRMNVMQ-UHFFFAOYSA-N 3,4-diamino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound NCC(N)C(C(O)=O)C1(F)CC1 IDLBQMQTRMNVMQ-UHFFFAOYSA-N 0.000 description 1
- YYMFMQGINGSALK-UHFFFAOYSA-N 3,4-diamino-2-cyclopropylbutanoic acid Chemical compound NCC(N)C(C(O)=O)C1CC1 YYMFMQGINGSALK-UHFFFAOYSA-N 0.000 description 1
- YBHCAAXCOVDOPM-UHFFFAOYSA-N 3,4-diamino-2-ethylbutanoic acid Chemical compound CCC(C(O)=O)C(N)CN YBHCAAXCOVDOPM-UHFFFAOYSA-N 0.000 description 1
- WINSMAQNWGIWPD-UHFFFAOYSA-N 3,4-diamino-2-methylbutanoic acid Chemical compound OC(=O)C(C)C(N)CN WINSMAQNWGIWPD-UHFFFAOYSA-N 0.000 description 1
- OZQHIQKQJPQMHF-UHFFFAOYSA-N 3,4-diamino-3-(1-fluorocyclopropyl)butanoic acid Chemical compound OC(=O)CC(N)(CN)C1(F)CC1 OZQHIQKQJPQMHF-UHFFFAOYSA-N 0.000 description 1
- BMUAPNPINJZBPZ-UHFFFAOYSA-N 3,4-diamino-3-cyclopropylbutanoic acid Chemical compound OC(=O)CC(N)(CN)C1CC1 BMUAPNPINJZBPZ-UHFFFAOYSA-N 0.000 description 1
- RZJYHYAHDCJBNG-UHFFFAOYSA-N 3,4-diamino-3-methylbutanoic acid Chemical compound NCC(N)(C)CC(O)=O RZJYHYAHDCJBNG-UHFFFAOYSA-N 0.000 description 1
- XQKAYTBBWLDCBB-UHFFFAOYSA-N 3,4-diaminobutanoic acid Chemical compound NCC(N)CC(O)=O XQKAYTBBWLDCBB-UHFFFAOYSA-N 0.000 description 1
- PIGOPELHGLPKLL-UHFFFAOYSA-N 3-(1-Pyrazolyl)-alanine Chemical compound OC(=O)C(N)CN1C=CC=N1 PIGOPELHGLPKLL-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- MVIPFBVXMASPHV-UHFFFAOYSA-N 3-(azaniumylmethyl)pentanoate Chemical compound CCC(CN)CC(O)=O MVIPFBVXMASPHV-UHFFFAOYSA-N 0.000 description 1
- DSYQMRHMLVMLEZ-UHFFFAOYSA-N 3-amino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound CC(N)C(C(O)=O)C1(F)CC1 DSYQMRHMLVMLEZ-UHFFFAOYSA-N 0.000 description 1
- CNIXAGWQEYLQPN-UHFFFAOYSA-N 3-amino-2-(1-fluorocyclopropyl)propanoic acid Chemical compound NCC(C(O)=O)C1(F)CC1 CNIXAGWQEYLQPN-UHFFFAOYSA-N 0.000 description 1
- XBWADSKORQXTME-UHFFFAOYSA-N 3-amino-2-cyclopropylbutanoic acid Chemical compound CC(N)C(C(O)=O)C1CC1 XBWADSKORQXTME-UHFFFAOYSA-N 0.000 description 1
- GWSRYTJGJLAQJM-UHFFFAOYSA-N 3-amino-2-cyclopropylpropanoic acid Chemical compound NCC(C(O)=O)C1CC1 GWSRYTJGJLAQJM-UHFFFAOYSA-N 0.000 description 1
- KGMSPEUDMJLUJD-UHFFFAOYSA-N 3-amino-2-ethylbutanoic acid Chemical compound CCC(C(C)N)C(O)=O KGMSPEUDMJLUJD-UHFFFAOYSA-N 0.000 description 1
- HBIBKHLPZISQSI-UHFFFAOYSA-N 3-amino-3-(1-fluorocyclopropyl)butanoic acid Chemical compound OC(=O)CC(N)(C)C1(F)CC1 HBIBKHLPZISQSI-UHFFFAOYSA-N 0.000 description 1
- WJJBIFDWZLRRLN-UHFFFAOYSA-N 3-amino-3-(aminomethyl)pentanoic acid Chemical compound CCC(N)(CN)CC(O)=O WJJBIFDWZLRRLN-UHFFFAOYSA-N 0.000 description 1
- OELQFMFNZSFSOD-UHFFFAOYSA-N 3-amino-3-cyclopropylbutanoic acid Chemical compound OC(=O)CC(N)(C)C1CC1 OELQFMFNZSFSOD-UHFFFAOYSA-N 0.000 description 1
- NFQAIWOMJQWGSS-UHFFFAOYSA-N 3-amino-3-methylbutanoic acid Chemical compound CC(C)(N)CC(O)=O NFQAIWOMJQWGSS-UHFFFAOYSA-N 0.000 description 1
- WCYAXBNGDLLWRW-UHFFFAOYSA-N 3-amino-3-methylpentanoic acid Chemical compound CCC(C)(N)CC(O)=O WCYAXBNGDLLWRW-UHFFFAOYSA-N 0.000 description 1
- AEOIJAMROWJLDU-UHFFFAOYSA-N 3-amino-4-(2-methylphenyl)hexanoic acid Chemical compound OC(=O)CC(N)C(CC)C1=CC=CC=C1C AEOIJAMROWJLDU-UHFFFAOYSA-N 0.000 description 1
- SVTWLDMIJVZQDH-UHFFFAOYSA-N 3-amino-4-(3-methylphenyl)hexanoic acid Chemical compound OC(=O)CC(N)C(CC)C1=CC=CC(C)=C1 SVTWLDMIJVZQDH-UHFFFAOYSA-N 0.000 description 1
- OKDROELELKNZTD-UHFFFAOYSA-N 3-amino-4-(3-methylphenyl)pentanoic acid Chemical compound OC(=O)CC(N)C(C)C1=CC=CC(C)=C1 OKDROELELKNZTD-UHFFFAOYSA-N 0.000 description 1
- VQWQTJIWRUQHHN-UHFFFAOYSA-N 3-amino-4-phenylhexanoic acid Chemical compound OC(=O)CC(N)C(CC)C1=CC=CC=C1 VQWQTJIWRUQHHN-UHFFFAOYSA-N 0.000 description 1
- UYEJDMAQVBOJDY-UHFFFAOYSA-N 3-amino-5-(2-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC=C1CCC(N)CC(O)=O UYEJDMAQVBOJDY-UHFFFAOYSA-N 0.000 description 1
- LQAPTTAUYDMEST-UHFFFAOYSA-N 3-amino-5-(3-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC(CCC(N)CC(O)=O)=C1 LQAPTTAUYDMEST-UHFFFAOYSA-N 0.000 description 1
- XOKGQDIAQWBCCF-UHFFFAOYSA-N 3-amino-6-(2-methylphenyl)hexanoic acid Chemical compound CC1=CC=CC=C1CCCC(N)CC(O)=O XOKGQDIAQWBCCF-UHFFFAOYSA-N 0.000 description 1
- PKVCUMVBCBYSEB-UHFFFAOYSA-N 3-amino-6-(3-methylphenyl)hexanoic acid Chemical compound CC1=CC=CC(CCCC(N)CC(O)=O)=C1 PKVCUMVBCBYSEB-UHFFFAOYSA-N 0.000 description 1
- XRPJKCWKLKTFIQ-UHFFFAOYSA-N 3-amino-6-methylheptanoic acid Chemical compound CC(C)CCC(N)CC(O)=O XRPJKCWKLKTFIQ-UHFFFAOYSA-N 0.000 description 1
- RRWPLOJQTOADRZ-UHFFFAOYSA-N 3-azaniumyl-2-methylbutanoate Chemical compound CC(N)C(C)C(O)=O RRWPLOJQTOADRZ-UHFFFAOYSA-N 0.000 description 1
- PBGLTHUKEHCADU-UHFFFAOYSA-N 3-azaniumyl-4-(2-methylphenyl)butanoate Chemical compound CC1=CC=CC=C1CC(N)CC(O)=O PBGLTHUKEHCADU-UHFFFAOYSA-N 0.000 description 1
- SMOOMZALOMCYEF-UHFFFAOYSA-N 3-azaniumyl-4-(3-methylphenyl)butanoate Chemical compound CC1=CC=CC(CC(N)CC(O)=O)=C1 SMOOMZALOMCYEF-UHFFFAOYSA-N 0.000 description 1
- HGWOSUKIFQMEIF-ZETCQYMHSA-N 3-bromo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Br)=C1 HGWOSUKIFQMEIF-ZETCQYMHSA-N 0.000 description 1
- ACWBBAGYTKWBCD-ZETCQYMHSA-N 3-chloro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(Cl)=C1 ACWBBAGYTKWBCD-ZETCQYMHSA-N 0.000 description 1
- BXRLWGXPSRYJDZ-UHFFFAOYSA-N 3-cyanoalanine Chemical compound OC(=O)C(N)CC#N BXRLWGXPSRYJDZ-UHFFFAOYSA-N 0.000 description 1
- VIIAUOZUUGXERI-ZETCQYMHSA-N 3-fluoro-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(F)=C1 VIIAUOZUUGXERI-ZETCQYMHSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- MQHLULPKDLJASZ-QMMMGPOBSA-N 3-methyl-L-tyrosine zwitterion Chemical compound CC1=CC(C[C@H](N)C(O)=O)=CC=C1O MQHLULPKDLJASZ-QMMMGPOBSA-N 0.000 description 1
- JVQIKJMSUIMUDI-UHFFFAOYSA-N 3-pyrroline Chemical compound C1NCC=C1 JVQIKJMSUIMUDI-UHFFFAOYSA-N 0.000 description 1
- QXZBMSIDSOZZHK-DOPDSADYSA-N 31362-50-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CNC=N1 QXZBMSIDSOZZHK-DOPDSADYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- MLVJMSRGLQCZDE-UHFFFAOYSA-N 4-[2-(9h-fluoren-9-ylmethoxycarbonyl)hydrazinyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 MLVJMSRGLQCZDE-UHFFFAOYSA-N 0.000 description 1
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 1
- IPXDGVZRRPNFRX-UHFFFAOYSA-N 4-amino-2-(1-fluorocyclopropyl)butanoic acid Chemical compound NCCC(C(O)=O)C1(F)CC1 IPXDGVZRRPNFRX-UHFFFAOYSA-N 0.000 description 1
- JFSHBZBVQPUEBZ-UHFFFAOYSA-N 4-amino-2-cyclopropylbutanoic acid Chemical compound NCCC(C(O)=O)C1CC1 JFSHBZBVQPUEBZ-UHFFFAOYSA-N 0.000 description 1
- SOOCLGXZSDVHSO-UHFFFAOYSA-N 4-amino-2-ethylbutanoic acid Chemical compound CCC(C(O)=O)CCN SOOCLGXZSDVHSO-UHFFFAOYSA-N 0.000 description 1
- URBRECLQFCFSNG-UHFFFAOYSA-N 4-amino-3-(1-fluorocyclopropyl)butanoic acid Chemical compound OC(=O)CC(CN)C1(F)CC1 URBRECLQFCFSNG-UHFFFAOYSA-N 0.000 description 1
- GMMGKUPDAMGCEW-UHFFFAOYSA-N 4-amino-3-cyclopropylbutanoic acid Chemical compound OC(=O)CC(CN)C1CC1 GMMGKUPDAMGCEW-UHFFFAOYSA-N 0.000 description 1
- CZGLBWZXGIAIBU-UHFFFAOYSA-N 4-amino-3-methylbutanoic acid Chemical compound NCC(C)CC(O)=O CZGLBWZXGIAIBU-UHFFFAOYSA-N 0.000 description 1
- ISBHKSHNQPXIFL-UHFFFAOYSA-N 4-amino-5-(2-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC=C1CC(N)CCC(O)=O ISBHKSHNQPXIFL-UHFFFAOYSA-N 0.000 description 1
- NIKHUROIIYNBOT-UHFFFAOYSA-N 4-amino-5-(3-methylphenyl)pentanoic acid Chemical compound CC1=CC=CC(CC(N)CCC(O)=O)=C1 NIKHUROIIYNBOT-UHFFFAOYSA-N 0.000 description 1
- AJEQGFVIQQCGSC-UHFFFAOYSA-N 4-amino-5-cyclohexylpentanoic acid Chemical compound OC(=O)CCC(N)CC1CCCCC1 AJEQGFVIQQCGSC-UHFFFAOYSA-N 0.000 description 1
- ONQHBUCEQVOBNN-UHFFFAOYSA-N 4-amino-6-(3-methylphenyl)hexanoic acid Chemical compound CC1=CC=CC(CCC(N)CCC(O)=O)=C1 ONQHBUCEQVOBNN-UHFFFAOYSA-N 0.000 description 1
- NXIZZVSUSXUIEX-UHFFFAOYSA-N 4-amino-6-methylheptanoic acid Chemical compound CC(C)CC(N)CCC(O)=O NXIZZVSUSXUIEX-UHFFFAOYSA-N 0.000 description 1
- AEBRINKRALSWNY-UHFFFAOYSA-N 4-azaniumyl-2-methylbutanoate Chemical compound OC(=O)C(C)CCN AEBRINKRALSWNY-UHFFFAOYSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- ZMGMDXCADSRNCX-UHFFFAOYSA-N 5,6-dihydroxy-1,3-diazepan-2-one Chemical compound OC1CNC(=O)NCC1O ZMGMDXCADSRNCX-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- NJASLZAPMXEJML-UHFFFAOYSA-N 7-benzyl-1-bromo-6,8-dihydro-5h-imidazo[1,5-a]pyrazine Chemical compound C1C2=C(Br)N=CN2CCN1CC1=CC=CC=C1 NJASLZAPMXEJML-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- ZOXJGFHDIHLPTG-BJUDXGSMSA-N Boron-10 Chemical compound [10B] ZOXJGFHDIHLPTG-BJUDXGSMSA-N 0.000 description 1
- 241000208199 Buxus sempervirens Species 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102100025841 Cholecystokinin Human genes 0.000 description 1
- 101800001982 Cholecystokinin Proteins 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 108010067110 Corticotropin-Like Intermediate Lobe Peptide Proteins 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- RQVLGLPAZTUBKX-UHFFFAOYSA-N D-vinylglycine Natural products C=CC(N)C(O)=O RQVLGLPAZTUBKX-UHFFFAOYSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010091873 DyNAzyme polymerase Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- YZJSUQQZGCHHNQ-UHFFFAOYSA-N Homoglutamine Chemical compound OC(=O)C(N)CCCC(N)=O YZJSUQQZGCHHNQ-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000004971 IR microspectroscopy Methods 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- 229930195714 L-glutamate Natural products 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- AEFLONBTGZFSGQ-VKHMYHEASA-N L-isoglutamine Chemical compound NC(=O)[C@@H](N)CCC(O)=O AEFLONBTGZFSGQ-VKHMYHEASA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- 241000272168 Laridae Species 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102400000821 Somatostatin-28 Human genes 0.000 description 1
- 101800004701 Somatostatin-28 Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- CRROPKNGCGVIOG-QCOJBMJGSA-N [des-Phe(8), des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(O)=O)CCC1 CRROPKNGCGVIOG-QCOJBMJGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- 150000001241 acetals Chemical group 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229910052767 actinium Inorganic materials 0.000 description 1
- QQINRWTZWGJFDB-UHFFFAOYSA-N actinium atom Chemical compound [Ac] QQINRWTZWGJFDB-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001263 acyl chlorides Chemical group 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001294 alanine derivatives Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- OYVAGSVQBOHSSS-WXFSZRTFSA-O bleomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](OC1C(C(O)C(O)C(CO)O1)OC1C(C(OC(N)=O)C(O)C(CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-WXFSZRTFSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- OQUUTERJWTYTHP-UHFFFAOYSA-N butanedioate;1h-tetrazol-1-ium Chemical compound [NH2+]1C=NN=N1.[NH2+]1C=NN=N1.[O-]C(=O)CCC([O-])=O OQUUTERJWTYTHP-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-N carbazic acid Chemical class NNC(O)=O OWIUPIRUAQMTTK-UHFFFAOYSA-N 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000005392 carboxamide group Chemical group NC(=O)* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940107137 cholecystokinin Drugs 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- ZYDMZKPAPSZILB-XDGGXQJNSA-N clilp Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)C1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C(C)C)C1=CC=CC=C1 ZYDMZKPAPSZILB-XDGGXQJNSA-N 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000007608 epigenetic mechanism Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000005308 ferrimagnetism Effects 0.000 description 1
- 230000005307 ferromagnetism Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 229940083094 guanine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000007453 hemicolectomy Methods 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 150000001469 hydantoins Chemical class 0.000 description 1
- 125000005597 hydrazone group Chemical group 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000005291 magnetic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000005389 magnetism Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000005935 nucleophilic addition reaction Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000005616 oxoacid group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000005408 paramagnetism Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011362 radionuclide therapy Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- GGYTXJNZMFRSLX-DFTNLTQTSA-N somatostatin-28 Chemical compound N([C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CSSC1)C(O)=O)[C@@H](C)O)[C@@H](C)O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CO GGYTXJNZMFRSLX-DFTNLTQTSA-N 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 208000025358 tongue carcinoma Diseases 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005641 tunneling Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to targeting agents, especially to tumor targeting agents, such as colon/colorectal primary tumor and metas- tases targeting agents, comprising at least one targeting unit and at least one effector unit, as well as to tumor targeting units and motifs, such as colon/colorectal primary tumor and metastases targeting units and motifs.
- tumor targeting agents such as colon/colorectal primary tumor and metas- tases targeting agents
- the present invention concerns pharmaceutical and diagnostic compositions comprising such targeting agents or targeting units, and the use of such targeting agents and targeting units as pharmaceuticals or as diagnostic tools.
- the invention further relates to the use of such targeting agents and targeting units for the preparation of pharmaceutical or diagnostic compositions.
- the invention relates to kits for diagnosing or treating cancer, such as colon/colorectal primary tumor and metastases.
- Malignant tumors are among the greatest health problems of man as well as animals, being one of the most common causes of death, also among young individuals. Available methods of treatment of cancer are quite limited, despite intensive research efforts during several decades. Although curative treatment, usually surgery in combination with chemotherapy and/or radiotherapy, is sometimes possible, malignant tumors still require a huge number of lives every year. In fact, curative treatment is rarely accomplished if the disease is not diagnosed early. In addition, certain tumor types can rarely, if ever, be cured. [0003] There are various reasons for this very undesirable situation, the most important one clearly being the fact that most treatment schedules, except surgery, lack sufficient selectivity.
- Chemotherapeutic agents commonly used do not act on the malignant cells of the tumors alone but are highly toxic to other cells as well, especially to rapidly dividing cell types, such as hemato- poietic and epithelial cells, resulting in highly undesirable side effects. The same applies to radiotherapy.
- colorectal cancer is the third most common cancer and the third leading cause of cancer-related mortality in the United States. Over the past decade, colorectal cancer incidence and mortality rates have modestly decreased or remained level. Until age 50, men and women have similar incidence and mortality rates; after age 50, men are more vulnerable.
- Surgery is the treatment of choice for colorectal cancer. Treatment depends on the stage of the disease and the overall health of the patient. Radical bowel resection, also called partial colectomy and hemicolectomy, is used to treat 80-90% of colorectal cancer patients. Chemotherapy and radiation therapy may be used as adjuvant treatment.
- Newer combinations of chemotherapy drugs such as FOLFOX (5-fluorouracil [5-FU], leucovorin, and oxaliplatin and FOFIRI (5-fluorouracil, leucovorin, and iri- notecan may be used to prevent recurrence following surgery or to shrink the tumor prior to surgery.
- FOLFOX fluorouracil [5-FU]
- FOFIRI fluorouracil, leucovorin, and iri- notecan
- blocking agents e.g. cetuximab, (an anti-EGF mAb) may also be used to treat metastatic colorectal cancer. These drugs prevent cancer cell receptors from receiving factors (e.g., epidermal growth factor) that cause cell growth, cell division, and additional metastasis. Blocking agents target specific cells so they usually do not cause systemic side effects. Side effects of these drugs include allergic reactions.
- antiangiogenic drugs is bevacizumab (an anti- VEGF mAb), which may also be used to treat advanced colorectal cancer.
- This medication prevents new blood vessels, which are necessary for tumor growth, from forming. It does not affect normal tissues that already have an established blood supply. Side effects include blood clots and high blood pressure.
- Immunotherapy or biological therapy, attempts to stimulate the immune system to fight disease and protect the body from side effects of chemotherapy.
- Immunotherapy agents that may be used to treat colorectal cancer include bacilli Calmette-Guerin (BCG) and levamisole. Immunotherapy may cause flu-like side effects such as chills, diarrhea, fever, anorexia, muscle aches and weakness, nausea and vomiting.
- Monoclonal antibodies specific to tumor cells have shown clinical promise as targeted agents for the treatment of e.g. lung cancer.
- There are some major limitations in antibody-targeted therapy based on two facts: the large size of the monoclonal antibodies and non-specific uptake of the antibody molecules by the liver and the reticuloendothelial system.
- the large size results in poor tumor penetration of antibody pharmaceuticals and causes often immune response, whereas non-specific uptake by the liver and the reticuloendothelial system results in dose-limiting toxicity to the liver and bone marrow.
- Another, hazardous disadvantage with the antibodies is their incorrect glycosylation when produced in cell culture.
- Targeting peptides are an excellent alternative for targeted treatment of human cancers, and due to relatively small size they may overcome some of the problems with antibody targeting. Advantages of peptides are: Greater stability - peptides can be stored at room temperature for weeks; lower manufacturing costs (synthetic production versus recombinant produc- tion); rapid pharmacokinetics; excretion route that can be modified; and higher activity per mass of final targeting agent. [0015] There are numerous publications disclosing peptides homing to different cell and tissue types. Some of these are claimed to be useful as cancer targeting peptides. Among the earliest identified homing peptides described are the integrin and NGR-receptor targeting peptides described by Ru- oslahti et al., in e.g., US Patent No 6,180,084.
- the present invention relates to tumor targeting units, targeting to colon primary tumor and metastases, having a peptide sequence C y - Y - G - F - X - W - G - Z - Cyy or a pharmaceutically or diagnostically or physiologically acceptable salt or derivative thereof, wherein Y is tyrosine, or a structural or functional analogue thereof; G is glycine, or a structural or functional analogue thereof; F is phenylalanine, or a structural or functional analogue thereof; X is alanine, valine, leucine or isoleucine, or a structural or functional analogue thereof; W is tryptophan, or a structural or functional analogue thereof; Z is glutamine or glutamic acid, or a structural or functional analogue thereof; and C y and Cyy are optional entities forming a cyclic structure.
- the targeting units of the present invention may be linear or cyclic or form part of a cyclic structure.
- the invention further relates to tumor targeting agents com- prising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit.
- the effector unit is a directly or indirectly detectable substance or a therapeutic substance.
- the invention further relates to tumor targeting agents further comprising optional units such as solubility enhancing units, preferably aque- ous enhancing units.
- the present invention further relates to diagnostic or pharmaceutical compositions comprising at least one targeting unit or at least one targeting agent according to the present invention, and to the use of targeting units or targeting agents according to the present invention for the preparation of a medicament for the treatment or diagnosis of cancer or cancer related diseases, especially for the treatment of colon cancer or its metastases.
- the present invention further relates to methods for treating or diagnosing cancer or cancer related diseases by providing to a patient in need thereof a diagnostically or therapeutically effective amount of a pharmaceutical composition according to the present invention for diagnosing or treat- ing colon cancer or its metastases.
- HCT-15-LM1 B
- HSC-3 C
- C8161T D
- control cell lines mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) to the immobilized targeting agent MJ012.
- Y-axis represents viable count.
- Figure 1 B shows the binding of cancer cell lines HCT-15 (A), HCT-15-LM1 (B), HSC-3 (C) and C8161T (D), and, control cell lines, mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) to the immobilized targeting agent MJ013.
- Y-axis represents viable count.
- Figure 2B shows the in vivo biodistribution of the targeting agent MJ018 after injection into the tail vein of tumor-bearing athymic mice.
- Y-axis represents the europium content in a tissue as compared to the europium content in a muscle.
- Figure 3 shows the results of a cytotoxicity assay as viable count vs. time. LoVo cells were treated with Cu(SAO) 2 (A), DMSO (B), 138 ⁇ g/ml HP203 (C) or 5 ⁇ g/ml HP203 (D).
- the invention provides novel tumor targeting agents that comprise at least one targeting unit and, optionally, at least one effector unit.
- the invention provides tar- geting units comprising at least one motif capable of targeting solid tumors of the colon.
- the present invention provides tumor targeting motifs and units that specifically target colon primary tumor cells and metastases.
- the targeting units according to the present invention are therapeutically and diagnosti- cally useful, especially in the treatment and diagnosis of cancer, including metastases, preferably tumors and metastases of the colon. Furthermore the targeting agents according to the present invention are useful for cell removal, selection, sorting and enrichment.
- Preferred pharmaceutical and diagnostic compositions comprise at least one targeting agent or at least one targeting unit comprising at least one motif according to the present invention and an optional unit which is an aqueous solubility-enhancing unit.
- a third object of the present invention is to provide novel diagnostic and therapeutic methods and kits for the treatment and/or diagnosis of cancer, preferably cancer of the colon, including metastases.
- the targeting units of this invention may be used as such or coupled to at least one effector unit.
- cancer is used herein in its broadest sense, and includes any disease or condition involving transformed or malignant cells.
- cancers are classified into five major categories, according to their tissue origin (histological type): Carcinomas, sarcomas, myelomas, and lymphomas, which are solid tumor type cancers, and leukemias, which are "liquid cancers".
- tissue origin human tissue origin
- cancer as used in the present invention, is intended to primarily include all types of diseases characterized by solid tumors, including disease states where there is no detectable solid tumor or where malignant or transformed cells, "cancer cells”, appear as diffuse infil- trates or sporadically among other cells in healthy tissue.
- colon cancer is herein intended to include both colon cancer and colorectal cancer.
- amino acid and "amino alcohol” are to be interpreted herein to include also diamino, triamino, oligoamino and polyamino ac- ids and alcohols; dicarboxyl, tricarboxyl, oligocarboxyl and polycarboxyl amino acids; dihydroxyl, trihydroxyl, oligohydroxyl and polyhydroxyl amino alcohols; and analogous compounds comprising more than one carboxyl group or hy- droxyl group and one or more amino groups.
- Any amino acid referred to in the present application is intended to include all isomers thereof, such as optical and geometrical isomers.
- peptide is meant, according to established terminology, a chain of amino acids (peptide units) linked together by peptide bonds to form an amino acid chain.
- Peptides may be linear or cyclic, and comprise branches, as described below.
- compounds comprising one or more D-amino acids, beta-amino acids and/or other unnatural amino acids (e.g. amino acids with unnatural side chains) are included in the term "peptide”.
- peptide is intended to include peptidyl analogues comprising modified amino acids.
- peptidyl analogues Some examples of possible reaction types that can be used to modify peptides, forming "peptidyl analogues", are e.g., condensation and nucleophilic addition reactions as well as esterification, amide formation, formation of substituted amides, N-alkylation, formation of hydrazides, and salt formation. Salt formation may be the formation of any type of salt, such as alkali or other metal salt, ammonium salt, salts with organic bases, acid addition salts etc. Peptidyl analogues may be synthesized either from the corresponding peptides or directly (via other routes).
- structural or functional analogues of the peptides of the invention is used to encompass compounds that do not consist of amino acids or not of amino acids alone, or some or all of whose building blocks are modified amino acids. Different types of building blocks can be used for this purpose, as is well appreciated by those skilled in the art.
- the function of these compounds in biological systems is essentially similar to the function of the peptides. The resemblance between these compounds and the original peptides is thus based on structural and functional similarities.
- Such compounds are called peptidomimetic analogues, as they mimic the function, conformation and/or structure of the original peptides and, for the purposes of the present invention, they are included in the term "peptide”.
- a functional analogue of a peptide according to the present invention is characterized by a binding ability with respect to the binding to tumors, tumor tissue, tumor cells or tumor endothelium which is essentially similar to that of the peptides they resemble.
- compounds like ben- zolactam or piperazine containing analogues based on the structure of the peptide bond comprising structures of the original amino acids can be used as amino acid analogues (Adams et al. 1999, J. Immunol. Methods, 231 : 249- 260; Nakanishi and Kahn, 1996, In: The practice of medical chemistry, pp. 571-590, Academic Press; Houghten et al., 1999, J. Med. Chem., 42: 3743- 3778; Nargund et al., 1998, J. Med. Chem., 41 : 3103-3127).
- Peptidomimetic substances may comprise for example one or more of the following structural components: reduced amides, hydroxyethylene and/or hydroxyethylamine isosteres, N -methyl amino acids, urea derivatives, thiourea derivatives, cyclic urea and/or thiourea derivatives, poly(ester imide)s, polyesters, esters, guanidine derivatives, cyclic gua-nidines, imidazoyl compounds, imidazolinyl compounds, imidazolidinyl corn-pounds, cyclic amines, cyclic esters, aromatic rings, bicyclic systems, hy- dantoins and/or thiohydantoins as well as various other structures.
- peptidomimetic compounds for the synthesis of peptidomimetic substances are available from a number of commercial sources (e.g. Peptide and Peptidomimetic Synthesis, Reagents for Drug Discovery, Fluka ChemieGmbH, Buchs, Switzer- land, 2000 and Novabio-chem 2000 Catalog, Calbiochem-Novabiochem AG, Laufelfingen, Switzerland, 2000).
- the resemblance between the peptidomi- metic compounds and the original peptides is based on structural and/or functional similarities.
- the peptidomimetic compounds mimic the properties of the original peptides and, for the purpose of the present application, their binding ability is similar to the peptides that they resemble.
- Peptidomimetic compounds can be made up, for example, of unnatural amino acids (such as D- amino acids or amino acids comprising unnatural side chains, or of beta-amino acids etc.), which do not appear in the original peptides, or they can be con- sidered to consist of or can be made from other compounds or structural units.
- Examples of synthetic peptidomimetic compounds comprise N-alkylamino cyclic urea, thiourea, polyesters, poly(ester imide)s, bicyclic guanidines, hydan- toins, thiohydantoins, and imidazol-pyridino-inoles (Houghten et al. 1999, ibid, and Nargund et al., 1998, ibid.).
- Such peptidomimetic compounds can be characterized as being "structural or functional analogues" of the peptides of this invention.
- the term "targeting unit” stands for a compound, a peptide or a structural or functional analogue thereof, capable of selectively targeting and selectively binding to tumor tissue, tumors, and, preferably, also to tumor stroma, tumor parenchyma and/or extracellular matrix (ECM) of tumors. More specifically, the targeting units may bind to a cell surface, to a specific molecule, molecular complex or structure on a cell surface or within the cells, extracellularly in the vicinity of cells or they may associate with the extracellular matrix present between the cells. The tar- geting units may also bind to the endothelial cells or the extracellular matrix of tumor vasculature. The targeting units may bind also to the tumor mass, tumor cells and extracellular matrix of metastases.
- the terms “targeting” or “binding” stand for adhesion, at-attachment, affinity or binding of the targeting units of this invention to tumors, tumor cells and/or tumor tissue to the extent that the binding can be objectively measured and determined e.g., by peptide competition experiments in vivo or ex vivo, on tumor biopsies in vitro or by immunological stainings in situ, or by other methods known by those skilled in the art.
- Tumor targeting means that the targeting units specifically bind to tumors when administered to a human or animal body. Another term used in the art for this specific association is "homing".
- Targeting units and targeting agents according to the present invention are considered to be "bound" to the tumor target in vitro, when the binding is strong enough to withstand normal sample treatment, such as washes and rinses with physiological saline or other physiologically acceptable salt or buffer solutions at physiological pH, or when bound to a tumor target in vivo long enough for the effector unit to exhibit its function on the target.
- the binding of the present targeting agents or targeting units to tumors is "selective" meaning that they do not bind to normal cells and organs, or bind to such to a significantly lower degree as compared to tumors.
- the binding of the present targeting agents to non-cancer cells tested is less than 45% of binding to the cancer cell lines.
- the present invention is based on the finding that a group of linear or cyclic peptides having specific amino acid sequences or motifs are capable of selectively targeting tumors, especially colon primary tumors and metastases, in vivo and tumor cells in vitro.
- the peptides of this invention when administered to a human or animal subject, are capable of selectively binding to tumors but do not bind to normal tissue in the body.
- the tumor targeting units according to the present invention were identified by bio-panning of phage display libraries.
- Phage display is a method whereby libraries of random peptides are expressed on the surface of a bacteriophage as part of the phage capsid protein pill by insertion of its encoding DNA sequence into gene III of the phage genome.
- the pill libraries display 3-5 copies of each individual peptide per phage particle (Smith and Scott, 1993, Methods Enzymol., 217: 228-257).
- Phage display peptide libraries were screened by bio- panning to select peptides that are specific to colon cancer.
- the principle of bio-panning comprises 1) exposing homogenized tissue samples to a phage library, 2) washing off unbound phages, and 3) rescuing the phages bound to the target tissue. Repeating steps 1-3 results in a selection of highly enriched peptides having a high binding affinity towards the target tissue compared to other peptides of the original phage library.
- a phage display peptide library was panned against tissue samples taken from primary tumors of colon cancer patients, as described in more detail in the Examples section.
- Y is tyrosine, or a structural or functional analogue thereof; G is glycine, or a structural or functional analogue thereof; F is phenylalanine, or a structural or functional analogue thereof; X is alanine, valine, leucine or isoleu- cine, or a structural or functional analogue thereof; W is tryptophan, or a structural or functional analogue thereof; Z is glutamine or glutamic acid, or a structural or functional analogue thereof; targets and exhibits selective binding to tumors and tumor cells and, especially, to colon/colorectal primary tumors and metastases.
- Y is tyrosine, or a structural or functional analogue thereof characterized either by its ability to structurally mimic tyrosine, for example by virtue of comprising a ring structure of a similar or related type, as compared to the ring structure of tyrosine; or by vir- tue of comprising another structure that sterically or electrically can be considered as an equivalent of the ring structure of tyrosine.
- structural and functional analogues of tyrosine may also be characterized by their ability to mimic the acid-base or electric or bond-conjugation or hydrogen-bond- formation or aromatic or other functional or related properties of tyrosine, e.g. by comprising one or more aromatic rings, one or more hydroxyl groups, often preferably phenolic hydroxyl groups, etc., as is understood by those skilled in the art.
- Structural and functional analogues of tyrosine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-fluorotyrosine, 3- fluorotyrosine, 2,3-difluorotyrosine, 2,5-difluorotyrosine, 2,6-difluorotyrosine, 2- chlorotyrosine, 3-chlorotyrosine, 2,3-dichlorotyrosine, 2,5-dichlorotyrosine, 2,6- dichlorotyrosine, 2-bromotyrosine, 3-bromotyrosine, 2,3-dibromotyrosine, 2,5- dibromotyrosine, 2,6-dibromotyrosine, 2-iodotyrosine, 3-iodotyrosine, 2,3- diiodotyrosine, 2,5-diiodotyrosine, 2,6-diiodotyrosine,
- G is glycine, or a structural of functional analogue thereof characterized by its ability to structurally mimic glycine for example by virtue of comprising a unit of minimal size, as compared to almost any other amino acid, by virtue of its lack of any highly bulky groups and structural fragments and parts and side chains that would cause marked steric hindrance and crowding, by virtue of its lack of aromatic or other ring structures, or by virtue of being otherwise sterically or electrically equivalent to the structure of glycine, e.g.
- Suitable structures may, for example, preferably comprise a small side chain such as a methyl or an ethyl group or their like or a halogenated methyl or ethyl group etc., or may be totally devoid of any side chain, which may also be preferable. Even a small monocyclic structure may be included, such as cyclopropyl group, but at least very large rings should be completely avoided. Such a monocyclic structure may or may not comprise also one or more heteroatom(s) or substituents etc. Suitable structures may, for example, also be beta-amino acids, gamma-amino acids etc.
- analogues of glycine need not be amino acids at all but may be for example amino alcohols, amino sugars, amino ketones etc. or may be devoid of any amino group, and so on, as is understood by those skilled in the art.
- Structural and functional analogues of glycine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-aminopropanoic acid, 3- aminopropanoic acid, 2-aminobutanoic acid, 3-aminobutanoic acid, 4- aminobutanoic acid, 2,3-diaminopropanoic acid, 2,3-diaminobutanoic acid, 3,4- diaminobutanoic acid, 2,4-diaminobutanoic acid, 2-amino-2-methylpropanoic acid, 3-amino-2-methylpropanoic acid, 2-amino-2-methylbutanoic acid, 3- amino-2-methylbutanoic acid, 4-amino-2-methylbutanoic acid, 2,3-diamino-2- methylpropanoic acid, 2,3-diamino-2-methylbutanoic acid, 3,4-diamino-2-
- F is phenylalanine, or a structural or functional analogue thereof, characterized by its ability to structurally mimic phenylalanine for example by virtue of comprising a ring structure of a similar or related type, as compared to the ring structure of phenylalanine, or by virtue of comprising another structure that sterically or electrically can be considered as an equivalent of the ring structure, e.g. by virtue of comprising at least one unsaturated bond that render structural rigidity as compared to saturated structures.
- Said ring structures may preferably comprise a monocyclic structure that may or may not comprise also one or more heteroatom(s), or may be for example bicyclic or tricyclic.
- Structural and functional analogues of phenylalanine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: phenylalanine, 2-amino-4- phenylbutanoic acid, 3-amino-4-phenylbutanoic acid, 2-amino-3-phenyl- butanoic acid, 2-amino-5-phenylpentanoic acid, 3-amino-5-phenylpentanoic acid, 4-amino-5-phenylpentanoic acid, 2-amino-4-phenylpentanoic acid, 3- amino-4-phenylpentanoic acid, 2-amino-3-phenylpentanoic acid, 2-amino-6- phenylhexanoic acid, 3-amino-6-phenylhexanoic acid, 4-amino-6-phenylhexan- oic acid, 2-amino-5-phenylalanine
- X is alanine, or a structural or functional analogue thereof.
- Such an analogue may prefera- bly have no side chain or may comprise in its side chain(s) maximally four, more preferably maximally three, still more preferably maximally two, non- hydrogen atoms.
- Structural or functional analogues of alanine include for example any optical isomers of compounds such as: 3-chloroalanine, 3- fluoroalanine, 2-aminobutanoic acid, 4-fluoro-2-aminobutanoic acid, 4-chloro- 2- aminobutanoic acid, 3-cyanoalanine, 3-cyclopropylalanine, 2-amino-3- butenoic acid and 2-amino-3-butynoic acid.
- X is valine or leucine or isoleucine, or a structural or functional analogue thereof.
- an analogue may for example be characterized by its ability to structurally mimic valine, leucine or isoleucine, for example by virtue of comprising at least one aliphatic, cycloaliphatic/alicyclic, or related side- chain or, generally, at least one side-chain comprising at least one hydrophobic structure or group or lipophilic structure or group, or generally by virtue of comprising at least one small side-chain that do not cause massive sterical hindrance, etc., as is understood by those skilled in the art.
- structural and functional analogues of valine, leucine and isoleucine may preferably be characterized by more than one of said features or properties.
- Structural and functional analogues of valine and leucine and isoleucine may be selected, for example, from any optical and geometrical isomers of the following compounds and their like: alanine, valine, leucine, isoleucine, norleucine, norvaline, allo-isoleucine, 2-aminobutanoic acid, 2- amino-2-methylpropionic acid, 2-amino-4,4-dimethylpentanoic acid, 4,5-dehyd- roleucine, 2-amino-6-isopropylamino-hexanoic acid, 4-amino-6-methylheptan- oic acid, 3-amino-6-methylheptanoic acid, 2-amino-6-methylheptanoic acid, terf-leucine, 4-amino-5-cyclohexyl-3-hydroxypentanoic acid, 4-amino-5-cyclo- hexylpentanoic acid, 2-amin
- any analogues of the aforementioned comprising in a side chain a branched, non-branched and/or ali- cyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to at least one carbon, ether-oxygens and thioether-sulphurs;
- ring structures not comprising nitrogen, or comprising more than one nitrogen atoms may be employed, etc., as is understood by those skilled in the art.
- structural and functional analogues of tryptophan may of- ten also be characterized by their ability to mimic the acid-base or electric or bond-conjugation or aromatic or other functional or related properties of trypto- phan, e.g. by comprising one or more aromatic rings, one or more nitrogen atoms, etc., as is understood by those skilled in the art.
- Structural and functional analogues of tryptophan may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-amino-3-(1-indolyl)-propionic acid, 2-amino-3-(2-indolyl)-propionic acid, 2-amino-3-(4-indolyl)-propionic acid, 2-amino-3-(5-indolyl)-propionic acid, 2-amino-3-(6-indolyl)-propionic acid, 2- amino-3-(7-indolyl)-propionic acid, 2-amino-4-(1-indolyl)-butyric acid, 2-amino- 4-(2-indolyl)-butyric acid, 2-amino-4-(3-indolyl)-butyric acid, 2-amino-4-(4- indolyl)-butyric acid, 2-amino-3-
- any amino acids and carboxylic acids comprising in at least one side chain or as at least one side chain: at least one indene, naphthalene, benzofuran, indole, benzo[b]thiophene, ben- zimidazole, benzothiazole, purine, quinoline, isoquinoline, cinnoline, quinoxa- line, azulene, fluorene, dibenzofuran, carbazole, anthracene, phenathrene, acridine, 1 ,10-phenanthroline, phenothiazine, pyrene, furan, pyrrole, 3- pyrroline, pyrrolidine, pyrazole, 2-pyrazoline, pyrazolidine, imidazole, oxazole, thiazole, 1 ,2,3-oxadiazole, 1 ,2,3-triazole, 1 ,2,4-triazole, 1 ,
- Z is glutamine, or a structural or functional analogue thereof.
- structural and functional analogues of glutamine may be characterized by their ability to structurally mimic glutamine for example by virtue of comprising in a side chain or in more than one side chains a carboxylamide (an amide) group or a structure of a similar or related type, as compared to the carboxylamide structure of glutamine, or by virtue of comprising another structure that sterically or electrically can be considered as an equivalent of the amide structure.
- One possibility is to use an unsubstituted carboxylamide function similar to that in glutamine (or a substituted one, or more than one carboxylamide functions, etc.) but in a side chain (or side chains) that is/are otherwise different form the side chain in glutamine, e.g. by virtue of comprising at least one heteroatom instead of at least one carbon atom, or virtue of being longer or shorter than the side chain of glutamine, or by virtue of comprising at least one double or triple bond between carbon atoms, or by comprising substituents such as a fluorine atom or an aromatic ring or an alkyl group or a hydroxyl group etc., or by virtue of being branched, etc., as is understood by those skilled in the art.
- the carboxylamide function of glutamine may be replaced e.g.
- Structural and functional analogues of glutamine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: glutamine, asparagine, isoglutamine, isoasparagine, beta-hydroxyglutamine, gamma- hydroxyglutamine, beta-hydroxyasparagine, beta-methyleneglutamine, gamma-methyleneglutamine, beta-methyleneasparagine, beta.gamma- dihydroxyglutamine, beta-methylglutamine, gamma-methylglutamine, beta- methylasparagine, beta.gamma-dimethylglutamine, beta-ethylglutamine, gamma-ethylglutamine, beta-ethylasparagine, beta.gamma-diethylglutamine, beta-propylglutamine, gamma-propylglutamine, beta-propylasparagine, beta.
- Z is glutamic acid, or a structural or functional analogue thereof comprising at least one oxygen atom capable of hydrogen bond formation, and preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, esterified hydroxamic acid function, alcoholic or phenolic hydroxyl group, esterified alcoholic or phenolic hydroxyl group, keto group or aldehyde function, and more preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, esterified hydroxamic acid function, alcoholic or phenolic hydroxyl group or esterified alcoholic or phenolic hydroxyl group, still more preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, alcoholic hydroxyl group or esterified alcoholic hydroxyl group, and most preferably comprising at least one carboxyl group or esterified carboxyl group; or comprising one or
- analogues of glutamic acid are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
- Such analogues may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: aspartic acid, 2-amino-1 ,6-heptanedioic acid, 3- amino-1 ,6-heptanedioic acid, 2-amino-3-methyl-1 ,6-heptanedioic acid, 3-ami- no-2-methyl-1 ,6-heptanedioic acid, 2-amino-4-methyl-1 ,6-heptanedioic acid, 2- amino-1 ,7-hexanedioic acid, 3-amino-1 ,7-hexanedioic acid, 2-amino-3-methyl- 1 ,7-hexanedioic acid,
- a preferred motif according to the present invention is a motif wherein X is valine and Z is glutamic acid, i.e., Y-G-F-V-W-G-E (SEQIDNO.1).
- Another preferred motif according to the present invention is a motif wherein X is valine and Z is glutamine, i.e., Y-G-F-V-W-G-Q (SEQ ID NO.2).
- Still another preferred motif according to the present inven- tion is a motif wherein X is leucine and Z is glutamine, i.e., Y-G-F-L-W- G-Q(SEQIDNO.3).
- Yet another preferred motif according to the present invention is a motif wherein X is leucine and Z is glutamic acid, i.e., Y-G-F-L- W-G-E(SEQIDNO.4).
- Yet another preferred motif according to the present invention is a motif wherein X is alanine and Z is glutamine, i.e., Y-G-F-A-W - G - Q (SEQ ID NO.5).
- Yet another preferred motif according to the present invention is a motif wherein X is alanine and Z is glutamic acid, i.e., Y-G-F-A- W-G-E(SEQIDNO.6).
- Yet another preferred motif according to the present invention is a motif wherein X is isoleucine and Z is glutamine, i.e., Y - G - F - I - W-G-Q(SEQIDNO.7).
- Yet another preferred motif according to the present inven- tion is a motif wherein X is isoleucine and Z is glutamic acid, i.e., Y-G-F-I -W-G-E(SEQIDNO.8).
- the motif Y - G - F - X- W - G - Z according to the present invention may form part of a larger structure, such as a peptide or some other structure.
- the compound or structure in question may also comprise more than one motif Y - G - F - X- W - G - Z, and the orientation of the mo- tifs may vary.
- Such peptides are highly advantageous for use as targeting units according to the present invention, e.g., because of their small size and their easy, reliable and cheap synthesis. Due to the small size of the peptides according to the present invention, the purification, analysis and quality control is easy and commercially useful.
- the targeting units according to the present invention are preferably linear.
- Linear peptides according to the present invention are fast, easy and cheap to prepare, as they do not require any further processing (cy- clization etc.) after synthesis and complicated orthogonal and other protections and extra functional groups are not needed that would be needed for cycliza- tion. It is furthermore easier to link additional units to linear peptides, for example because, there is no need to "reserve" functional groups for the purpose of cyclization, or to use expensive and complicated orthogonal protections, etc.
- the efficient degrada- tion of linear peptides in the human body is an advantage compared to the use of more slowly degrading substances, e.g., in diagnostic applications where rapid clearance is desired.
- cyclic peptides are preferred.
- the targeting units according to the present invention may also be cyclic.
- Cyclic peptides are usually more stable in vivo and in many other biological systems than are their non-cyclic counterparts, as is known in the art. More stable peptides according to the present invention are highly preferred for certain purposes, for example in certain therapeutic applications.
- Preferred targeting units according to the present invention may have at least a sequence [0095] Cy-Y-G-F-X-W-G-Z -Cyy
- Y-G-F-X-W-G-Z is a tumor targeting motif as defined above, and C y and Cyy are optional entities forming a cyclic structure.
- CyS-S-Cyy indicates a cystine. Because of the easy availability and low price of cysteine, this type of structure is a preferred one.
- the -S-S- bridge need not, however, be between cysteine units but may also exist between other amino acids or other moieties containing -SH groups.
- Such structures may comprise more than one Y-G-F-X- W - G - Z motif between the cysteine units, and may comprise additional amino acids and structural or functional analogues thereof outside the cyclic structure.
- Highly preferred targeting units according to the present invention having a cyclic structure by virtue of a disulphide bridge, are CYGFVWGEC (SEQ ID NO. 9), CYGFVWGQC (SEQ ID NO. 10), CYGFLWGQC (SEQ ID NO. 11), CYGFLWGEC (SEQ ID NO. 12), CYGFAWGQC (SEQ ID NO. 13), CYGFAWGEC (SEQ ID NO. 14), CYGFIWGQC (SEQ ID NO.15) and CYGFIWGEC (SEQ ID NO.16).
- cyclic structure is the formation of an amide bond to give a lactam, or ester bond to give a lactone, or hydrazone, hydrazine, oxime, thioether or other type of bond to give a cyclic structure.
- Lactams i.e. lactam bridged peptides can be of several subtypes, such as "head to tail”, wherein the ends of the peptide chain are directly linked together (carboxy terminus coupled to amino terminus), "head to side chain” and “side chain to tail”, wherein one end of the peptide chain is linked to side chain of an amino acid residue elsewhere in the peptide (carboxy or amino terminus coupled to one side chain amino or carboxyl group), and “side chain to side chain” (amino group of one side chain coupled to carboxyl group of another side chain).
- C-terminus and C-terminal refer to the carboxylic end of the peptide chain, which may be free, or coupled to another moiety.
- N-terminus and N-terminal refer to the amino end of the peptide chain, which may be free, or coupled to another moiety.
- Preferred structures include compounds of the general formula [0107] C y - Y - G - F - X -W - G - Z - Cyy
- Cy is glutamic acid, aspartic, or a structural or functional analogue thereof when Cyy is lysine, ornithine, or a structural or functional analogue thereof; or Cy is lysine, ornithine, or a structural or functional analogue thereof when Cyy is glutamic acid, aspartic, or a structural or functional analogue thereof.
- Examples of structural or functional analogues of lysine and ornithine include any optical isomers of lysine or ornithine, and structural and/or functional analogues thereof, that preferably comprise at least one amino group or substituted amino group or other nitrogen-containing group that has or can through protonation gain a positive charge.
- examples of structural or functional analogues of lysine can be characterized by the presence of two amino groups or substituted amino groups (such as the monoethylamino group) or equivalents thereof, as well as the presence of at least one carboxyl group or its equivalent (such as an acyl chloride group), in the molecule.
- Structural or functional analogues of lysine and ornithine may be selected e.g. from the group of ornithine, lysine, any C-methylated analogues of ornithine or lysine, any C 1 C -dimethylated analogues of ornithine or lysine, 2,4-diaminobutanoic acid, 2,7-diaminoheptanoic acid, 2,8- diaminooctanoic acid, 2,4-diamino-3-methylbutanoic acid, 2,7-diamino-3- methyl-heptanoic acid, 2,8-diamino-3-methyl-octanoic acid, 2,4-diamino-2- methylbutanoic acid, 2,7-diamino-2-methyl-heptanoic acid, 2,8-diamino-2- methyl-octanoic acid, 2,4-d
- C y is selected from the group consisting of a diamino acid (such as lysine, ornithine, or a structural or functional analogue thereof) and an N-terminal D-amino acid, when Cyy is selected from the group consisting of an L-amino dicarboxylic acid (such as glutamic acid, aspartic acid, or a structural or functional analogue thereof).
- a diamino acid such as lysine, ornithine, or a structural or functional analogue thereof
- N-terminal D-amino acid when Cyy is selected from the group consisting of an L-amino dicarboxylic acid (such as glutamic acid, aspartic acid, or a structural or functional analogue thereof).
- Preferred linear or lactam-bridged targeting units according to the present invention are aYGFVWGEE (SEQ ID NO. 17), aYGFVWGQE (SEQ ID NO. 18), aYGFLWGQE (SEQ ID NO. 19), aYGFLWGEE (SEQ ID NO. 20), aYGFAWGQE (SEQ ID NO. 21 ), aYGFAWGEE (SEQ ID NO. 22), aYGFIWGQE (SEQ ID NO. 23), aYGFIWGEE (SEQ ID NO. 24), where a is D- alanine. In the sequence listings, D-alanine is denoted Xaa. Targeting agents according to the present invention
- targeting agents comprising at least one tumor targeting unit according to the present invention, and at least one effector unit (EU), target to and exhibit selective binding to cancer cells and cancer tissues.
- EU effector unit
- the tumor targeting agents according to the present invention may optionally comprise unit(s) such as linkers, solubility modifiers, stabilizers, charge modifiers, spacers, lysis or reaction or reactivity modifiers, internalizing units or internalization enhancers or membrane interaction units or other local route, attachment, binding or distribution affecting units or other related units.
- unit(s) such as linkers, solubility modifiers, stabilizers, charge modifiers, spacers, lysis or reaction or reactivity modifiers, internalizing units or internalization enhancers or membrane interaction units or other local route, attachment, binding or distribution affecting units or other related units.
- the tumor targeting agents of the invention may have different structures such as any of the non-limiting types schematically shown below:
- EU indicates "effector unit”
- TU indicates “targeting unit”
- n, m and k are independently any integers except 0.
- spacers or linkers such as amino acids and their analogues, such as long-chain omega-amino acids, to prevent the targeting units from being 'disturbed' steri- cally or electronically, or otherwise hindered or 'hidden', by effector units or other units of the targeting agent.
- Preferred targeting agents according to the present invention comprise a structure EU-TU-OU, TU-EU-OU or TU-OU-EU, wherein TU is a targeting unit according to the present invention as defined above; and EU and
- OU effector or optional units selected from the group consisting of: [0124] effector units, linker units, solubility modifier units, stabilizer units, charge modifier units, spacer units, lysis and/or reaction and/or reactivity modifier units, internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units, adsorption enhancer units, and other related units; and
- peptide sequences comprising no more than 20, preferably no more than 12, more preferably no more than 6, natural and/or unnatural amino acids;
- effector unit For the purposes of this invention, the term "effector unit"
- EU means molecules or radicals or other chemical entities or large particles such as colloidal particles and their like; liposomes, nanoparticles or micro- granules and their like.
- Suitable effector units may also comprise nanodevices or nanochips or their like; or a combination of any of the aforementioned, and optionally chemical structures for the attachment of the constituents of the effector unit to each other or to other parts of the targeting agents. Effector units may also contain moieties that modify the stability or solubility of the effector units.
- Preferred effects provided by the effector units according to the pre-sent invention are therapeutic (biological, chemical or physical) effects on the targeted tumor; properties that enable the detection or imaging of tumors or tumor cells for diagnostic purposes; or binding abilities that relate to the use of the targeting agents in different applications.
- a preferred (biological) activity of the effector units according to the present invention is a therapeutic effect.
- therapeutic activities are for example, cytotoxicity, cytostatic effects, ability to cause differentiation of cells or to increase their degree of differentiation or to cause phenotypic changes or metabolic changes, chemotactic activities, immuno- modulating activities, pain relieving activities, radioactivity, ability to affect the cell cycle, ability to cause apoptosis, hormonal activities, enzymatic activities, ability to transfect cells, gene transferring activities, ability to mediate "knockout” of one or more genes, ability to cause gene replacements or "knock-in", ability to decrease, inhibit or block gene or protein expression, antiangiogenic activities, ability to collect heat or other energy from external radiation or electric or magnetic fields, ability to affect transcription, translation or replication of the cell's genetic information or external related information, and to affect post- transcriptional or post-translational events, and so on.
- Other preferred therapeutic uses enabled by the effector units according to the present invention may be the administration of an enzyme capable of hydrolyzing for example an ester bond or other bonds or the administration of a targeted enzyme according to the present invention.
- NCT-active substances any substance that by virtue of its ability to become radioac- tive by capture of slow neutrons can be used for neutron capture therapy (i.e. that emits radiation after having captured slow neutrons).
- Examples of preferred functions of the effector units according to the present invention suitable for detection are radioactivity, paramagnetism, ferromagnetism, ferri magnetism, or any type of magnetism, or ability to be detected by NMR spectroscopy, or ability to be detected by EPR (ESR) spectroscopy, or suitability for PET imaging (PET-active substances) and/or SPECT imaging (SPECT-active substances).
- PET-active substances any substance that can be used for positron emission tomography (PET).
- SPECT-active substances is meant any substance that can be used for single photon emission computer tomography (SPECT) by virtue of its abil- ity to emit photons.
- Preferred detectable substances according to the present invention may comprise a chelator; a complexed metal such as a rare earth metal, a paramagnetic metal, a fluorescent metal (e.g. Eu, Tb or Ho), a radioactive metal, a PET-active substance or a SPECT-active substance; an enriched isotope; radioactive material such as beta-emittor or alpha emittor; a paramagnetic substance; an affinity label; a fluorescent label (e.g. fluorescein or rhodamine) or a luminescent label.
- a complexed metal such as a rare earth metal, a paramagnetic metal, a fluorescent metal (e.g. Eu, Tb or Ho), a radioactive metal, a PET-active substance or a SPECT-active substance; an enriched isotope; radioactive material such as beta-emittor or alpha emittor; a paramagnetic substance; an affinity label; a fluorescent label (e.g.
- Preferred binding abilities of an effector unit according to the pre-sent invention include, for example: a) ability to bind metal ion(s) e.g. by chelation, b) ability to bind a cytotoxic, apoptotic or metabolism affecting substance or a substance capable of being converted in situ into such a substance, c) ability to bind to a substance or structure such as a histidine tag or other tag, d) ability to bind to an enzyme or a modified enzyme, e) ability to bind to biotin or analogues thereof, f) ability to bind to avidin or analogues thereof, g) ability to bind to integrins or other substances involved in cell adhesion, migration, or intracellular signaling, h) ability to bind to phages, i) ability to bind to lymphocytes or other blood cells, j) ability to bind to any preselected material by virtue of the presence of antibodies or structures selected by biopanning or by other methods
- binding may be the result of e.g. chelation, formation of covalent bonds, antibody-antigen-type affinity, ion pair or ion associate formation, specific interactions of the avidin-biotin-type, or the result of any type or mode of binding or affinity.
- metals for chelation are fluorescent metals such as europium (Eu), terbium (Tb) or holmium (Ho).
- the effector units or parts of them may also be a part of the targeting units themselves.
- the effector unit may for ex- ample be one or more atoms or nuclei of the targeting unit, such as radioactive atoms (such as carbon-13, carbon-11 , carbon-14, fluorine-18 or tritium) or atoms that can be made radioactive (e.g. boron-10), or paramagnetic atoms (e.g. gadolinium (Gd) or iron) or atoms that are easily detected by MRI or NMR spectroscopy.
- radioactive atoms such as carbon-13, carbon-11 , carbon-14, fluorine-18 or tritium
- atoms that can be made radioactive e.g. boron-10
- paramagnetic atoms e.g. gadolinium (Gd) or iron
- effector units are, for example, boron- comprising structures such as carborane-type structures.
- the effector units may be linked to the targeting units by any type of bond or structure or any combinations of them that are strong enough so that most, or preferably all or essentially all of the effector units of the targeting agents remain linked to the targeting units during the essential (neces- sary) targeting process, e.g. in a human or animal subject or in a biological sample under study or treatment.
- effector units or parts of them may remain linked to the targeting units, or they may be partly or completely hydrolyzed or otherwise disintegrated from the latter, either by a spontaneous chemical reaction or equilibrium or by a spontaneous enzymatic process or other biological process, or as a result of an intentional operation or procedure such as the administration of hydrolytic enzymes or other chemical substances. It is also possible that the enzymatic process or other reaction is caused or enhanced by the administration of a targeted substance such as an enzyme in accordance with the present invention.
- the targeting according to the present invention may be very rapid, even non-specific hydrolysis that occurs every-where in the body may be acceptable and usable for hydrolyzing one or more effector unit(s) intentionally, since such hydrolysis may in suitable cases (e.g., steric hindrance, or even without any such hindering effects) be so slow that the targeting agents are safely targeted in spite of the presence of hydrolytic enzymes of the body, as those skilled in the art very well understand.
- the formation of insoluble products or products rapidly absorbed into cells or bound to their surfaces after hydrolysis may also be beneficial for the targeted effector units or their fragments etc. to remain in the tumors or their closest vicinity.
- the effector units may comprise structures, features, fragments, molecules or the like that make possible, cause directly or indirectly, an "amplification" of the therapeutic or other effect, of signal detection, of the binding of preselected substances, including biological material, molecules, ions, microbes or cells.
- Such "amplification” may, for example, be based on one or more of the following non-limiting types:
- the effector units comprise more than one entity capable of bind- ing e.g. a protein, thus making direct amplification possible;
- Preferred effector units according to the present invention may be selected from the following group:
- nucleic acids include aptamers, peptide nucleic acids (PNA) and anti-sense oligonucleotides
- the effector unit may comprise cytostatic/cytotoxic agents such as 5-fluorouracil, leucovorin, oxaliplatin, irinotecan, or polyketidic antracyclines including doxorubicin and daunorubicin.
- cytostatic/cytotoxic agents such as 5-fluorouracil, leucovorin, oxaliplatin, irinotecan, or polyketidic antracyclines including doxorubicin and daunorubicin.
- the effec- tor unit comprises radiation emitting substances such as alpha-emittors, beta- emittors, gamma-emittors or NCT-active substances.
- the effector units may comprise copper chelates such as trans- bis(salicylaldoximato)copper(ll) and its analogues, or platinum compounds such as cisplatin and carboplatin.
- mitosis inhibitors/taxanes such as paclitaxel or docetaxel
- anti-metabolites such as gemsitabine or metotrexate
- vinca alkaloids such as vinorelbine or vincristine
- alkylating agents such as isophosphamide or cyclophosphamide
- antibiotics such as bleomycine or mitomycine
- topoisomerase inhibitors such as irinotecane or topotecane.
- apoptosis-inducing structure for example, the peptide sequence KLAKLAK that has been reported to interact with mitochondrial membranes inside cells, can be included (Ellerby et al. 1999, Nat. Med., 9: 1032-1038).
- the targeting units and agents of the invention can, for example, be used [0155] a) coupled or connected to magnetic particles,
- the targeting agents and targeting units of the present invention may optionally comprise further units, such as:
- linker units for coupling targeting units, effector units, or other optional units of the present invention to each other;
- solubility modifying units for modifying the solubility of the targeting agents or their hydrolysis products;
- stabilizer units for stabilizing the structure of the targeting units or agents during synthesis, modification, processing, storage or use in vivo or in vitro; charge modifying units for modifying the electrical charges of the targeting units or agents or their starting materials;
- spacer units for increasing the distance between specific units of the targeting agents or their starting materials, for releasing or decreasing steric hindrance or structural strain of the products or their starting materials; [0164] reactivity modifier units; [0165] internalizing units or enhancer units for enhancing targeting or uptake of the targeting agents;
- adsorption enhancer units such as fat soluble or water soluble structures that for example enhance absorption of the targeting agents in vivo; or other related units.
- [0168] for linking units that comprise amino groups: cyclic anhydrides, dicarboxylic or multivalent, optionally activated or derivatized, carboxylic acids, compounds with two or more reactive halogens or compounds with at least one reactive halogen atom and at least one carboxyl group; [0169] 2. for linking units that comprise carboxyl groups or derivatives thereof: compounds with at least two similar or different groups such as amino, substituted amino, hydroxyl, -NHNH 2 or substituted forms thereof, other known groups for the purpose (activators may be used);
- polycarboxylic substances such as EDTA, DTPA or polycarboxylic acids, or anhydrides, esters or acyl halides thereof;
- hydrazinocarboxylic acids or their like preferably so that the hydrazino moiety or the carboxyl group is protected or activated, such as 4-(FMOC-hydrazino)benzoic acid;
- Suitable solubility modifier units may comprise, for example: [0177] - for increasing aqueous solubility: Molecules comprising
- Units comprising (long) aliphatic branched or non-branched alkyl or alkenyl groups, cyclic non-aromatic groups such as the cyclohexyl group, aromatic rings or steroidal structures.
- One especially preferred aqueous-solubility enhancing unit comprises at least one unit according to Formula I:
- m is an integer of value 1 to 4.
- (A) s is a spacer group wherein each A is independently CR1R2, [0185] each Ri and R 2 is independently selected from the group of hydrogen, hydroxyl, Ci -3 alkyl and Ci -3 hydroxyalkyl,
- s is an integer of value 0 to 5
- Y is selected from COOH, CONH 2 , NH 2 and guanyl
- (A) q is a spacer group wherein each A is independently CRiR 2 , [0191] q is an integer of value 1 to 5,
- each R 1 , R 2 and R 3 is independently selected from the group of hydro- gen, hydroxyl, C 1-3 alkyl and C 1-3 hydroxyalkyl, and
- Units comprising positive, negative or both types of charges can be used as charge modifier units, as can also structures that are converted or can be converted into units with positive, negative or both types of charges.
- Spacer units may be very important, and the need to use such units depends on the other components of the structure (e.g. the type of biologically active agents used, and their mechanisms of action) and the synthetic procedures used.
- Suitable spacer units may include for example long aliphatic chains or sugar-type structures (to avoid too high lipophilicity), or large rings. Suitable compounds are available in the art. One preferred group of spacer units are omega-amino acids with long chains. Such compounds can also be used (simultaneously) as linker units between an amino-comprising unit and a carboxyl-comprising unit. Many such compounds are commercially available, both as such and in the forms of various protected derivatives.
- Units that are susceptible to hydrolysis may be very advantageous in cases where it is desired that the effector units are liberated from the targeting agents e.g. for internalization, intra- or extracellular DNA or receptor binding.
- Suitable units for this purpose include, for example, structures comprising one or more ester or acetal functionality.
- Various proteases may be used for the purposes mentioned.
- Many groups used for making pro-drugs may be suitable for the purpose of increasing or causing hydrolysis, lytic reactions or other decomposition processes.
- the effector units, the targeting units and the optional units according to the present invention may simultaneously serve more than one function.
- a targeting unit may simultaneously be an effector unit or comprise several effector units; a spacer unit may simultaneously be a linker unit or a charge modifier unit or both; a stabilizer unit may be an effector unit with properties different from those of another effector unit, and so on.
- An effector unit may, for example, have several similar or even completely different functions.
- the tumor targeting agents comprise more than one different effector units.
- the effector units may be, for example, diagnostic and therapeutic units.
- targeting agents that comprise an effector unit comprising boron atoms (preferably isotope-enriched boron) and groups detectable e.g. by PET, SPECT or NMRI.
- an effector unit comprising boron atoms (preferably isotope-enriched boron) and groups detectable e.g. by PET, SPECT or NMRI.
- the targeting units and targeting agents may, if desired, be used in combination with one or more "classical" or other tumor therapeutic modalities such as surgery, chemotherapy, other targeting modalities, radiotherapy, immunotherapy etc.
- the targeting units according to the present invention are preferably synthetic peptides.
- Peptides can be synthesized by a large variety of well-known techniques, such as solid-phase methods (FMOC-, BOC-, and other protection schemes, various resin types), solution methods (FMOC, BOC and other variants) and combinations of these. Automated apparatuses/ devices for the purpose are available commercially, as are also routine synthesis and purification services. All of these approaches are very well known to those skilled in the art.
- protecting groups are often used for protecting amino, carboxyl, hydroxyl, guanyl and -SH groups, and for any reactive groups/functions.
- Protection may also be orthogonal and/or semi/quasi/pseudo- orthogonal.
- Protecting and activating groups, substances and their uses are exemplified in the Examples and are described in the references cited herein, and are also described in a large number of books and other sources of information commonly known in the art.
- Cyclic peptides are usually especially stable in biological milieu, and are thus preferred. Cyclic structures according to the present inven- tion may be synthesized by methods based on the use of orthogonally protected amino acids, as described in e.g., International Patent Publication WO 2004/031218, incorporated herein by reference.
- the targeting units and agents according to the present invention may also be prepared as fusion proteins or by other suitable recombi- nant DNA methods known in the art. Such an approach for preparing the peptides according to the present invention is preferred especially when the effector units and/or other optional units are peptides or proteins.
- One example of a useful protein effector unit is glutathione-S-transferase (GST).
- the targeting units and targeting agents of the invention There are acknowledged problems related to peptides intended for diagnostic or therapeutic use. One of these problems stems from the length of the sequence: The longer it grows, the more difficult the synthesis of the desired product becomes, especially if there are other synthetic problems such as the presence of difficult residues that require protection- deprotection or cause side reactions. [0211] As compared to known peptides that contain long and difficult-to-make sequences with problematic amino acid residues, the peptides of the present invention are clearly superior. The targeting units of this invention can be synthesized easily and reliably.
- an advantage as compared to many prior art peptides is that the targeting units and motifs of this invention do not need to comprise the problematic basic amino acids lysine and histidine, both of which may cause serious side-reactions in peptide synthesis, and, due to which the yield of the desired product might be lowered radically or even the product might be impossible to obtain in adequate amounts or with adequate quality.
- the peptides of the present invention are much easier and cheaper to produce than most targeting peptides of the prior art.
- the targeting units of the present invention are also highly advantageous due to their specificity, non-toxicity and non-immunogenicity.
- the effector units and optional additional units may be linked to the targeting peptide when it is still connected to the resin, without the risk that the removal of the protecting groups will cause destruction of the effector or optional units. Similar advantages apply to solution syntheses.
- Another important advantage of the present invention and the products, methods and uses according to it is the highly selective and po- tent targeting of the products.
- the products and methods of in the present invention are highly advantageous because of several reasons. Potential immunological and related risks are obvious in the case of large biomolecules. Allergic reactions are of great concern with such products, in contrast to small synthetic molecules such as the targeting agents, units and motifs of the present invention.
- the products and methods described in the present invention are highly advantageous because their structure can be easily modified if needed or desired. Specific amino acids such as histidine, and threonine can be omitted, if desired, and very few functional groups are necessary. On the other hand, it is possible, without disturbing the targeting effect, to include various different structural units, to obtain specific desired properties that are of special value in specific applications.
- the targeting units and targeting agents according to the present invention are useful in cancer diagnostics and therapy, as they selectively tar-get to tumors, especially to colon tumors in vivo, as shown in the Examples.
- the effector unit may be chosen according to the desired effect, de- tection or therapy. The desired effect may also be achieved by including the effector in the targeting unit as such.
- the targeting unit itself may be e.g., radioactively labeled.
- the present invention also relates to diagnostic compositions comprising an effective amount of at least one targeting agent according to the present invention.
- a diagnostically effective amount of the targeting agents according to the present invention may range from 1 femtomol to 10 mmols, depending for example on the effector unit of choice.
- a diagnostic composition according to the present invention may, optionally, comprise carriers, solvents, vehicles, suspending agents, labeling agents and other additives commonly used in diagnostic compositions.
- Such diagnostic compositions are useful in diagnosing tumors, tumor cells and metastasis, especially tumors of the colon, more specifically colon primary tumors and metastases, in animals as well as in human subjects.
- a diagnostic composition according to the present invention may be formulated as a liquid, gel or solid formulation or as an inhalation formulation, etc., preferably as an aqueous liquid, containing a targeting agent according to the present invention in a concentration ranging from about 1 x 10 "10 mg/l mg/l to 25 x 10 4 mg/l.
- the compositions may further comprise stabilizing agents, detergents, such as polysorbates, as well as other additives. The concentrations of these components may vary significantly depending on the formulation used.
- the diagnostic compositions may be used in vivo or in vitro.
- the targeting agents and targeting units according to the present invention are useful in veterinary and human therapy.
- the present invention also includes the use of the targeting agents and targeting units for the manufacture of pharmaceutical compositions for the treatment of cancer.
- the present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of at least one targeting agent according to the present invention.
- the pharmaceutical compositions may be used to treat, prevent or ameliorate cancer diseases, by administering a therapeutically effective dose of the pharmaceutical composition comprising targeting agents or targeting units according to the present invention or therapeutically acceptable salts, esters or other derivatives thereof.
- the compositions may also include different combinations of targeting agents and targeting units together with labeling agents, imaging agents, drugs and other additives.
- a therapeutically effective amount of a targeting agent according to the present invention may vary depending on the formulation of the pharmaceutical composition.
- a pharmaceutical composition according to the present invention may comprise a targeting agent in a concentration varying from about 0.00001 mg/l to 250 g/l, more preferably about 0.001 mg/l to 50 g/l, most preferably 0.01 mg/l to 20 g/l.
- a pharmaceutical composition according to the present invention is useful for administration of a targeting agent according to the present invention.
- Pharmaceutical compositions suitable for per oral use, for intravenous or local injection, or infusion, or inhalation are particularly preferred.
- the pharmaceutical corn-positions may be used in vivo or ex vivo.
- the preparations may be lyophilized and reconstituted before ad-ministration or may be stored for example as a solutions, suspensions, suspension-solutions etc. ready for administration or in any form or shape in general, including powders, concentrates, frozen liquids, and any other types. They may also consist of separate entities to be mixed and, possibly, otherwise handled and/or treated etc. before use. Liquid formulations provide the advantage that they can be administered without reconstitution.
- the pH of the solution product is in the range of about 1 to about 12, preferably close to physiological pH.
- the osmolality of the solution can be adjusted to a preferred value using for example sodium chloride and/or sugars, polyols and/or amino acids and/or similar components.
- the compositions may further comprise pharmaceutically acceptable excipients and/or stabilizers, such as albumin, sugars and various polyols, as well as any acceptable additives, or other active ingredients such as chemotherapeutic agents.
- the present invention also relates to methods for treating cancer, especially solid tumors by administering to an animal subject, including a human patient, in need of such treatment a therapeutically efficient amount of a pharmaceutical composition according to the present invention.
- Therapeutic doses may be determined empirically by testing the targeting agents and targeting units in available in vitro or in vivo test sys- terns. Suitable therapeutically effective dosage may then be estimated from these experiments.
- Amounts and regimens for the administration of the tumor targeting agents according to the present invention can be determined readily by those with ordinary skill in the clinical art of treating cancer. Generally, the dosage will vary depending upon considerations such as: type of targeting agent employed; age; health; medical conditions being treated; kind of concurrent treatment, if any; frequency of treatment and the nature of the effect desired; gender; duration of the symptoms; and, counterindications, if any, and other variables to be adjusted by the individual physician.
- Preferred doses for ad-ministration to human patients of targeting units or agents according to the present invention may vary from about 1 x 10 "9 mg to about 40 mg per kg of body weight as a bolus or repeatedly, e.g., as daily doses.
- the targeting units and targeting agents and pharmaceutical corn-positions of the present invention may also be used as targeting devices for delivery of DNA or RNA or structural and functional analogues thereof, such as phosphorothioates, or peptide nucleic acids (PNA) into tumors and their metastases or to isolated cells and organs in vitro; i.e. as tools for gene therapy both in vivo and in vitro.
- the targeting agents or targeting units may be parts of viral capsids or envelopes, of liposomes or other "containers" of DNA/RNA or related substances, or may be directly coupled to the DNA/RNA or other molecules mentioned above.
- the targeting units and agents according to the present invention may also be modified to improve stability, e.g. lengthen the biological half-life thereof by increasing the retention or stability of the targeting unit in the desired environment such as mammalian circulation.
- stability e.g. lengthen the biological half-life thereof by increasing the retention or stability of the targeting unit in the desired environment such as mammalian circulation.
- Such properties are achieved by standard pharmaceutical formulation chemistry tools and include introduction of non-hydrolysable bonds, glycosylation, pegulation as well as mixing with pharmaceutically acceptable diluents, adjuvants, carriers or vehicles well know to a person skilled in the art.
- the targeting units may also be chemically modified to decrease in vivo proteolytic digestion thereof by meth- ods known in the art.
- kits and components of kits for diagnosing, detecting or analyzing cancer or cancer cells in vivo and in vitro comprise at least one targeting agent or targeting unit of this invention together with diagnostic entities enabling detection.
- the kit may comprise for example a targeting agent or a targeting unit coupled to a unit for detection by e.g. immunological methods, radiation or enzymatic methods or other methods known in the art.
- the targeting units and agents of this invention as well as the targeting motifs and sequences can be used as lead compounds to design peptidomimetics for any of the purposes described above.
- the targeting units and agents as well as the targeting motifs and sequences of the present invention, as such or as coupled to other materials can be used for the isolation, purification and identification of the cells, molecules and related biological targets.
- the following examples are given to further illustrate preferred embodiments of the present invention, but are not intended to limit the scope of the invention. It will be obvious to a person skilled in the art, as the technology advances, that the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described above but may vary within the scope of the claims.
- Phage display library Standard procedures according to Smith and Scott (ibid.) were used. Phage display library used for screening of clinical samples was cloned in fUSE5 vector and was of the cyclic structure CX7C. The E.coli strain K91 kan was used as host for phage amplification.
- Tissue samples were surgically removed from lung metastases of colorectal cancer patients. Part of the sample was taken for pathological examination, rest was placed in ice cold DMEM-PI (Dulbecco's medium containing protease inhibitors Pl; 10 mM PMSF (Phenyl-methyl-sulphonyl-fluoride), Aprotinin (10 mg/ml) Leupeptin (10 mg/ml)). Tissue samples were minced with a razor blade in a small cell culture plate in 1 ml of DMEM containing protease inhibitors. The samples were transferred to an eppendorf tube and washed with 1 ml DMEM-PI.
- Pl protease inhibitors Pl
- PMSF Phenyl-methyl-sulphonyl-fluoride
- infected bacteria were plated on LB agar plates con- taining 40 ⁇ g/ml tetracycline (tet) as follows: Three parallel plates of three dilu- tions (1 :250, 1 :2500, 1 :25000) and the rest of the above K91 kan culture in 300 ⁇ l aliquots. The plates were incubated overnight at +37 0 C.
- the pellet was re-suspended in 1 ml of TBS containing 0.02% NaN3 and stored at +4 0 C.
- the titre of the TBS phage stock was determined as described above.
- the setting for the PCR program used was 96 0 C for 5 min followed by a cycle of three steps 1 ) 92 0 C for 30 seconds, 2) 6O 0 C for 30 seconds and 3) 72 0 C for 1 minute. This cycle of three steps was repeated 35 times.
- the sequences of the primers used in PCR amplification were 5'- gCAAgCTgATAAACCgATACAATTAAAgg- 3' for F1-F and 5'-gCCC TCA TAg TTA gCg TAA CgA TC- 3' for F1-R.
- Peptides selectively binding to lung tumors are the following: CYGFVWGEC and CYGFLWGQC.
- the enriched peptide sequences were collected from ex vivo panning round three.
- the spacer unit reagent Fmoc-11-amino-3,6,9-undecanoic acid was purchased from University of Kuopio, Finland, and had been prepared as described previously (Boumrah, Deradji et al., Tetrahedron, 1997, 56: 6977-6992).
- the spacer unit reagent Fmoc-12-amino-4,7,10- trioxadodecanoic acid (for TEGC) was purchased from NeoMPS.
- Linker 2-aminoethanethiol was produced via the cleavage of the cysteamine resin.
- Linker 1 ,2-diamino ethane was produced via the cleavage of the diamino ethane resin.
- the thiol-reactive labeling reagent, the europium(lll) chelate of p-iodoacetamidobenzyl-DTPA was prepared from 2-(4-Aminobenzyl)- diethylenetriaminepenta (f-butyl acetate) purchased from Macrocyclics, Dallas,
- 'Ac' denotes: CH 3 C(O) i.e. acetyl (not actinium).
- 'ADGA' denotes: Ala-Asp-Gly-Ala.
- 'AMB-DTPA-Eu' denotes:
- 'amide' denotes: NH 2 group connected to carbonyl (e.g. at the C- terminus of a peptide).
- 'CYGFVWGEC denotes: Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys.
- 'Ac-aYGFVWGEE' denotes: CH 3 C(O)-(D-Ala)-Tyr-Gly-Phe-Val-Trp-Gly-
- 'a*YGFVWGEE*' denotes: (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*; lactam bridge between amino terminus of D-AIa* and the side chain COOH of
- GIuVDTPA' denotes: diethylenetriamine-N,N,N',N",N"-pentaacetic acid.
- 'EAT denotes: 2-Aminoethanethiol, also called ethyleneaminothiol, i.e.
- Teg' denotes: NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 -C(O).
- Teg3' denotes: Teg-Teg-Teg, i.e. (NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -
- TEGC denotes: NH-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -O-CH 2 CH 2 -C(O).
- the funnel was loaded with the appropriate solid phase synthesis resin and solutions for each treatment, shaken effectively with the aid of a "wrist movement" bottle shaker for an appropriate period of time, followed by filtration effected with a moderate argon gas pressure.
- 1 DCM 1 means shaking with dichloromethane
- 1 DMF 1 means shaking with N,N-dimethylformamide (DMF may be replaced by NMP, i.e., N-methylpyrrolidinone).
- the FMOC-amino acid (0.75 mmol) was dissolved in approximately 3 ml of DMF, treated for 1 min with a solution of 0.75 mmol of HBTU dissolved in 1.5 ml of a 0.5 M solution of HOBt in DMF, and then immediately treated with 1.07 ml of a 1.4 M DIPEA solution in DMF for 5 min; exceptionally 2, 4, 6-tri methyl pyridine was used instead of DIPEA in the case of the activation of FMOC-Cys(Trt)-OH.
- HBTU 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3- tetramethyluronium hexafluorophosphate, CAS No. [94790-37-1], Applied Bio- systems Cat. No. 401091 , molecular weight: 379.3 g/mol;
- HOBt 1-Hydroxybenzotriazole, CAS No. 2592-
- DIPEA N,N-Diisopropylethylamine, CAS No. 7087-68-5, molecular weight 129.24 g/mol, Acros Organics Cat. No. 115221000.
- the procedure described above is repeated in several cycles using different FMOC-amino acids, containing suitable protecting groups, to produce a "resin-bound" peptide (i.e., resinous source of an appropriate pep- tide).
- the procedure provides also a way to connect certain linker units, for instance FMOC-Teg (i.e., Fmoc-11-amino-3,6,9-undecanoyl moiety), to the resin-bound peptide.
- the very first unit (at the C-terminal end of the sequence) can be connected to Rink amide resin or to cysteamine resin by means of this general coupling method described above; in the case of cys- teamine resin the initial treatment with piperidine (steps 3 to 11 ) is not necessary at the first cycle.
- the first cycle was carried out with 0.25 mmol of activated reagent in step 12 above (instead of usual 0.75 mmol) followed by resin capping between steps 12 and 13 by means of acetylation for 30 min using reagent mixture: 2 ml of acetic anhydride and 1 ml of 2,4,6-trimethylpyridine mixed in 4 ml of DMF.
- TFA trifluoroacetic acid
- Maldi-tof negative ion reflector mode [0319] External standards: cholecystokinin and glucagon or [GIuI]- fibrinogen peptide B.
- Matrix alpha-cyano ⁇ -hydroxycinnamic acid (saturated solution in acetone).
- Sample preparation [0321] The specimen was mixed at a 10-100 picomol/microliter concentration with the matrix solution as described and dried onto the target.
- M+1 i.e., the one proton adduct
- M+1 signal pattern was accompanied by a similar but markedly weaker band of peaks at M+23 (Na + adduct).
- bands at M+1 and M+23 also bands at M+39 (K + adduct) or M+56 (Fe + adduct) could be observed in many cases.
- ADGA-CYG FLWGQC-Teg3-amide i.e. Ala-Asp-Gly-Ala-Cys-Tyr-Gly-Phe-Leu-Trp-Gly-Gln-Cys-Teg-Teg-Teg-NH 2 , that has solubility-enhancing units and is cyclic by virtue of disulfide bond be- tween the two cysteines (Cys)
- the crude peptide was cyclized according to the air oxidation protocol described above and purified by RP-HP
- ADGA-CWEGGLYFC-Teg3-amide i.e. Ala-Asp-Gly-Ala-Cys-Trp-Glu-Gly-Gly-Leu-Tyr-Phe-Cys-Teg-Teg-NH2
- ADGA-CWEGGLYFC-Teg3-amide i.e. Ala-Asp-Gly-Ala-Cys-Trp-Glu-Gly-Gly-Leu-Tyr-Phe-Cys-Teg-Teg-Teg-NH2
- Cys cysteines
- the N-terminus was acetylated according to the general protocol described above and the compound was cleaved off the resin, as described above, and cyclized in 0.05 M ammonium bicarbonate solution exposed by air at room temperature over night, and then purified by RP-HPLC.
- cystine-bridged targeting agent Acetyl- CYGFVWGEC-(TEGC-Glu) 2 -NHCH2CH2NHC(S)-p-NH-Benzyl-DTPA-Eu comprising a europium chelating effector unit, a solubility-enhancing spacer unit and a targeting unit CYGFVWGEC, i.e.
- Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys cyclic by virtue of the disulfide bond between the cysteines (Cys) was performed as follows: 2.5 mol equivalents (0.00363 mmol) of ITC-DTPA (p-SCN-Benzyl-DTPA, Macrocyclics, Dallas Texas, MW: 649.92 g/mol) was dissolved in 0.33 ml of 0.05 M aqueous Na- HCO 3 .
- the compound was purified by RP-HPLC at water- acetonitrile eluent gradient buffered by 0.05 M ammonium acetate, and the desired product was identified by MALDI-TOF mass spectrometry: Observed positive ions M+1 : 2497.80 Da, M+Na: 2521.80 Da, M+K: 2537.77 Da. [0339] Calculated isotopic M: 2498.814 Da.
- Acetyl-(D-Ala)-Trp-Glu-Tyr-Gly-Val-Gly-Phe-Glu-(TEGC-Glu) 2 -EAT comprising a sulfhydryl bearing linker unit via a solubility-enhancing spacer unit at the C- terminus of the peptide sequence, was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including unusual Fmoc-TEGC-OH that was used in the regular manner).
- the N-terminus was acetylated according to the general protocol described above and after release from the resin the crude peptide was purified by RP-HPLC.
- Acetyl-(D-Ala)-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu-(Teg-Glu) 2 -EAT comprising targeting unit aYGFVWGEE and sulfhydryl bearing linker agent via solubility- enhancing spacer units at the C-terminus of the targeting unit was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner).
- the N-terminus was acetylated according to the general protocol described above and after release from the resin the crude peptide was purified by RP-HPLC.
- lactam-bridged targeting agent a*YGFVWGEE*-Teg-Glu i.e. (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*-Teg- GIu
- a lactam bridge between the N-terminus and the side- chain of E* (glutamic acid) and bearing a solubility-enhancing unit at the C- terminus of the targeting unit was carried out manually according to the general protocol described above and was based on Fmoc-Glu(OtBu)-Wang resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner).
- the lactam bridge was prepared according to the general protocol described above and the peptide was purified by RP-HPLC.
- lactam-bridged targeting agent a*YGFVWGEE*-(Teg-Glu) 2 -EAT i.e. (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*-(Teg-Glu) 2 -EAT (lactam bridge be- tween N-terminus of a* and side chain COOH group of E*) comprising the targeting unit a*YGFVWGEE* and a sulfhydryl bearing linker agent via solubility- enhancing spacer units at the C-terminus of the targeting unit, was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner).
- the lactam bridge was prepared according to the general protocol described above and the peptide was purified by
- CH 2 C(O)-p-aminobenzyl-DTPA-Eu comprising targeting unit aYGFVWGEE and a europium-bearing DTPA chelate coupled via a thioether bond (included in 1 AMB 1 linkage) and solubility-enhancing spacer units at the C-terminus of the targeting unit, was carried out in aq NaHCO 3 .at pH 8.5.
- the peptide (MJ012, 1 eq) was dissolved in 0.05 M NaHCO 3 and the Eu 3+ -chelate of (p- iodoacetamidobenzyl)diethylenetriamine-N,N,N',N",N"-penta-acetic acid (Eu- DTPA-IAA, 2 eq) in 0.05 NaHCO 3 was added to the peptide solution. After this, pH was adjusted to 8.5, the solution was protected from light and allowed to stay overnight at 37 0 C
- the DTPA-Eu labeled peptide was purified by RP- HPLC at water-acetonitrile eluent gradient buffered by 0.05 M ammonium acetate.
- the peptide (MJ013, 1 eq) was dissolved in 0.05 M NaHCO 3 and the Eu 3+ -chelate of (p- iodoacetamidobenzyl)diethylenetriamine-N,N,N',N",N"-penta-acetic acid (Eu- DTPA-IAA, 2-3 eq) in 0.05 NaHCO 3 was added to the peptide solution. After pH was adjusted to 8.5, the solution was protected from light and allowed to stay overnight at 37 0 C The DTPA-Eu labeled peptide was purified by RP- HPLC at water-acetonitrile eluent gradient buffered by 0.05 M ammonium ace- tate.
- HCT-15 human colorectal cancer HCT-15 cell line (ATCC: CCL- 225), called herein also "HCT-15"
- RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 1% penicillin/streptomycin, 10% fetal bovine serum.
- LoVo The human colon adenocarcinoma cell line LoVo (ATCC:CCL-229), called herein "LoVo", was cultured in Ham's F-12 medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, 1.5 g/L sodium bicarbonate and 10% fetal bovine serum.
- the colorectal cancer cell line HCT-15-LM1 was developed as follows. The cell culture was started with cancer cells from lung metastases which had developed after injection of human colorectal cancer HCT-15 cells into the bloodstream of a mouse. The inoculation procedure was then repeated with HCT-15-LM1 cells leading to the establishment of another metastatic cell line, HCT-15-LM2.
- the mouse fibroblast line NIH3T3, called herein also "NIH3T3", has been described previously by Koga et al. in Gann, 1979, 70: 585-591.
- the cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
- mice vascular endothelial cell line SVEC4-10 has been described previously by O'Connell et al. in J. Immunol., 1990, 144: 521-525.
- the cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
- C8161T The human melanoma cell line C8161 has been described previously by Welch et al. in Int. J. Cancer, 1991 , 47: 227-237.
- a more metas- tatic cell line C8161T, called herein also "C8161T” was developed by culturing cells from a subcutaneous melanoma tumor developed after inoculation of C8161 melanoma cells on the flank of a nude mouse. The cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
- HSC-3 human oral squamous cell carcinoma line HSC-3
- HSC-3 JCRB Cell Bank 0623, National Institute of Health Sciences, Japan
- FBS fetal bovine serum
- penicillin/streptomycin 1% penicillin/streptomycin
- L-glutamate 1% penicillin/streptomycin
- sodium pyruvate 0.4 ng/ml hydrocortisone.
- Maleimide activated clear strip plate (Pierce, Prod#. 15150) were coated with targeting agents of this invention at a concentration of 30 ⁇ g/ml. The incubation was carried out of overnight at 2O 0 C. The binding buffer containing unbound peptide was removed from the wells. [0368] The wells were blocked with blocking buffer (0.5% BSA,
- PBS phosphate buffer saline
- FIG. 1 The results of the cell binding assay showing the selective binding of cancer cell lines to the targeting agents are shown in Figure 1.
- the colon cancer cell lines HCT-15 (A), HCT-15-LM1 (B), tongue carcinoma HSC-3 (C) and melanoma cell line C8161T (D) bind selectively to the immobilized targeting agents MJ012 (Figure 1A) and MJ013 ( Figure 1 B), whereas the control cell lines, mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) show significantly less binding.
- the results are shown as measured absorbance at 560 nm.
- biodistribution of the targeting agents MJ017 and MJ018 (described in Example 2) is shown for primary tumors of HTC-15 and lung metastases of HCT-15-LM1. It is shown that the tested targeting agents according to the present invention selectively target to primary tumors in vivo as well as lung metastases but not to normal tissues or organs.
- the used targeting agent shows highly selective tumor and metastase targeting properties.
- LoVo cell line (described in example 3) was exposed to two different concentrations (5 ⁇ g/ml and 138 ⁇ g/ml) of targeting unit HP203 (described in Example2) for three days to test the toxicity of the peptides.
- the measurement of cell viability was done with MTT (Thiazolyl blue, Sigma M-5655) tetrazolium salt. MTT is cleaved to water-insoluble formazan dye by the "succinate-tetrazolium reductase" system, which is active only in viable cells.
- HP203 targeting unit was found non-toxic for the tested cell line whereas CuSAO 2 7.5 ⁇ g/ml, used as a positive control, showed 100% cell killing.
- targeting unit HP203 (described in Example 2) was injected i.v. into the tail vein of three Athymic nude mice in a volume of 100 ⁇ l of sterile physiological saline. The behavior of mice was observed during 30 min right after injection and during 15 min on the following day (comparison to non-injected mouse). Injection of targeting unit HP203 did not have any toxic effect on mice.
- This example is provided to show that targeting units MJ017 and MJ018 (described in Example 2) when coupled to cytotoxic substances can be used as therapeutic agents for the treatment of colon cancer.
- Example 3 Production of experimental colon cancer tumors is described in Example 3. Mice bearing colon cancer tumors on their flanks are divided into two groups: Control animals receiving a standard dose of a cytotoxic substance administrated intravenously, and the test animals receiving an equal amount of said cytotoxic substance coupled to targeting unit MJ017 or MJ018. Body weight loss, indicating toxicity and tumor growth delay indicating antitumor activity are followed. Weight and tumor size are measured every third day for four weeks. The experiment is terminated before the final endpoint if the body weight of the animal is reduced by 30% from the baseline. [0396] Net body weight loss is calculated as:
Abstract
The present invention relates to tumor targeting units comprising a peptide sequence Cy-Y-G-F-X-W-G-Z-Cyy, or a pharmaceutically or physiologically acceptable salt thereof. The invention further relates to tumor targeting agents comprising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit. The present invention further relates to diagnostic or pharmaceutical compositions comprising at least one targeting unit or at least one targeting agent according to the present invention, and to the use of targeting units or targeting agents according to the present invention for the preparation of a medicament for the treatment of cancer or cancer related diseases, especially for the treatment of colon/colorectal cancer or its metastases.
Description
DIAGNOSTIC AND THERAPEUTIC AGENTS
Field of the invention
[0001] The present invention relates to targeting agents, especially to tumor targeting agents, such as colon/colorectal primary tumor and metas- tases targeting agents, comprising at least one targeting unit and at least one effector unit, as well as to tumor targeting units and motifs, such as colon/colorectal primary tumor and metastases targeting units and motifs. Further, the present invention concerns pharmaceutical and diagnostic compositions comprising such targeting agents or targeting units, and the use of such targeting agents and targeting units as pharmaceuticals or as diagnostic tools. The invention further relates to the use of such targeting agents and targeting units for the preparation of pharmaceutical or diagnostic compositions. Furthermore, the invention relates to kits for diagnosing or treating cancer, such as colon/colorectal primary tumor and metastases.
Background of the invention
[0002] Malignant tumors are among the greatest health problems of man as well as animals, being one of the most common causes of death, also among young individuals. Available methods of treatment of cancer are quite limited, despite intensive research efforts during several decades. Although curative treatment, usually surgery in combination with chemotherapy and/or radiotherapy, is sometimes possible, malignant tumors still require a huge number of lives every year. In fact, curative treatment is rarely accomplished if the disease is not diagnosed early. In addition, certain tumor types can rarely, if ever, be cured. [0003] There are various reasons for this very undesirable situation, the most important one clearly being the fact that most treatment schedules, except surgery, lack sufficient selectivity. Chemotherapeutic agents commonly used do not act on the malignant cells of the tumors alone but are highly toxic to other cells as well, especially to rapidly dividing cell types, such as hemato- poietic and epithelial cells, resulting in highly undesirable side effects. The same applies to radiotherapy.
[0004] In addition, two major problems plague the non-surgical treatment of malignant solid tumors. Physiological barriers within tumors impede the delivery of therapeutics at effective concentrations to all cancer cells,
and acquired drug resistance resulting from genetic and epigenetic mechanisms reduces the effectiveness of available drugs.
[0005] Also in the diagnosis of cancer and of metastases, including the follow-up of patients and the study of the effects of treatment on tumors and metastases, reliable, sensitive and more selective methods and agents would be a great advantage. All methods currently in use, such as nuclear magnetic resonance imaging, X-ray methods, histological staining methods still lack agents that are capable of targeting an entity for detection specifically or selectively to tumor tissues, metastases or tumor cells and/or to tumor endo- thelium.
[0006] According to The National Cancer Institute colorectal cancer is the third most common cancer and the third leading cause of cancer-related mortality in the United States. Over the past decade, colorectal cancer incidence and mortality rates have modestly decreased or remained level. Until age 50, men and women have similar incidence and mortality rates; after age 50, men are more vulnerable.
[0007] The prognosis of patients with colon cancer is clearly related to the degree of penetration of the tumor through the bowel wall, the presence or absence of nodal involvement, and the presence or absence of distant me- tastases. These three characteristics form the basis for all staging systems developed for this disease. Bowel obstruction and bowel perforation are indicators of poor prognosis.
[0008] Surgery is the treatment of choice for colorectal cancer. Treatment depends on the stage of the disease and the overall health of the patient. Radical bowel resection, also called partial colectomy and hemicolectomy, is used to treat 80-90% of colorectal cancer patients. Chemotherapy and radiation therapy may be used as adjuvant treatment.
[0009] Chemotherapy is a systemic treatment that often uses a combination of drugs to slow tumor growth and destroy cancer cells. It is often used as a first-line treatment for metastatic colorectal cancer. A combination of chemotherapy drugs (5-fluorouracil [5-FU], leucovorin, and irinotecan), administered intravenously, is standard treatment for metastatic colorectal cancer. Side effects include diarrhea, mucositis, neutropenia and alopecia. Newer combinations of chemotherapy drugs, such as FOLFOX (5-fluorouracil [5-FU], leucovorin, and oxaliplatin and FOFIRI (5-fluorouracil, leucovorin, and iri-
notecan may be used to prevent recurrence following surgery or to shrink the tumor prior to surgery.
[0010] In addition to chemotherapy drugs, blocking agents, e.g. cetuximab, (an anti-EGF mAb) may also be used to treat metastatic colorectal cancer. These drugs prevent cancer cell receptors from receiving factors (e.g., epidermal growth factor) that cause cell growth, cell division, and additional metastasis. Blocking agents target specific cells so they usually do not cause systemic side effects. Side effects of these drugs include allergic reactions.
[0011] An example of antiangiogenic drugs is bevacizumab (an anti- VEGF mAb), which may also be used to treat advanced colorectal cancer. This medication prevents new blood vessels, which are necessary for tumor growth, from forming. It does not affect normal tissues that already have an established blood supply. Side effects include blood clots and high blood pressure. [0012] Immunotherapy, or biological therapy, attempts to stimulate the immune system to fight disease and protect the body from side effects of chemotherapy. Immunotherapy agents that may be used to treat colorectal cancer include bacilli Calmette-Guerin (BCG) and levamisole. Immunotherapy may cause flu-like side effects such as chills, diarrhea, fever, anorexia, muscle aches and weakness, nausea and vomiting. [0013] Monoclonal antibodies specific to tumor cells have shown clinical promise as targeted agents for the treatment of e.g. lung cancer. There are some major limitations in antibody-targeted therapy based on two facts: the large size of the monoclonal antibodies and non-specific uptake of the antibody molecules by the liver and the reticuloendothelial system. The large size results in poor tumor penetration of antibody pharmaceuticals and causes often immune response, whereas non-specific uptake by the liver and the reticuloendothelial system results in dose-limiting toxicity to the liver and bone marrow. Another, hazardous disadvantage with the antibodies is their incorrect glycosylation when produced in cell culture. [0014] Targeting peptides are an excellent alternative for targeted treatment of human cancers, and due to relatively small size they may overcome some of the problems with antibody targeting. Advantages of peptides are: Greater stability - peptides can be stored at room temperature for weeks; lower manufacturing costs (synthetic production versus recombinant produc- tion); rapid pharmacokinetics; excretion route that can be modified; and higher activity per mass of final targeting agent.
[0015] There are numerous publications disclosing peptides homing to different cell and tissue types. Some of these are claimed to be useful as cancer targeting peptides. Among the earliest identified homing peptides described are the integrin and NGR-receptor targeting peptides described by Ru- oslahti et al., in e.g., US Patent No 6,180,084.
[0016] International Patent publication WO 02/057299 describes a peptide suggested to inhibit cancer cell proliferation by binding to VEGF-R3.
[0017] No publications disclosing peptides selectively targeting colon cancer cells have been identified. Thus, there is a need for targeting agents useful in diagnosis and therapy of colon cancer.
Brief description of the invention
[0018] The present invention relates to tumor targeting units, targeting to colon primary tumor and metastases, having a peptide sequence Cy - Y - G - F - X - W - G - Z - Cyy or a pharmaceutically or diagnostically or physiologically acceptable salt or derivative thereof, wherein Y is tyrosine, or a structural or functional analogue thereof; G is glycine, or a structural or functional analogue thereof; F is phenylalanine, or a structural or functional analogue thereof; X is alanine, valine, leucine or isoleucine, or a structural or functional analogue thereof; W is tryptophan, or a structural or functional analogue thereof; Z is glutamine or glutamic acid, or a structural or functional analogue thereof; and Cy and Cyy are optional entities forming a cyclic structure. The targeting units of the present invention may be linear or cyclic or form part of a cyclic structure.
[0019] The invention further relates to tumor targeting agents com- prising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit. Preferably the effector unit is a directly or indirectly detectable substance or a therapeutic substance.
[0020] The invention further relates to tumor targeting agents further comprising optional units such as solubility enhancing units, preferably aque- ous enhancing units.
[0021] The present invention further relates to diagnostic or pharmaceutical compositions comprising at least one targeting unit or at least one targeting agent according to the present invention, and to the use of targeting units or targeting agents according to the present invention for the preparation of a medicament for the treatment or diagnosis of cancer or cancer related diseases, especially for the treatment of colon cancer or its metastases.
[0022] The present invention further relates to methods for treating or diagnosing cancer or cancer related diseases by providing to a patient in need thereof a diagnostically or therapeutically effective amount of a pharmaceutical composition according to the present invention for diagnosing or treat- ing colon cancer or its metastases.
Brief description of the drawings
[0023] In the following the invention will be described in greater detail by means of preferred embodiments with reference to the attached drawings, in which [0024] Figure 1A shows the binding of cancer cell lines HCT-15 (A),
HCT-15-LM1 (B), HSC-3 (C) and C8161T (D), and control cell lines, mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) to the immobilized targeting agent MJ012. Y-axis represents viable count.
[0025] Figure 1 B shows the binding of cancer cell lines HCT-15 (A), HCT-15-LM1 (B), HSC-3 (C) and C8161T (D), and, control cell lines, mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) to the immobilized targeting agent MJ013. Y-axis represents viable count.
[0026] Figure 2A shows the in vivo biodistribution of the targeting agent MJ017 after injection into the tail vein of tumor-bearing athymic mice. A= tumor, B= heart, C= lung, D= liver, E= spleen, F= small intestine and G= brain. Y-axis represents the europium content in a tissue as compared to the europium content in a muscle.
[0027] Figure 2B shows the in vivo biodistribution of the targeting agent MJ018 after injection into the tail vein of tumor-bearing athymic mice. A= tumor, B= heart, C= lung, D= liver, E= spleen, F= small intestine and G= brain. Y-axis represents the europium content in a tissue as compared to the europium content in a muscle.
[0028] Figure 3 shows the results of a cytotoxicity assay as viable count vs. time. LoVo cells were treated with Cu(SAO)2 (A), DMSO (B), 138 μg/ml HP203 (C) or 5 μg/ml HP203 (D).
Detailed description of the invention
[0029] It is an object of the present invention to provide novel tumor targeting agents that comprise at least one targeting unit and, optionally, at least one effector unit. In an important embodiment, the invention provides tar- geting units comprising at least one motif capable of targeting solid tumors of
the colon. As a specific embodiment, the present invention provides tumor targeting motifs and units that specifically target colon primary tumor cells and metastases.
[0030] The targeting units according to the present invention, op- tionally coupled to at least one effector unit, are therapeutically and diagnosti- cally useful, especially in the treatment and diagnosis of cancer, including metastases, preferably tumors and metastases of the colon. Furthermore the targeting agents according to the present invention are useful for cell removal, selection, sorting and enrichment. [0031] It is a second object of this invention to provide pharmaceutical and diagnostic compositions comprising at least one targeting agent or at least one targeting unit comprising at least one motif according to the present invention. Such compositions may be used to destroy tumors or hinder their growth, or for the diagnosis of cancer. [0032] Preferred pharmaceutical and diagnostic compositions comprise at least one targeting agent or at least one targeting unit comprising at least one motif according to the present invention and an optional unit which is an aqueous solubility-enhancing unit.
[0033] As early diagnosis of metastases is very important for suo cessful treatment of cancer, an important use of the targeting units and targeting agents of this invention is in early diagnosis of tumor metastases.
[0034] A third object of the present invention is to provide novel diagnostic and therapeutic methods and kits for the treatment and/or diagnosis of cancer, preferably cancer of the colon, including metastases. [0035] The targeting units of this invention may be used as such or coupled to at least one effector unit.
[0036] For the purpose of this invention, the term "cancer" is used herein in its broadest sense, and includes any disease or condition involving transformed or malignant cells. In the art, cancers are classified into five major categories, according to their tissue origin (histological type): Carcinomas, sarcomas, myelomas, and lymphomas, which are solid tumor type cancers, and leukemias, which are "liquid cancers". The term cancer, as used in the present invention, is intended to primarily include all types of diseases characterized by solid tumors, including disease states where there is no detectable solid tumor or where malignant or transformed cells, "cancer cells", appear as diffuse infil-
trates or sporadically among other cells in healthy tissue. The term "colon cancer" is herein intended to include both colon cancer and colorectal cancer.
[0037] The terms "amino acid" and "amino alcohol" are to be interpreted herein to include also diamino, triamino, oligoamino and polyamino ac- ids and alcohols; dicarboxyl, tricarboxyl, oligocarboxyl and polycarboxyl amino acids; dihydroxyl, trihydroxyl, oligohydroxyl and polyhydroxyl amino alcohols; and analogous compounds comprising more than one carboxyl group or hy- droxyl group and one or more amino groups. Any amino acid referred to in the present application is intended to include all isomers thereof, such as optical and geometrical isomers.
[0038] By the term "peptide" is meant, according to established terminology, a chain of amino acids (peptide units) linked together by peptide bonds to form an amino acid chain. Peptides may be linear or cyclic, and comprise branches, as described below. For the purposes of the present invention, also compounds comprising one or more D-amino acids, beta-amino acids and/or other unnatural amino acids (e.g. amino acids with unnatural side chains) are included in the term "peptide". For the purposes of the present invention, the term "peptide" is intended to include peptidyl analogues comprising modified amino acids. Such modifications may for example comprise the introduction or presence of a substituent; the introduction or presence of an "extra" functional group such as an amino, hydrazino, carboxyl, formyl (aldehyde) or keto group, or another moiety; and the absence or removal of a functional group or other moiety. The term also includes analogues modified in the amino and/or carboxy termini, such as peptide amides and N-substituted am- ides, peptide hydrazides, N-substituted hydrazides, peptide esters, and their like, and peptides that do not comprise the amino-terminal -NH2 group or that comprise e.g. a modified amino-terminal amino group or an imino or a hydrazino group instead of the amino-terminal amino group, and peptides that do not comprise the carboxy-terminal carboxyl group or comprise a modified group instead of it, and so on.
[0039] Some examples of possible reaction types that can be used to modify peptides, forming "peptidyl analogues", are e.g., condensation and nucleophilic addition reactions as well as esterification, amide formation, formation of substituted amides, N-alkylation, formation of hydrazides, and salt formation. Salt formation may be the formation of any type of salt, such as alkali or other metal salt, ammonium salt, salts with organic bases, acid addition
salts etc. Peptidyl analogues may be synthesized either from the corresponding peptides or directly (via other routes).
[0040] The expression "structural or functional analogues" of the peptides of the invention is used to encompass compounds that do not consist of amino acids or not of amino acids alone, or some or all of whose building blocks are modified amino acids. Different types of building blocks can be used for this purpose, as is well appreciated by those skilled in the art. The function of these compounds in biological systems is essentially similar to the function of the peptides. The resemblance between these compounds and the original peptides is thus based on structural and functional similarities. Such compounds are called peptidomimetic analogues, as they mimic the function, conformation and/or structure of the original peptides and, for the purposes of the present invention, they are included in the term "peptide".
[0041] A functional analogue of a peptide according to the present invention is characterized by a binding ability with respect to the binding to tumors, tumor tissue, tumor cells or tumor endothelium which is essentially similar to that of the peptides they resemble. For example, compounds like ben- zolactam or piperazine containing analogues based on the structure of the peptide bond comprising structures of the original amino acids can be used as amino acid analogues (Adams et al. 1999, J. Immunol. Methods, 231 : 249- 260; Nakanishi and Kahn, 1996, In: The practice of medical chemistry, pp. 571-590, Academic Press; Houghten et al., 1999, J. Med. Chem., 42: 3743- 3778; Nargund et al., 1998, J. Med. Chem., 41 : 3103-3127).
[0042] A large variety of different types of peptidomimetic sub- stances have been reported in the scientific and patent literature and are well known to those skilled in the art. Peptidomimetic substances (analogues) may comprise for example one or more of the following structural components: reduced amides, hydroxyethylene and/or hydroxyethylamine isosteres, N -methyl amino acids, urea derivatives, thiourea derivatives, cyclic urea and/or thiourea derivatives, poly(ester imide)s, polyesters, esters, guanidine derivatives, cyclic gua-nidines, imidazoyl compounds, imidazolinyl compounds, imidazolidinyl corn-pounds, cyclic amines, cyclic esters, aromatic rings, bicyclic systems, hy- dantoins and/or thiohydantoins as well as various other structures. Many types of compounds for the synthesis of peptidomimetic substances are available from a number of commercial sources (e.g. Peptide and Peptidomimetic Synthesis, Reagents for Drug Discovery, Fluka ChemieGmbH, Buchs, Switzer-
land, 2000 and Novabio-chem 2000 Catalog, Calbiochem-Novabiochem AG, Laufelfingen, Switzerland, 2000). The resemblance between the peptidomi- metic compounds and the original peptides is based on structural and/or functional similarities. Thus, the peptidomimetic compounds mimic the properties of the original peptides and, for the purpose of the present application, their binding ability is similar to the peptides that they resemble. Peptidomimetic compounds can be made up, for example, of unnatural amino acids (such as D- amino acids or amino acids comprising unnatural side chains, or of beta-amino acids etc.), which do not appear in the original peptides, or they can be con- sidered to consist of or can be made from other compounds or structural units. Examples of synthetic peptidomimetic compounds comprise N-alkylamino cyclic urea, thiourea, polyesters, poly(ester imide)s, bicyclic guanidines, hydan- toins, thiohydantoins, and imidazol-pyridino-inoles (Houghten et al. 1999, ibid, and Nargund et al., 1998, ibid.). Such peptidomimetic compounds can be characterized as being "structural or functional analogues" of the peptides of this invention.
[0043] For the purpose of the present invention, the term "targeting unit" stands for a compound, a peptide or a structural or functional analogue thereof, capable of selectively targeting and selectively binding to tumor tissue, tumors, and, preferably, also to tumor stroma, tumor parenchyma and/or extracellular matrix (ECM) of tumors. More specifically, the targeting units may bind to a cell surface, to a specific molecule, molecular complex or structure on a cell surface or within the cells, extracellularly in the vicinity of cells or they may associate with the extracellular matrix present between the cells. The tar- geting units may also bind to the endothelial cells or the extracellular matrix of tumor vasculature. The targeting units may bind also to the tumor mass, tumor cells and extracellular matrix of metastases.
[0044] Generally, the terms "targeting" or "binding" stand for adhesion, at-attachment, affinity or binding of the targeting units of this invention to tumors, tumor cells and/or tumor tissue to the extent that the binding can be objectively measured and determined e.g., by peptide competition experiments in vivo or ex vivo, on tumor biopsies in vitro or by immunological stainings in situ, or by other methods known by those skilled in the art. Tumor targeting means that the targeting units specifically bind to tumors when administered to a human or animal body. Another term used in the art for this specific association is "homing". Targeting units and targeting agents according to the present
invention are considered to be "bound" to the tumor target in vitro, when the binding is strong enough to withstand normal sample treatment, such as washes and rinses with physiological saline or other physiologically acceptable salt or buffer solutions at physiological pH, or when bound to a tumor target in vivo long enough for the effector unit to exhibit its function on the target.
[0045] The binding of the present targeting agents or targeting units to tumors is "selective" meaning that they do not bind to normal cells and organs, or bind to such to a significantly lower degree as compared to tumors. The binding of the present targeting agents to non-cancer cells tested is less than 45% of binding to the cancer cell lines.
[0046] Pharmaceutically or physiologically or diagnostically acceptable salts and derivatives of the targeting units and agents of the present invention include e.g. salts, esters, amides, hydrazides, N-substituted amides, N-substituted hydrazides, hydroxamic acid derivatives, decarboxylated and N- substituted derivatives thereof. Other suitable pharmaceutically acceptable derivatives are readily acknowledged by those skilled in the art.
[0047] The present invention is based on the finding that a group of linear or cyclic peptides having specific amino acid sequences or motifs are capable of selectively targeting tumors, especially colon primary tumors and metastases, in vivo and tumor cells in vitro. Thus, the peptides of this invention, when administered to a human or animal subject, are capable of selectively binding to tumors but do not bind to normal tissue in the body.
[0048] The tumor targeting units according to the present invention were identified by bio-panning of phage display libraries. Phage display is a method whereby libraries of random peptides are expressed on the surface of a bacteriophage as part of the phage capsid protein pill by insertion of its encoding DNA sequence into gene III of the phage genome. The pill libraries display 3-5 copies of each individual peptide per phage particle (Smith and Scott, 1993, Methods Enzymol., 217: 228-257). [0049] Phage display peptide libraries were screened by bio- panning to select peptides that are specific to colon cancer. The principle of bio-panning comprises 1) exposing homogenized tissue samples to a phage library, 2) washing off unbound phages, and 3) rescuing the phages bound to the target tissue. Repeating steps 1-3 results in a selection of highly enriched peptides having a high binding affinity towards the target tissue compared to other peptides of the original phage library. In the present invention a phage
display peptide library was panned against tissue samples taken from primary tumors of colon cancer patients, as described in more detail in the Examples section.
Targeting motifs according to the present invention [0050] It has now surprisingly been found that a seven-amino-acid motif
[0051] Y - G - F - X -W - G - Z,
[0052] wherein Y is tyrosine, or a structural or functional analogue thereof; G is glycine, or a structural or functional analogue thereof; F is phenylalanine, or a structural or functional analogue thereof; X is alanine, valine, leucine or isoleu- cine, or a structural or functional analogue thereof; W is tryptophan, or a structural or functional analogue thereof; Z is glutamine or glutamic acid, or a structural or functional analogue thereof; targets and exhibits selective binding to tumors and tumor cells and, especially, to colon/colorectal primary tumors and metastases.
[0053] According to the present invention, Y is tyrosine, or a structural or functional analogue thereof characterized either by its ability to structurally mimic tyrosine, for example by virtue of comprising a ring structure of a similar or related type, as compared to the ring structure of tyrosine; or by vir- tue of comprising another structure that sterically or electrically can be considered as an equivalent of the ring structure of tyrosine. Typically, structural and functional analogues of tyrosine may also be characterized by their ability to mimic the acid-base or electric or bond-conjugation or hydrogen-bond- formation or aromatic or other functional or related properties of tyrosine, e.g. by comprising one or more aromatic rings, one or more hydroxyl groups, often preferably phenolic hydroxyl groups, etc., as is understood by those skilled in the art.
[0054] Many types of structural and functional analogues of tyrosine are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0055] Structural and functional analogues of tyrosine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-fluorotyrosine, 3- fluorotyrosine, 2,3-difluorotyrosine, 2,5-difluorotyrosine, 2,6-difluorotyrosine, 2-
chlorotyrosine, 3-chlorotyrosine, 2,3-dichlorotyrosine, 2,5-dichlorotyrosine, 2,6- dichlorotyrosine, 2-bromotyrosine, 3-bromotyrosine, 2,3-dibromotyrosine, 2,5- dibromotyrosine, 2,6-dibromotyrosine, 2-iodotyrosine, 3-iodotyrosine, 2,3- diiodotyrosine, 2,5-diiodotyrosine, 2,6-diiodotyrosine, 2,3,5-trifluorotyrosine, 2,3,6-trifluorotyrosine, 2,3,5,6-tetrafluorotyrosine, 2,3,5-trichlorotyrosine, 2,3,6- trichlorotyrosine, 2,3,5,6-tetrachlorotyrosine, 2,3,5-tribromotyrosine, 2,3,6- tribromotyrosine, 2,3,5,6-tetrabromotyrosine, 2,3,5-triiodotyrosine, 2,3,6- triiodotyrosine, 2,3,5,6-tetraiodotyrosine, other di-, tri- and tetrahalogenated tyrosines, 2-methyltyrosine, 3-methyltyrosine, 2,3-dimethyltyrosine, 2,5- dimethyltyrosine, 2,6-dimethyltyrosine, 2-ethyltyrosine, 3-ethyltyrosine, 2,3- diethyltyrosine, 2,5-diethyltyrosine, 2,6-diethyltyrosine, other mono-, di-, tri- and tetraalkylated tyrosines, phosphotyrosine, tyrosine esterified at the phenolic hydroxyl with acetic or fluorocaetic or difluoroacetic or trifluoroacetic or formic or propionic acid or other carboxylic acid, tyrosine etherified at the phenolic hydroxyl with methanol or ethanol or other alcohol, alpha- methyltyrosine, alpha-ethyltyrosine, alpha-propyltyrosine, other alpha-alkylated tyrosines, (2-hydroxyphenyl)-alanine, (3-hydroxyphenyl)-alanine, (2,3- dihydroxyphenyl)-alanine, (2,4-dihydroxyphenyl)-alanine, (2,5- dihydroxyphenyl)-alanine, (2,6-dihydroxyphenyl)-alanine, (3,4- dihydroxyphenyl)-alanine, (3,5-dihydroxyphenyl)-alanine, trihydroxyphenyl- alanines, tetrahydroxyphenyl-alanines, pentahydroxyphenyl-alanine, (ring- hydroxyl)-esterified forms of said hydroxylated phenyalanines (both those esterified at all hydroxyl functions and those not esterified at all hydroxyl functions), 4-(4-hydroxyphenyl)-2-aminobutanoic acid, other tyrosine ana- logues comprising a longer aliphatic part between the carboxyl function and the aromatic ring than in tyrosine, 3-[3-hydroxy-(1-naphtyl)]-2-aminopropionic acid and its analogues carrying the phenolic hydroxyl at another position in the naphtyl ring system or carrying more than one hydroxyl functions in the naphtyl ring system, 3-(4-hydroxycyclohexyl)-2-aminopropionic acid and its analogues carrying the alcoholic hydroxyl at another position in the ring system or carrying more than one hydroxyl functions in the ring system.
[0056] According to the present invention, G is glycine, or a structural of functional analogue thereof characterized by its ability to structurally mimic glycine for example by virtue of comprising a unit of minimal size, as compared to almost any other amino acid, by virtue of its lack of any highly bulky groups and structural fragments and parts and side chains that
would cause marked steric hindrance and crowding, by virtue of its lack of aromatic or other ring structures, or by virtue of being otherwise sterically or electrically equivalent to the structure of glycine, e.g. by virtue of having only a very small side chain, or by virtue of having no marked or pronounced lipohilicity or hydrophobicity, or by virtue of having no pronounced unsaturated character or aromatic character, or by having no special structural rigidity such as that of unsaturated structures.
[0057] Suitable structures may, for example, preferably comprise a small side chain such as a methyl or an ethyl group or their like or a halogenated methyl or ethyl group etc., or may be totally devoid of any side chain, which may also be preferable. Even a small monocyclic structure may be included, such as cyclopropyl group, but at least very large rings should be completely avoided. Such a monocyclic structure may or may not comprise also one or more heteroatom(s) or substituents etc. Suitable structures may, for example, also be beta-amino acids, gamma-amino acids etc. instead of being natural alpha-amino acids, and also in that case may for example comprise a small side chain such as a methyl or an ethyl group or their like or a halogenated methyl or ethyl group etc. or may be totally devoid of any side chain. Of course, also in the case of structural and functional analogues of glycine, the analogues need not be amino acids at all but may be for example amino alcohols, amino sugars, amino ketones etc. or may be devoid of any amino group, and so on, as is understood by those skilled in the art.
[0058] Many types of structural and functional analogues of glycine are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0059] Structural and functional analogues of glycine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-aminopropanoic acid, 3- aminopropanoic acid, 2-aminobutanoic acid, 3-aminobutanoic acid, 4- aminobutanoic acid, 2,3-diaminopropanoic acid, 2,3-diaminobutanoic acid, 3,4- diaminobutanoic acid, 2,4-diaminobutanoic acid, 2-amino-2-methylpropanoic acid, 3-amino-2-methylpropanoic acid, 2-amino-2-methylbutanoic acid, 3- amino-2-methylbutanoic acid, 4-amino-2-methylbutanoic acid, 2,3-diamino-2- methylpropanoic acid, 2,3-diamino-2-methylbutanoic acid, 3,4-diamino-2- methylbutanoic acid, 2,4-diamino-2-methylbutanoic acid, 2-amino-3-
methylbutanoic acid, 3-amino-3-methylbutanoic acid, 4-amino-3- methylbutanoic acid, 2,3-diamino-3-methylpropanoic acid, 2,3-diamino-3- methylbutanoic acid, 3,4-diamino-3-methylbutanoic acid, 2,4-diamino-3- methylbutanoic acid, 2-amino-2-ethylbutanoic acid, 3-amino-2-ethylbutanoic acid, 4-amino-2-ethylbutanoic acid, 2,3-diamino-2-ethylpropanoic acid, 2,3- diamino-2-ethylbutanoic acid, 3,4-diamino-2-ethylbutanoic acid, 2,4-diamino-2- ethylbutanoic acid, 2-amino-3-ethylbutanoic acid, 3-amino-3-ethylbutanoic acid, 4-amino-3-ethylbutanoic acid, 2,3-diamino-3-ethylpropanoic acid, 2,3- diamino-3-ethylbutanoic acid, 3,4-diamino-3-ethylbutanoic acid, 2,4-diamino-3- ethylbutanoic acid, 2-amino-2-cyclopropylethanoic acid, 2-amino-2- cyclopropylpropanoic acid, 3-amino-2-cyclopropylpropanoic acid, 2-amino-2- cyclopropylbutanoic acid, 3-amino-2-cyclopropylbutanoic acid, 4-amino-2- cyclopropylbutanoic acid, 2,3-diamino-2-cyclopropylpropanoic acid, 2,3-diami- no-2-cyclopropylbutanoic acid, 3,4-diamino-2-cyclopropylbutanoic acid, 2,4- diamino-2-cyclopropylbutanoic acid, 2-amino-3-cyclopropylbutanoic acid, 3- amino-3-cyclopropylbutanoic acid, 4-amino-3-cyclopropylbutanoic acid, 2,3- diamino-3-cyclopropylpropanoic acid, 2,3-diamino-3-cyclopropylbutanoic acid, 3,4-diamino-3-cyclopropylbutanoic acid, 2,4-diamino-3-cyclopropylbutanoic acid, 2-amino-2-(fluorocyclopropyl)-ethanoic acid, 2-amino-2-(fluorocycloprop- yl)-propanoic acid, 3-amino-2-(fluorocyclopropyl)-propanoic acid, 2-amino-2- (fluorocyclopropyl)-butanoic acid, 3-amino-2-(fluorocyclopropyl)-butanoic acid, 4-amino-2-(fluorocyclopropyl)-butanoic acid, 2,3-diamino-2-(fluorocyclopropyl)- propanoic acid, 2,3-diamino-2-(fluorocyclopropyl)-butanoic acid, 3,4-diamino-2- (fluorocyclopropyl)-butanoic acid, 2,4-diamino-2-(fluorocyclopropyl)-butanoic acid, 2-amino-3-(fluorocyclopropyl)-butanoic acid, 3-amino-3-(fluorocyclo- propyl)-butanoic acid, 4-amino-3-(fluorocyclopropyl)-butanoic acid, 2,3-diami- no-3-(fluorocyclopropyl)-propanoic acid, 2,3-diamino-3-(fluorocyclopropyl)- butanoic acid, 3,4-diamino-3-(fluorocyclopropyl)-butanoic acid, and 2,4-diami- no-3-(fluorocyclopropyl)-butanoic acid. [0060] According to the present invention, F is phenylalanine, or a structural or functional analogue thereof, characterized by its ability to structurally mimic phenylalanine for example by virtue of comprising a ring structure of a similar or related type, as compared to the ring structure of phenylalanine, or by virtue of comprising another structure that sterically or electrically can be considered as an equivalent of the ring structure, e.g. by virtue of comprising at least one unsaturated bond that render structural rigidity
as compared to saturated structures. Said ring structures may preferably comprise a monocyclic structure that may or may not comprise also one or more heteroatom(s), or may be for example bicyclic or tricyclic. Also ring structures comprising at least one substituent may be employed, etc., as is understood by those skilled in the art. Typically, structural and functional analogues of phenylalanine may also be characterized by their ability to mimic the electric or bond-conjugation or aromatic or steric or other functional or related properties of phenylalanine, e.g. by comprising at least one aromatic ring, etc., as is understood by those skilled in the art. [0061] Many types of structural and functional analogues of phenylalanine are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0062] Structural and functional analogues of phenylalanine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: phenylalanine, 2-amino-4- phenylbutanoic acid, 3-amino-4-phenylbutanoic acid, 2-amino-3-phenyl- butanoic acid, 2-amino-5-phenylpentanoic acid, 3-amino-5-phenylpentanoic acid, 4-amino-5-phenylpentanoic acid, 2-amino-4-phenylpentanoic acid, 3- amino-4-phenylpentanoic acid, 2-amino-3-phenylpentanoic acid, 2-amino-6- phenylhexanoic acid, 3-amino-6-phenylhexanoic acid, 4-amino-6-phenylhexan- oic acid, 2-amino-5-phenylhexanoic acid, 2-amino-4-phenylhexanoic acid, 2- amino-3-phenylhexanoic acid, 2-amino-4-phenylhexanoic acid, 3-amino-4- phenylhexanoic acid, 2-amino-3-phenylhexanoic acid, 2-amino-4-(1-napht- yl)butanoic acid, 3-amino-4-(1-naphtyl)butanoic acid, 2-amino-3-(1-naphtyl)- butanoic acid, 2-amino-5-(1-naphtyl)pentanoic acid, 3-amino-5-(1-naphtyl)- pentanoic acid, 4-amino-5-(1-naphtyl)pentanoic acid, 2-amino-4-(1-naphtyl)- pentanoic acid, 3-amino-4-(1-naphtyl)pentanoic acid, 2-amino-3-(1-naphtyl)- pentanoic acid, 2-amino-6-(1-naphtyl)hexanoic acid, 3-amino-6-(1-naphtyl)- hexanoic acid, 4-amino-6-(1-naphtyl)hexanoic acid, 2-amino-5-(1-naphtyl)- hexanoic acid, 2-amino-4-(1-naphtyl)hexanoic acid, 2-amino-3-(1-naphtyl)- hexanoic acid, 2-amino-4-(1-naphtyl)hexanoic acid, 3-amino-4-(1-naphtyl)- hexanoic acid, 2-amino-3-(1-naphtyl)hexanoic acid, 2-amino-4-(2-naphtyl)- butanoic acid, 3-amino-4-(2-naphtyl)butanoic acid, 2-amino-3-(2-naphtyl)- butanoic acid, 2-amino-5-(2-naphtyl)pentanoic acid, 3-amino-5-(2-naphtyl)- pentanoic acid, 4-amino-5-(2-naphtyl)pentanoic acid, 2-amino-4-(2-naphtyl)-
pentanoic acid, 3-amino-4-(2-naphtyl)pentanoic acid, 2-amino-3-(2-naphtyl)- pentanoic acid, 2-amino-6-(2-naphtyl)hexanoic acid, 3-amino-6-(2-naphtyl)- hexanoic acid, 4-amino-6-(2-naphtyl)hexanoic acid, 2-amino-5-(2-naphtyl)- hexanoic acid, 2-amino-4-(2-naphtyl)hexanoic acid, 2-amino-3-(2-naphtyl)- hexanoic acid, 2-amino-4-(2-naphtyl)hexanoic acid, 3-amino-4-(2-naphtyl)- hexanoic acid, 2-amino-3-(2-naphtyl)hexanoic acid, 2-amino-4-(2-methyl- phenyl)butanoic acid, 3-amino-4-(2-methylphenyl)butanoic acid, 2-amino-3-(2- methylphenyl)butanoic acid, 2-amino-5-(2-methylphenyl)pentanoic acid, 3- amino-5-(2-methylphenyl)pentanoic acid, 4-amino-5-(2-methylphenyl)pentan- oic acid, 2-amino-4-(2-methylphenyl)pentanoic acid, 3-amino-4-(2-methylphen- yl)pentanoic acid, 2-amino-3-(2-methylphenyl)pentanoic acid, 2-amino-6-(2- methylphenyl)hexanoic acid, 3-amino-6-(2-methylphenyl)hexanoic acid, 4-ami- no-6-(2-methylphenyl)hexanoic acid, 2-amino-5-(2-methylphenyl)hexanoic acid, 2-amino-4-(2-methylphenyl)hexanoic acid, 2-amino-3-(2-methylphenyl)- hexanoic acid, 2-amino-4-(2-methylphenyl)hexanoic acid, 3-amino-4-(2- methylphenyl)hexanoic acid, 2-amino-3-(2-methylphenyl)hexanoic acid, 2-ami- no-4-(3-methylphenyl)butanoic acid, 3-amino-4-(3-methylphenyl)butanoic acid, 2-amino-3-(3-methylphenyl)butanoic acid, 2-amino-5-(3-methylphenyl)pentan- oic acid, 3-amino-5-(3-methylphenyl)pentanoic acid, 4-amino-5-(3-methyl- phenyl)pentanoic acid, 2-amino-4-(3-methylphenyl)pentanoic acid, 3-amino-4- (3-methylphenyl)pentanoic acid, 2-amino-3-(3-methylphenyl)pentanoic acid, 2- amino-6-(3-methylphenyl)hexanoic acid, 3-amino-6-(3-methylphenyl)hexanoic acid, 4-amino-6-(3-methylphenyl)hexanoic acid, 2-amino-5-(3-methylphenyl)- hexanoic acid, 2-amino-4-(3-methylphenyl)hexanoic acid, 2-amino-3-(3-meth- ylphenyl)hexanoic acid, 2-amino-4-(3-methylphenyl)hexanoic acid, 3-amino-4- (3-methylphenyl)hexanoic acid, 2-amino-3-(3-methylphenyl)hexanoic acid, 2- amino-4-phenylbutanoic acid, 3-amino-4-phenylbutanoic acid, 2-amino-3- phenylbutanoic acid, 2-amino-5-phenylpentanoic acid, 3-amino-5-phenyl- pentanoic acid, 4-amino-5-phenylpentanoic acid, 2-amino-4-phenylpentanoic acid, 3-amino-4-phenylpentanoic acid, 2-amino-3-phenylpentanoic acid, 2-ami- no-6-phenylhexanoic acid, 3-amino-6-phenylhexanoic acid, 4-amino-6-phenyl- hexanoic acid, 2-amino-5-phenylhexanoic acid, 2-amino-4-phenylhexanoic acid, 2-amino-3-phenylhexanoic acid, 2-amino-4-phenylhexanoic acid, 3-ami- no-4-phenylhexanoic acid, and 2-amino-3-phenylhexanoic acid. [0063] In one preferred embodiment of the invention, X is alanine, or a structural or functional analogue thereof. Such an analogue may prefera-
bly have no side chain or may comprise in its side chain(s) maximally four, more preferably maximally three, still more preferably maximally two, non- hydrogen atoms. Structural or functional analogues of alanine include for example any optical isomers of compounds such as: 3-chloroalanine, 3- fluoroalanine, 2-aminobutanoic acid, 4-fluoro-2-aminobutanoic acid, 4-chloro- 2- aminobutanoic acid, 3-cyanoalanine, 3-cyclopropylalanine, 2-amino-3- butenoic acid and 2-amino-3-butynoic acid.
[0064] In another preferred embodiment according to the present invention, X is valine or leucine or isoleucine, or a structural or functional analogue thereof. Such an analogue may for example be characterized by its ability to structurally mimic valine, leucine or isoleucine, for example by virtue of comprising at least one aliphatic, cycloaliphatic/alicyclic, or related side- chain or, generally, at least one side-chain comprising at least one hydrophobic structure or group or lipophilic structure or group, or generally by virtue of comprising at least one small side-chain that do not cause massive sterical hindrance, etc., as is understood by those skilled in the art. Typically, structural and functional analogues of valine, leucine and isoleucine may preferably be characterized by more than one of said features or properties.
[0065] Many types of structural and functional analogues of valine and leucine and isoleucine are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0066] Structural and functional analogues of valine and leucine and isoleucine may be selected, for example, from any optical and geometrical isomers of the following compounds and their like: alanine, valine, leucine, isoleucine, norleucine, norvaline, allo-isoleucine, 2-aminobutanoic acid, 2- amino-2-methylpropionic acid, 2-amino-4,4-dimethylpentanoic acid, 4,5-dehyd- roleucine, 2-amino-6-isopropylamino-hexanoic acid, 4-amino-6-methylheptan- oic acid, 3-amino-6-methylheptanoic acid, 2-amino-6-methylheptanoic acid, terf-leucine, 4-amino-5-cyclohexyl-3-hydroxypentanoic acid, 4-amino-5-cyclo- hexylpentanoic acid, 2-amino-2-cyclohexylacetic acid, 2-amino-3-cyclohexyl- propionic acid, 2-amino-4-cyclohexylbutanoic acid, 2-amino-3-cyclopentyl- propionic acid, 2-amino-4-cyclopentylbutanoic acid, 2-amino-3-cyclobutyl- propionic acid, 2-amino-4-cyclobutylbutanoic acid, 2-amino-3-cyclopropyl- propionic acid, 2-amino-4-cyclopropylbutanoic acid, 2-amino-3-(1-cyclopenten- yl)-propionic acid, 2-amino-4-(1-cyclopentenyl)-butanoic acid, 2-amino-3-ethyl-
sulfanylpropionic acid, 2-amino-3-methylsulfanylpropionic acid, 3-fluoroalanine, 3-chloroalanine, 3,3-dicyclohexylalanine, 2-amino-3-propenoic acid, 2-amino- 4,4-dimethylpentanoic acid or statine,
[0067] or from the group consisting of any Λ/-methyl analogues of any one of the aforementioned, any Λ/-ethyl analogues of any of the aforementioned, any other Λ/-alkyl analogues of any of the aforementioned, any alpha- methyl analogues (2-methyl-analogues) of any of the aforementioned, any alpha-ethyl analogues (2-ethyl analogues) of any of the aforementioned, and any other alpha-alkyl analogues (2-alkyl analogues) of any of the aforemen- tioned;
[0068] or from the group consisting of any analogues of the aforementioned comprising in a side chain a branched, non-branched and/or ali- cyclic structure with at least two similar or different atoms selected from the group of carbon atoms, silicon atoms, halogen atoms bonded to at least one carbon, ether-oxygens and thioether-sulphurs;
[0069] or, more generally, from the group consisting of branched, non-branched and/or cyclic non-aromatic, lipophilic and/or hydrophobic amino acids and amino acid analogues and derivatives and structural or functional analogues thereof, and of amino acids and carboxylic acids and amino acid analogues and derivatives and carboxylic acid analogues and derivatives that have at least one lipophilic carborane-type or other lipophilic boron-containing side chain or its equivalent or other lipophilic cage-type structure.
[0070] According to the present invention, W is tryptophan, or a structural or functional analogue thereof, characterized by its ability to structur- ally mimic tryptophan, for example by virtue of comprising a ring structure of a similar or related type, as compared to the ring structure of tryptophan, or by virtue of comprising another structure that sterically or electrically can be considered as an equivalent of the ring structure, e.g. by virtue of at least one unsaturated bond that render structural rigidity as compared to unsaturated struo tures. Such ring structures may preferably comprise a bicyclic structure that may or may not comprise nitrogen, or may be for example monocyclic or tricyclic. Also ring structures not comprising nitrogen, or comprising more than one nitrogen atoms, may be employed, etc., as is understood by those skilled in the art. Typically, structural and functional analogues of tryptophan may of- ten also be characterized by their ability to mimic the acid-base or electric or bond-conjugation or aromatic or other functional or related properties of trypto-
phan, e.g. by comprising one or more aromatic rings, one or more nitrogen atoms, etc., as is understood by those skilled in the art.
[0071] Many types of structural and functional analogues of tryptophan are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0072] Structural and functional analogues of tryptophan may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: 2-amino-3-(1-indolyl)-propionic acid, 2-amino-3-(2-indolyl)-propionic acid, 2-amino-3-(4-indolyl)-propionic acid, 2-amino-3-(5-indolyl)-propionic acid, 2-amino-3-(6-indolyl)-propionic acid, 2- amino-3-(7-indolyl)-propionic acid, 2-amino-4-(1-indolyl)-butyric acid, 2-amino- 4-(2-indolyl)-butyric acid, 2-amino-4-(3-indolyl)-butyric acid, 2-amino-4-(4- indolyl)-butyric acid, 2-amino-4-(5-indolyl)-butyric acid, 2-amino-4-(6-indolyl)- butyric acid, 2-amino-4-(7-indolyl)-butyric acid, 2-amino-3-(1-benzimidazolyl)- propionic acid, 2-amino-3-(2-benzimidazolyl)-propionic acid, 2-amino-3-(4- benzimidazolyl)-propionic acid, 2-amino-3-(5-benzimidazolyl)-propionic acid, 2- amino-3-(6-benzimidazolyl)-propionic acid, 2-amino-3-(7-benzimidazolyl)- propionic acid, 2-amino-4-(1-benzimidazolyl)-butyric acid, 2-amino-4-(2- benzimidazolyl)-butyric acid, 2-amino-4-(4-benzimidazolyl)-butyric acid, 2- amino-4-(5-benzimidazolyl)-butyric acid, 2-amino-4-(6-benzimidazolyl)-butyric acid, 2-amino-4-(7-benzimidazolyl)-butyric acid, 2-amino-3-(1-indenyl)- propionic acid, 2-amino-3-(2-indenyl)-propionic acid, 2-amino-3-(3-indenyl)- propionic acid, 2-amino-3-(4-indenyl)-propionic acid, 2-amino-3-(5-indenyl)- propionic acid, 2-amino-3-(6-indenyl)-propionic acid, 2-amino-3-(7-indenyl)- propionic acid, 2-amino-3-(8-indenyl)-propionic acid, 2-amino-4-(1-indenyl)- butyric acid, 2-amino-4-(2-indenyl)-butyric acid, 2-amino-4-(3-indenyl)-butyric acid, 2-amino-4-(4-indenyl)-butyric acid, 2-amino-4-(5-indenyl)-butyric acid, 2- amino-4-(6-indenyl)-butyric acid, 2-amino-4-(7-indenyl)-butyric acid, 2-amino- 4-(8-indenyl)-butyric acid, 2-amino-3-(2-purinyl)-propionic acid, 2-amino-3-(6- purinyl)-propionic acid, 2-amino-3-(8-purinyl)-propionic acid, 2-amino-3-(9- purinyl)-propionic acid, 2-amino-4-(2-purinyl)-butyric acid, 2-amino-4-(6- purinyl)-butyric acid, 2-amino-4-(8-purinyl)-butyric acid, 2-amino-4-(9-purinyl)- butyric acid, 2-amino-3-(2-benzothienyl)-propionic acid, 2-amino-3-(3- benzothienyl)-propionic acid, 2-amino-3-(4-benzothienyl)-propionic acid, 2- amino-3-(5-benzothienyl)-propionic acid, 2-amino-3-(6-benzothienyl)-propionic
acid, 2-amino-3-(7-benzothienyl)-propionic acid, 2-amino-4-(2-benzothienyl)- butyric acid, 2-amino-4-(3-benzothienyl)-butyric acid, 2-amino-4-(4- benzothienyl)-butyric acid, 2-amino-4-(5-benzothienyl)-butyric acid, 2-amino-4- (6-benzothienyl)-butyric acid, 2-amino-4-(7-benzothienyl)-butyric acid, 2- amino-3-(1-naphtyl)-propionic acid, 2-amino-3-(2-naphtyl)-propionic acid, 2- amino-4-(1-naphtyl)-butyric acid, 2-amino-4-(2-naphtyl)-butyric acid, 2-amino- 3-(2-pyridyl)-propionic acid, 2-amino-3-(3-pyridyl)-propionic acid, 2-amino-3-(4- pyridyl)-propionic acid, 2-amino-4-(2-pyridyl)-butyric acid, 2-amino-4-(3- pyridyl)-butyric acid, 2-amino-4-(4-pyridyl)-butyric acid, 2-amino-3-(1-pyrrolyl)- propionic acid, 2-amino-3-(2-pyrrolyl)-propionic acid, 2-amino-3-(3-pyrrolyl)- propionic acid, 2-amino-3-(4-pyrrolyl)-propionic acid, 2-amino-4-(1-pyrrolyl)- butyric acid, 2-amino-4-(2-pyrrolyl)-butyric acid, 2-amino-4-(3-pyrrolyl)-butyric acid, 2-amino-4-(4-pyrrolyl)-butyric acid, 2-amino-3-(2-pyridyl)-propionic acid, 2-amino-3-(3-pyridyl)-propionic acid, 2-amino-3-(4-pyridyl)-propionic acid, 2- amino-4-(2-pyridyl)-butyric acid, 2-amino-4-(3-pyridyl)-butyric acid, 2-amino-4- (4-pyridyl)-butyric acid, 2-amino-3-(3-pyridazinyl)-propionic acid, 2-amino-3-(4- pyridazinyl)-propionic acid, 2-amino-4-(3-pyridazinyl)-butyric acid, 2-amino-4- (4-pyridazinyl)-butyric acid, 2-amino-3-(2-pyrimidinyl)-propionic acid, 2-amino- 3-(4-pyrimidinyl)-propionic acid, 2-amino-3-(5-pyrimidinyl)-propionic acid, 2- amino-3-(6-pyrimidinyl)-propionic acid, 2-amino-4-(2-pyrimidinyl)-butyric acid, 2-amino-4-(4-pyrimidinyl)-butyric acid, 2-amino-4-(5-pyrimidinyl)-butyric acid, 2-amino-4-(6-pyrimidinyl)-butyric acid, 2-amino-3-(1-pyrrolyl)-propionic acid, 2- amino-3-(2-pyrrolyl)-propionic acid, 2-amino-3-(3-pyrrolyl)-propionic acid, 2- amino-4-(1-pyrrolyl)-butyric acid, 2-amino-4-(2-pyrrolyl)-butyric acid, 2-amino- 4-(3-pyrrolyl)-butyric acid, 2-amino-3-(1-pyrrolinyl)-propionic acid, 2-amino-3- (2-pyrrolinyl)-propionic acid, 2-amino-3-(3-pyrrolinyl)-propionic acid, 2-amino-4- (i-pyrrolinyl)-butyric acid, 2-amino-4-(2-pyrrolinyl)-butyric acid, 2-amino-4-(3- pyrrolinyl)-butyric acid, 2-amino-3-(1-pyrrolidinyl)-propionic acid, 2-amino-3-(2- pyrrolidinyl)-propionic acid, 2-amino-3-(3-pyrrolidinyl)-propionic acid, 2-amino- 4-(1-pyrrolidinyl)-butyric acid, 2-amino-4-(2-pyrrolidinyl)-butyric acid, 2-amino- 4-(3-pyrrolidinyl)-butyric acid, 2-amino-3-(1-pyrazolyl)-propionic acid, 2-amino- 3-(3-pyrazolyl)-propionic acid, 2-amino-3-(4-pyrazolyl)-propionic acid, 2-amino- 3-(5-pyrazolyl)-propionic acid, 2-amino-4-(1-pyrazolyl)-butyric acid, 2-amino-4- (3-pyrazolyl)-butyric acid, 2-amino-4-(4-pyrazolyl)-butyric acid, 2-amino-4-(5- pyrazolyl)-butyric acid, 2-amino-3-(1-pyrazolinyl)-propionic acid, 2-amino-3-(3- pyrazolinyl)-propionic acid, 2-amino-3-(4-pyrazolinyl)-propionic acid, 2-amino-
3-(5-pyrazolinyl)-propionic acid, 2-amino-4-(1-pyrazolinyl)-butyric acid, 2- amino-4-(3-pyrazolinyl)-butyric acid, 2-amino-4-(4-pyrazolinyl)-butyric acid, 2- amino-4-(5-pyrazolinyl)-butyric acid, 2-amino-3-(1-pyrazolidinyl)-propionic acid, 2-amino-3-(2-pyrazolidinyl)-propionic acid, 2-amino-3-(3-pyrazolidinyl)- propionic acid, 2-amino-3-(4-pyrazolidinyl)-propionic acid, 2-amino-3-(5- pyrazolidinyl)-propionic acid, 2-amino-4-(1-pyrazolidinyl)-butyric acid, 2-amino- 4-(2-pyrazolidinyl)-butyric acid, 2-amino-4-(3-pyrazolidinyl)-butyric acid, 2- amino-4-(4-pyrazolidinyl)-butyric acid, 2-amino-4-(5-pyrazolidinyl)-butyric acid, 2-amino-3-(1 -imidazolyl)-propionic acid, 2-amino-3-(2-imidazolyl)-propionic acid, 2-amino-3-(4-imidazolyl)-propionic acid, 2-amino-3-(5-imidazolyl)- propionic acid, 2-amino-4-(1-imidazolyl)-butyric acid, 2-amino-4-(2-imidazolyl)- butyric acid, 2-amino-4-(4-imidazolyl)-butyric acid, 2-amino-4-(5-imidazolyl)- butyric acid;
[0073] or from the group consisting of any substituted and unsubsti- tuted acetic, valeric and other branched and non-branched carboxylic acid analogues of any of said propionic and/or butyric acids;
[0074] or from the group consisting of any amino acids and carboxylic acids comprising in at least one side chain or as at least one side chain: at least one indene, naphthalene, benzofuran, indole, benzo[b]thiophene, ben- zimidazole, benzothiazole, purine, quinoline, isoquinoline, cinnoline, quinoxa- line, azulene, fluorene, dibenzofuran, carbazole, anthracene, phenathrene, acridine, 1 ,10-phenanthroline, phenothiazine, pyrene, furan, pyrrole, 3- pyrroline, pyrrolidine, pyrazole, 2-pyrazoline, pyrazolidine, imidazole, oxazole, thiazole, 1 ,2,3-oxadiazole, 1 ,2,3-triazole, 1 ,2,4-triazole, 1 ,3,4-thiadiazole, pyri- dine, pyridazine, pyrimidine, pyradine, piperazine and/or 1 ,3,5-triazine ring/system/radical/substituent;
[0075] or from the group consisting of any carboxylic acids and amino acids that comprise in at least one side chain or as at least one side chain: at least one ring selected from the group of: bicyclic structures compris- ing one aromatic or heteroaromatic 6-ring and one 5-ring comprising at least one nitrogen atom, bicyclic structures comprising at least one aromatic or heteroaromatic 6-ring, tricyclic structures comprising one aromatic or heteroaromatic 6-ring and one 5-ring comprising at least one nitrogen atom, tricyclic structures comprising at least one aromatic or heteroaromatic 6-ring, bicyclic structures comprising at least one 5-ring comprising at least one nitrogen atom, tricyclic structures comprising at least one 5-ring comprising at least one
nitrogen atom, tetracyclic structures comprising at least one aromatic and/or heteroaromatic ring and/or at least one ring comprising at least one nitrogen atom, monocyclic structures comprising at least one nitrogen atom, other aromatic and heteroaromatic structures and structures comprising at least one aromatic or pseudoaromatic ring, other structures comprising at least one 4- or 5- or 6- or 7-ring that comprises at least one nitrogen atom.
[0076] According to one preferred embodiment of the present invention, Z is glutamine, or a structural or functional analogue thereof. Typically, structural and functional analogues of glutamine may be characterized by their ability to structurally mimic glutamine for example by virtue of comprising in a side chain or in more than one side chains a carboxylamide (an amide) group or a structure of a similar or related type, as compared to the carboxylamide structure of glutamine, or by virtue of comprising another structure that sterically or electrically can be considered as an equivalent of the amide structure. One possibility is to use an unsubstituted carboxylamide function similar to that in glutamine (or a substituted one, or more than one carboxylamide functions, etc.) but in a side chain (or side chains) that is/are otherwise different form the side chain in glutamine, e.g. by virtue of comprising at least one heteroatom instead of at least one carbon atom, or virtue of being longer or shorter than the side chain of glutamine, or by virtue of comprising at least one double or triple bond between carbon atoms, or by comprising substituents such as a fluorine atom or an aromatic ring or an alkyl group or a hydroxyl group etc., or by virtue of being branched, etc., as is understood by those skilled in the art. Typically, structural and functional analogues of glutamine may also be characterized by their ability to mimic the electric or double-bond or steric or other functional or related properties of glutamine, e.g. by comprising at least one C=O or C=N or other double bond, or by comprising at least one carbon with electrical properties similar to those of the carbon in the carboxamide group, or by containing at least one nitrogen atom, etc., as is understood by those skilled in the art. The carboxylamide function of glutamine may be replaced e.g. by an Λ/-substituted or an Λ/,Λ/-disubstituted carboxylamide functionality or by another acylamide functionality or by a carboxylic acyl hydrazide or other acyl hydrazide functionality or a substituted hydrazide group or by a hydroxamic acid function or by a substituted hydroxamic acid function or by an aldoxime group or a ketoxime group or a substituted aldoxime group or a substituted ketoxime
group or an aldehyde-derived hydrazone or a ketone-derived hydrazone group, or by other suitable functionality known by those skilled in the art. Also unsubstituted and substituted amidino and guanidino groups may come into question. [0077] Many types of structural and functional analogues of glutamine are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art.
[0078] Structural and functional analogues of glutamine may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: glutamine, asparagine, isoglutamine, isoasparagine, beta-hydroxyglutamine, gamma- hydroxyglutamine, beta-hydroxyasparagine, beta-methyleneglutamine, gamma-methyleneglutamine, beta-methyleneasparagine, beta.gamma- dihydroxyglutamine, beta-methylglutamine, gamma-methylglutamine, beta- methylasparagine, beta.gamma-dimethylglutamine, beta-ethylglutamine, gamma-ethylglutamine, beta-ethylasparagine, beta.gamma-diethylglutamine, beta-propylglutamine, gamma-propylglutamine, beta-propylasparagine, beta.gamma-dipropylglutamine, beta-cyclopropylglutamine, gamma- cyclopropylglutamine, beta-cyclopropylasparagine, beta.gamma- dicyclopropylglutamine, beta-(difluoromethyl)-glutamine, gamma-
(difluoromethyl)-glutamine, beta-(difluoromethyl)-asparagine, beta.gamma- bis(difluoromethyl)-glutamine, 2,6-diamino-6-oxo-hexanoic acid, 2,7-diamino-7- oxo-heptanoic acid, 2,6-diamino-3-methyl-6-oxo-hexanoic acid, 2,7-diamino-3- methyl-7-oxo-heptanoic acid, 2,6-diamino-3-ethyl-6-oxo-hexanoic acid, 2,7- diamino-3-ethyl-7-oxo-heptanoic acid, 2,6-diamino-3-propyl-6-oxo-hexanoic acid, 2,7-diamino-3-propyl-7-oxo-heptanoic acid, 2,6-diamino-3-cyclopropyl-6- oxo-hexanoic acid, 2,7-diamino-3-cyclopropyl-7-oxo-heptanoic acid, 2,6- diamino-3-hydroxy-6-oxo-hexanoic acid, 2,7-diamino-3-hydroxy-7-oxo- heptanoic acid, 2,6-diamino-4-methyl-6-oxo-hexanoic acid, 2,7-diamino-4- methyl-7-oxo-heptanoic acid, 2,6-diamino-4-ethyl-6-oxo-hexanoic acid, 2,7- diamino-4-ethyl-7-oxo-heptanoic acid, 2,6-diamino-4-propyl-6-oxo-hexanoic acid, 2,7-diamino-4-propyl-7-oxo-heptanoic acid, 2,6-diamino-4-cyclopropyl-6- oxo-hexanoic acid, 2,7-diamino-4-cyclopropyl-7-oxo-heptanoic acid, 2,6- diamino-4-hydroxy-6-oxo-hexanoic acid, 2,7-diamino-4-hydroxy-7-oxo-heptan- oic acid, 2,6-diamino-5-methyl-6-oxo-hexanoic acid, 2,7-diamino-5-methyl-7-
oxo-heptanoic acid, 2,6-diamino-5-ethyl-6-oxo-hexanoic acid, 2,7-diamino-5- ethyl-7-oxo-heptanoic acid, 2,6-diamino-5-propyl-6-oxo-hexanoic acid, 2,7- diamino-5-propyl-7-oxo-heptanoic acid, 2,6-diamino-5-cyclopropyl-6-oxo- hexanoic acid, 2,7-diamino-5-cyclopropyl-7-oxo-heptanoic acid, 2,6-diamino-5- hydroxy-6-oxo-hexanoic acid, 2,7-diamino-5-hydroxy-7-oxo-heptanoic acid, as well as from the (amide-Λ/)-monomethylated, (amide-Λ/)-monoethylated, (amide-Λ/)-monopropylated, other (amide-Λ/)-monomalkylated and (amide-Λ/)- dialkylated derivatives of any of the aforementioned compounds.
[0079] In another preferred embodiment according to the present invention, Z is glutamic acid, or a structural or functional analogue thereof comprising at least one oxygen atom capable of hydrogen bond formation, and preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, esterified hydroxamic acid function, alcoholic or phenolic hydroxyl group, esterified alcoholic or phenolic hydroxyl group, keto group or aldehyde function, and more preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, esterified hydroxamic acid function, alcoholic or phenolic hydroxyl group or esterified alcoholic or phenolic hydroxyl group, still more preferably comprising at least one carboxyl group, esterified carboxyl group, hydroxamic acid function, alcoholic hydroxyl group or esterified alcoholic hydroxyl group, and most preferably comprising at least one carboxyl group or esterified carboxyl group; or comprising one or more other oxo acid functional groups, selected preferably from the group of: -SO3 ", -OSO3 ", any inorganic phosphate group or its ester.
[0080] Many further types of structural and functional analogues of glutamic acid are commercially available, and many more are described in the chemical literature known by those skilled in the art, and further ones can be synthesized by those skilled in the art. Such analogues may be selected, for example, from any optical and geometrical isomers of the following non-limiting compounds and their like: aspartic acid, 2-amino-1 ,6-heptanedioic acid, 3- amino-1 ,6-heptanedioic acid, 2-amino-3-methyl-1 ,6-heptanedioic acid, 3-ami- no-2-methyl-1 ,6-heptanedioic acid, 2-amino-4-methyl-1 ,6-heptanedioic acid, 2- amino-1 ,7-hexanedioic acid, 3-amino-1 ,7-hexanedioic acid, 2-amino-3-methyl- 1 ,7-hexanedioic acid, 3-amino-2-methyl-1 ,7-hexanedioic acid, 2-amino-4- methyl-1 ,7-hexanedioic acid, 4-amino-1 ,7-hexanedioic acid, 4-amino-3-methyl- 1 ,7-hexanedioic acid, 2-amino-4-methyl-1 ,7-hexanedioic acid, 3-amino-4- methyl-1 ,7-hexanedioic acid, 2-amino-5-methyl-1 ,7-hexanedioic acid, 3-meth-
yl-aspartic acid, 3-methyl-glutamic acid, 2-amino-4-phenyl-1,6-heptanedioic acid, 3-amino-4-phenyl-1,6-heptanedioic acid, 2-amino-3-methyl-3-phenyl-1 ,6- heptanedioic acid, 3-amino-2-ethyl-1,6-heptanedioic acid, 2-amino-4-ethyl-1 ,6- heptanedioic acid, 2-amino-4-phenyl-1,7-hexanedioic acid, 3-amino-5-phenyl- 1 ,7-hexanedioic acid, 2-amino-3-ethyl-1 ,7-hexanedioic acid, 3-amino-2-ethyl- 1 ,7-hexanedioic acid, 2-amino-4-ethyl-1 ,7-hexanedioic acid, 4-amino-2-phenyl- 1 ,7-hexanedioic acid, 4-amino-3-ethyl-1 ,7-hexanedioic acid, 2-amino-4-ethyl- 1 ,7-hexanedioic acid, 3-amino-4-ethyl-1 ,7-hexanedioic acid, 2-amino-5-ethyl- 1 ,7-hexanedioic acid, or from the group consisting of the omega-methyl esters of said compounds, the omega-ethyl esters of said compounds, the omega- cyclopropyl esters of said compounds and the omega hydroxamic acid analogues of said compounds.
[0081] A preferred motif according to the present invention is a motif wherein X is valine and Z is glutamic acid, i.e., Y-G-F-V-W-G-E (SEQIDNO.1).
[0082] Another preferred motif according to the present invention is a motif wherein X is valine and Z is glutamine, i.e., Y-G-F-V-W-G-Q (SEQ ID NO.2).
[0083] Still another preferred motif according to the present inven- tion is a motif wherein X is leucine and Z is glutamine, i.e., Y-G-F-L-W- G-Q(SEQIDNO.3).
[0084] Yet another preferred motif according to the present invention is a motif wherein X is leucine and Z is glutamic acid, i.e., Y-G-F-L- W-G-E(SEQIDNO.4). [0085] Yet another preferred motif according to the present invention is a motif wherein X is alanine and Z is glutamine, i.e., Y-G-F-A-W - G - Q (SEQ ID NO.5).
[0086] Yet another preferred motif according to the present invention is a motif wherein X is alanine and Z is glutamic acid, i.e., Y-G-F-A- W-G-E(SEQIDNO.6).
[0087] Yet another preferred motif according to the present invention is a motif wherein X is isoleucine and Z is glutamine, i.e., Y - G - F - I - W-G-Q(SEQIDNO.7).
[0088] Yet another preferred motif according to the present inven- tion is a motif wherein X is isoleucine and Z is glutamic acid, i.e., Y-G-F-I -W-G-E(SEQIDNO.8).
[0089] The motif Y - G - F - X- W - G - Z according to the present invention may form part of a larger structure, such as a peptide or some other structure. The compound or structure in question may also comprise more than one motif Y - G - F - X- W - G - Z, and the orientation of the mo- tifs may vary.
Targeting units according to the present invention
[0090] It has also been found that peptides, including structural or functional analogues thereof as defined herein, comprising a tumor targeting motif according to the present invention target to and exhibit selective binding to tumors, especially to colon primary tumor and metastases.
[0091] Such peptides are highly advantageous for use as targeting units according to the present invention, e.g., because of their small size and their easy, reliable and cheap synthesis. Due to the small size of the peptides according to the present invention, the purification, analysis and quality control is easy and commercially useful.
[0092] The targeting units according to the present invention are preferably linear. Linear peptides according to the present invention are fast, easy and cheap to prepare, as they do not require any further processing (cy- clization etc.) after synthesis and complicated orthogonal and other protections and extra functional groups are not needed that would be needed for cycliza- tion. It is furthermore easier to link additional units to linear peptides, for example because, there is no need to "reserve" functional groups for the purpose of cyclization, or to use expensive and complicated orthogonal protections, etc. In some preferred embodiments of the present invention, the efficient degrada- tion of linear peptides in the human body is an advantage compared to the use of more slowly degrading substances, e.g., in diagnostic applications where rapid clearance is desired.
[0093] In another embodiment of the present invention cyclic peptides are preferred. Thus the targeting units according to the present invention may also be cyclic. Cyclic peptides are usually more stable in vivo and in many other biological systems than are their non-cyclic counterparts, as is known in the art. More stable peptides according to the present invention are highly preferred for certain purposes, for example in certain therapeutic applications.
[0094] Preferred targeting units according to the present invention may have at least a sequence
[0095] Cy-Y-G-F-X-W-G-Z -Cyy
[0096] wherein, Y-G-F-X-W-G-Z is a tumor targeting motif as defined above, and Cy and Cyy are optional entities forming a cyclic structure.
[0097] Preferred structures are such where Cy and Cyy are amino acids or analogues thereof containing a thiol group, such as homocysteine or cysteine or analogues thereof, or another structure comprising a thiol group or an oxidized thiol group. One preferred cyclic structure type is characterized by the presence of a disulphide bond (e.g., between cysteine moieties). Non- limiting examples of cyclic structures are, for example, compounds of the for- mula:
[0098] Cy-Y-G-F-X-W-G-Z -Cyy [0099]| s-S I
[0100] where CyS-S-Cyy indicates a cystine. Because of the easy availability and low price of cysteine, this type of structure is a preferred one. [0101] The -S-S- bridge need not, however, be between cysteine units but may also exist between other amino acids or other moieties containing -SH groups. Such structures may comprise more than one Y-G-F-X- W - G - Z motif between the cysteine units, and may comprise additional amino acids and structural or functional analogues thereof outside the cyclic structure.
[0102] Highly preferred targeting units according to the present invention having a cyclic structure by virtue of a disulphide bridge, are CYGFVWGEC (SEQ ID NO. 9), CYGFVWGQC (SEQ ID NO. 10), CYGFLWGQC (SEQ ID NO. 11), CYGFLWGEC (SEQ ID NO. 12), CYGFAWGQC (SEQ ID NO. 13), CYGFAWGEC (SEQ ID NO. 14), CYGFIWGQC (SEQ ID NO.15) and CYGFIWGEC (SEQ ID NO.16).
[0103] Other preferred possibilities of forming the cyclic structure is the formation of an amide bond to give a lactam, or ester bond to give a lactone, or hydrazone, hydrazine, oxime, thioether or other type of bond to give a cyclic structure.
[0104] Lactams, i.e. lactam bridged peptides can be of several subtypes, such as "head to tail", wherein the ends of the peptide chain are directly linked together (carboxy terminus coupled to amino terminus), "head to side chain" and "side chain to tail", wherein one end of the peptide chain is linked to side chain of an amino acid residue elsewhere in the peptide (carboxy
or amino terminus coupled to one side chain amino or carboxyl group), and "side chain to side chain" (amino group of one side chain coupled to carboxyl group of another side chain).
[0105] The terms "C-terminus" and "C-terminal" refer to the carboxylic end of the peptide chain, which may be free, or coupled to another moiety. Moreover, The terms "N-terminus" and "N-terminal" refer to the amino end of the peptide chain, which may be free, or coupled to another moiety.
[0106] Preferred structures include compounds of the general formula [0107] Cy- Y - G - F - X -W - G - Z - Cyy
[0108] as defined above, wherein Cy and Cyy are residues forming a lactam bridge, such as terminal amino acids, aspartic acid (D), glutamic acid (E), lysine (K), ornithine (O), or analogues thereof comprising no more than 12 carbon atoms. [0109] In a preferred embodiment according to the present invention, Cy is glutamic acid, aspartic, or a structural or functional analogue thereof when Cyy is lysine, ornithine, or a structural or functional analogue thereof; or Cy is lysine, ornithine, or a structural or functional analogue thereof when Cyy is glutamic acid, aspartic, or a structural or functional analogue thereof. [0110] Examples of structural or functional analogues of lysine and ornithine include any optical isomers of lysine or ornithine, and structural and/or functional analogues thereof, that preferably comprise at least one amino group or substituted amino group or other nitrogen-containing group that has or can through protonation gain a positive charge. [0111] Further, examples of structural or functional analogues of lysine can be characterized by the presence of two amino groups or substituted amino groups (such as the monoethylamino group) or equivalents thereof, as well as the presence of at least one carboxyl group or its equivalent (such as an acyl chloride group), in the molecule. [0112] Structural or functional analogues of lysine and ornithine may be selected e.g. from the group of ornithine, lysine, any C-methylated analogues of ornithine or lysine, any C1C -dimethylated analogues of ornithine or lysine, 2,4-diaminobutanoic acid, 2,7-diaminoheptanoic acid, 2,8- diaminooctanoic acid, 2,4-diamino-3-methylbutanoic acid, 2,7-diamino-3- methyl-heptanoic acid, 2,8-diamino-3-methyl-octanoic acid, 2,4-diamino-2- methylbutanoic acid, 2,7-diamino-2-methyl-heptanoic acid, 2,8-diamino-2-
methyl-octanoic acid, 2,4-diamino-2-methylbutanoic acid, 2,7-diamino-2- methyl-heptanoic acid, 2,8-diamino-2-methyl-octanoic acid, 2,4-diamino-2,3- dimethyl-butanoic acid, 2,4-diamino-3-methylbutanoic acid, 2,7-diamino-3- methyl-heptanoic acid, 2,8-diamino-3-methyl-octanoic acid, 2,4-diamino-2- methylbutanoic acid, 2,7-diamino-2-methyl-heptanoic acid, 2,8-diamino-2- methyl-octanoic acid, 2,4-diamino-2-methylbutanoic acid, 2,7-diamino-2- methyl-heptanoic acid, 2,8-diamino-2-methyl-octanoic acid, 2,7-diamino-3- ethyl-heptanoic acid, 2,8-diamino-3-ethyl-octanoic acid, 2,7-diamino-2-ethyl- heptanoic acid, 2,8-diamino-2-ethyl-octanoic acid, 2,4-diamino-2-ethylbutanoic acid, 2,7-diamino-2-ethyl-heptanoic acid, 2,8-diamino-2-ethyl-octanoic acid, 2,7-diamino-3-ethyl-heptanoic acid, 2,8-diamino-3-ethyl-octanoic acid, 2,4- diamino-3-ethyl-1-cyclohexanoic acid, 2,5-diamino-1-cyclohexanoic acid, 2,8- diamino-3-ethyl-1 -cyclooctanoic acid, 2,4-diamino-3-ethyl-1 -cycloheptanoic acid, or 2,5-diamino-1-cyclononanoic acid. [0113] In a preferred embodiment of the present invention, Cy is selected from the group consisting of a diamino acid (such as lysine, ornithine, or a structural or functional analogue thereof) and an N-terminal D-amino acid, when Cyy is selected from the group consisting of an L-amino dicarboxylic acid (such as glutamic acid, aspartic acid, or a structural or functional analogue thereof).
[0114] "N-terminal D-amino acid" refers to an amino acid, which is a D-stereoisomer, located at the amino terminal end of the peptide chain, and bonded by its terminal amino group to a lactam bridge that may be of the "head to side chain"-type. [0115] In a further preferred embodiment of the present invention, the lactam is a "head to side chain" lactam, wherein Cy is a D-amino acid, such as D-alanine (a), and Cyy is an L-amino dicarboxylic acid, such as glutamic acid, which may be coupled via its C-terminal carboxyl with another moiety, such as a linker.
[0116] Preferred linear or lactam-bridged targeting units according to the present invention are aYGFVWGEE (SEQ ID NO. 17), aYGFVWGQE (SEQ ID NO. 18), aYGFLWGQE (SEQ ID NO. 19), aYGFLWGEE (SEQ ID NO. 20), aYGFAWGQE (SEQ ID NO. 21 ), aYGFAWGEE (SEQ ID NO. 22), aYGFIWGQE (SEQ ID NO. 23), aYGFIWGEE (SEQ ID NO. 24), where a is D- alanine. In the sequence listings, D-alanine is denoted Xaa.
Targeting agents according to the present invention
[0117] It has now also been found that targeting agents comprising at least one tumor targeting unit according to the present invention, and at least one effector unit (EU), target to and exhibit selective binding to cancer cells and cancer tissues.
[0118] The tumor targeting agents according to the present invention may optionally comprise unit(s) such as linkers, solubility modifiers, stabilizers, charge modifiers, spacers, lysis or reaction or reactivity modifiers, internalizing units or internalization enhancers or membrane interaction units or other local route, attachment, binding or distribution affecting units or other related units. Such additional units of the tumor targeting agents according to the present invention may be coupled to each other by any means suitable for that purpose.
[0119] Many possibilities are known to those skilled in the art for linking structures, molecules and groups of the types in question or of related types, to each other. The various units may be linked either directly or with the aid of one or more identical, similar and/or different linker units. The tumor targeting agents of the invention may have different structures such as any of the non-limiting types schematically shown below:
1. EU ■ ■ TL I
2. (EU) n - (TU)m
3. (EU) n - (TU)m - (EU)k
4. TU
\
EU
/
TU
5. EU
\
TU
/
EU
[0120] where EU indicates "effector unit" and TU indicates "targeting unit" and n, m and k are independently any integers except 0.
[0121] In a targeting agent according to the present invention, as in many other medicinal and other substances, it may be wise to include spacers or linkers, such as amino acids and their analogues, such as long-chain omega-amino acids, to prevent the targeting units from being 'disturbed' steri- cally or electronically, or otherwise hindered or 'hidden', by effector units or other units of the targeting agent.
[0122] In targeting agents according to the present invention, it may be useful for increased activity to use dendrimeric or cyclic structures for example to provide a possibility to incorporate multiple effector units or additional units per targeting unit.
[0123] Preferred targeting agents according to the present invention comprise a structure EU-TU-OU, TU-EU-OU or TU-OU-EU, wherein TU is a targeting unit according to the present invention as defined above; and EU and
OU are effector or optional units (OU) selected from the group consisting of: [0124] effector units, linker units, solubility modifier units, stabilizer units, charge modifier units, spacer units, lysis and/or reaction and/or reactivity modifier units, internalizing and/or internalization enhancer and/or membrane interaction units and/or other local route and/or local attachment/local binding and/or distribution affecting units, adsorption enhancer units, and other related units; and
[0125] peptide sequences and other structures comprising at least one such unit; and
[0126] peptide sequences comprising no more than 20, preferably no more than 12, more preferably no more than 6, natural and/or unnatural amino acids; and
[0127] natural and unnatural amino acids comprising no more than 25 non-hydrogen atoms and an unlimited number of hydrogen atoms;
[0128] as well as salts, esters, derivatives and analogues thereof.
Effector units [0129] For the purposes of this invention, the term "effector unit"
(EU) means molecules or radicals or other chemical entities or large particles such as colloidal particles and their like; liposomes, nanoparticles or micro- granules and their like. Suitable effector units may also comprise nanodevices or nanochips or their like; or a combination of any of the aforementioned, and optionally chemical structures for the attachment of the constituents of the effector unit to each other or to other parts of the targeting agents. Effector units
may also contain moieties that modify the stability or solubility of the effector units.
[0130] Preferred effects provided by the effector units according to the pre-sent invention are therapeutic (biological, chemical or physical) effects on the targeted tumor; properties that enable the detection or imaging of tumors or tumor cells for diagnostic purposes; or binding abilities that relate to the use of the targeting agents in different applications.
[0131] A preferred (biological) activity of the effector units according to the present invention is a therapeutic effect. Examples of such therapeutic activities, are for example, cytotoxicity, cytostatic effects, ability to cause differentiation of cells or to increase their degree of differentiation or to cause phenotypic changes or metabolic changes, chemotactic activities, immuno- modulating activities, pain relieving activities, radioactivity, ability to affect the cell cycle, ability to cause apoptosis, hormonal activities, enzymatic activities, ability to transfect cells, gene transferring activities, ability to mediate "knockout" of one or more genes, ability to cause gene replacements or "knock-in", ability to decrease, inhibit or block gene or protein expression, antiangiogenic activities, ability to collect heat or other energy from external radiation or electric or magnetic fields, ability to affect transcription, translation or replication of the cell's genetic information or external related information, and to affect post- transcriptional or post-translational events, and so on.
[0132] Other preferred therapeutic uses enabled by the effector units according to the present invention may be the administration of an enzyme capable of hydrolyzing for example an ester bond or other bonds or the administration of a targeted enzyme according to the present invention.
[0133] One further preferred therapeutic use enabled by the effector units according to the present invention may be the use of neutron capture therapy-active (NCT-active) substances as effector units. By NCT-active substances is meant any substance that by virtue of its ability to become radioac- tive by capture of slow neutrons can be used for neutron capture therapy (i.e. that emits radiation after having captured slow neutrons).
[0134] Examples of preferred functions of the effector units according to the present invention suitable for detection are radioactivity, paramagnetism, ferromagnetism, ferri magnetism, or any type of magnetism, or ability to be detected by NMR spectroscopy, or ability to be detected by EPR (ESR) spectroscopy, or suitability for PET imaging (PET-active substances) and/or
SPECT imaging (SPECT-active substances). By PET-active substances is meant any substance that can be used for positron emission tomography (PET). By SPECT-active substances is meant any substance that can be used for single photon emission computer tomography (SPECT) by virtue of its abil- ity to emit photons.
[0135] Other examples of preferred properties of the effector units according to the present invention suitable for direct or indirect detection include presence of an immunogenic structure, or the presence of an antibody or antibody fragment or antibody-type structure, or the presence of a gold parti- cle, or the presence of biotin or avidin or other protein, and/or luminescent and/or fluorescent and/or phosphorescent activity or the ability to enhance detection of tumors, tumor cells, endothelial cells and metastases in electron microscopy, light microscopy (UV and/or visible light), infrared microscopy, atomic force microscopy or tunneling microscopy, and so on. [0136] Preferred detectable substances according to the present invention may comprise a chelator; a complexed metal such as a rare earth metal, a paramagnetic metal, a fluorescent metal (e.g. Eu, Tb or Ho), a radioactive metal, a PET-active substance or a SPECT-active substance; an enriched isotope; radioactive material such as beta-emittor or alpha emittor; a paramagnetic substance; an affinity label; a fluorescent label (e.g. fluorescein or rhodamine) or a luminescent label.
[0137] Preferred binding abilities of an effector unit according to the pre-sent invention include, for example: a) ability to bind metal ion(s) e.g. by chelation, b) ability to bind a cytotoxic, apoptotic or metabolism affecting substance or a substance capable of being converted in situ into such a substance, c) ability to bind to a substance or structure such as a histidine tag or other tag, d) ability to bind to an enzyme or a modified enzyme, e) ability to bind to biotin or analogues thereof, f) ability to bind to avidin or analogues thereof, g) ability to bind to integrins or other substances involved in cell adhesion, migration, or intracellular signaling, h) ability to bind to phages, i) ability to bind to lymphocytes or other blood cells,
j) ability to bind to any preselected material by virtue of the presence of antibodies or structures selected by biopanning or by other methods, k) ability to bind to material used for signal production or amplification, I) ability to bind to therapeutic substances.
[0138] Such binding may be the result of e.g. chelation, formation of covalent bonds, antibody-antigen-type affinity, ion pair or ion associate formation, specific interactions of the avidin-biotin-type, or the result of any type or mode of binding or affinity. [0139] In one preferred embodiment according to the present invention metals for chelation are fluorescent metals such as europium (Eu), terbium (Tb) or holmium (Ho).
[0140] One or more of the effector units or parts of them may also be a part of the targeting units themselves. Thus, the effector unit may for ex- ample be one or more atoms or nuclei of the targeting unit, such as radioactive atoms (such as carbon-13, carbon-11 , carbon-14, fluorine-18 or tritium) or atoms that can be made radioactive (e.g. boron-10), or paramagnetic atoms (e.g. gadolinium (Gd) or iron) or atoms that are easily detected by MRI or NMR spectroscopy. Further examples of effector units are, for example, boron- comprising structures such as carborane-type structures.
[0141] The effector units may be linked to the targeting units by any type of bond or structure or any combinations of them that are strong enough so that most, or preferably all or essentially all of the effector units of the targeting agents remain linked to the targeting units during the essential (neces- sary) targeting process, e.g. in a human or animal subject or in a biological sample under study or treatment.
[0142] The effector units or parts of them may remain linked to the targeting units, or they may be partly or completely hydrolyzed or otherwise disintegrated from the latter, either by a spontaneous chemical reaction or equilibrium or by a spontaneous enzymatic process or other biological process, or as a result of an intentional operation or procedure such as the administration of hydrolytic enzymes or other chemical substances. It is also possible that the enzymatic process or other reaction is caused or enhanced by the administration of a targeted substance such as an enzyme in accordance with the present invention.
[0143] One possibility is that the effector units or parts thereof are hydrolyzed from the targeting agent or hydrolyzed into smaller units by the effect of one or more of the various hydrolytic enzymes present in tumors (e.g., intracellular^, in the cell membrane or in the extracellular matrix) or in their near vicinity.
[0144] Taking into account that the targeting according to the present invention may be very rapid, even non-specific hydrolysis that occurs every-where in the body may be acceptable and usable for hydrolyzing one or more effector unit(s) intentionally, since such hydrolysis may in suitable cases (e.g., steric hindrance, or even without any such hindering effects) be so slow that the targeting agents are safely targeted in spite of the presence of hydrolytic enzymes of the body, as those skilled in the art very well understand. The formation of insoluble products or products rapidly absorbed into cells or bound to their surfaces after hydrolysis may also be beneficial for the targeted effector units or their fragments etc. to remain in the tumors or their closest vicinity.
[0145] In one preferred embodiment of the invention, the effector units may comprise structures, features, fragments, molecules or the like that make possible, cause directly or indirectly, an "amplification" of the therapeutic or other effect, of signal detection, of the binding of preselected substances, including biological material, molecules, ions, microbes or cells.
[0146] Such "amplification" may, for example, be based on one or more of the following non-limiting types:
- the binding, by the effector units, of other materials that can fur- ther bind other substances (for example, antibodies, fluorescent antibodies, other "labeled" substances, substances such as avidin), preferably so that several molecules or "units" of the further materials can be bound per each effector unit;
- the effector units comprise more than one entity capable of bind- ing e.g. a protein, thus making direct amplification possible;
- amplification in more than one steps.
[0147] Preferred effector units according to the present invention may be selected from the following group:
- cytostatic or cytotoxic agents - apoptosis causing or enhancing agents
- enzymes or enzyme inhibitors
- antimetabolites
- agents capable of disturbing membrane functions
- radioactive or paramagnetic substances
- substances comprising one or more metal ions - substances comprising boron, gadolinium, litium
- substances suitable for neutron capture therapy, e.g. boron or carborane
- labeled substances
- intercalators and substances comprising them - oxidants or reducing agents
- amino acids, nucleic acids, nucleotides and their analogues (including aptamers, peptide nucleic acids (PNA) and anti-sense oligonucleotides)
- metal chelates or chelating agents. [0148] In a preferred embodiment of the invention, the effector unit may comprise cytostatic/cytotoxic agents such as 5-fluorouracil, leucovorin, oxaliplatin, irinotecan, or polyketidic antracyclines including doxorubicin and daunorubicin.
[0149] In another preferred embodiment of the invention, the effec- tor unit comprises radiation emitting substances such as alpha-emittors, beta- emittors, gamma-emittors or NCT-active substances.
[0150] In further preferred embodiments of the invention, the effector units may comprise copper chelates such as trans- bis(salicylaldoximato)copper(ll) and its analogues, or platinum compounds such as cisplatin and carboplatin.
[0151] More specifically, for the treatment of colon cancer, in combination with conventional therapeutics, such as platinum compounds, the following effector units or their structural or functional analogs may be used: mitosis inhibitors/taxanes such as paclitaxel or docetaxel; anti-metabolites such as gemsitabine or metotrexate; vinca alkaloids such as vinorelbine or vincristine; alkylating agents such as isophosphamide or cyclophosphamide; antibiotics such as bleomycine or mitomycine; or topoisomerase inhibitors such as irinotecane or topotecane.
[0152] Different types of structures, substances and groups are known that can be used to cause or enhance e.g., internalization into cells, including for example RQIKIWFQNRRMKWKK; Penetratin (Prochiantz, 1996,
Curr. Op. Neurobiol., 6: 629-634), as well as stearyl derivatives (Promega Notes Magazine, 2000).
[0153] As an apoptosis-inducing structure, for example, the peptide sequence KLAKLAK that has been reported to interact with mitochondrial membranes inside cells, can be included (Ellerby et al. 1999, Nat. Med., 9: 1032-1038).
[0154] For use in embodiments of the present invention that include cell sorting or any related applications, the targeting units and agents of the invention can, for example, be used [0155] a) coupled or connected to magnetic particles,
[0156] b) adsorbed, coupled, linked or connected to plastic, glass or other solid, porous, fibrous material-type or other surface(s) and their like,
[0157] c) adsorbed, covalently bonded or otherwise linked, coupled or connected into or onto one or more substance(s) or material(s) that can be used in columns or related systems
[0158] d) adsorbed, covalently bonded or otherwise linked, coupled or connected into or onto one or more substance(s) or material(s) that can be precipitated, centrifuged or otherwise separated or removed.
Optional units (ou) of the targeting agents according to the present in- vention
[0159] The targeting agents and targeting units of the present invention may optionally comprise further units, such as:
[0160] linker units for coupling targeting units, effector units, or other optional units of the present invention to each other; [0161] solubility modifying units for modifying the solubility of the targeting agents or their hydrolysis products;
[0162] stabilizer units for stabilizing the structure of the targeting units or agents during synthesis, modification, processing, storage or use in vivo or in vitro; charge modifying units for modifying the electrical charges of the targeting units or agents or their starting materials;
[0163] spacer units for increasing the distance between specific units of the targeting agents or their starting materials, for releasing or decreasing steric hindrance or structural strain of the products or their starting materials; [0164] reactivity modifier units;
[0165] internalizing units or enhancer units for enhancing targeting or uptake of the targeting agents;
[0166] adsorption enhancer units, such as fat soluble or water soluble structures that for example enhance absorption of the targeting agents in vivo; or other related units.
[0167] A large number of suitable linker units are known in the art. Examples of suitable linkers are:
[0168] 1. for linking units that comprise amino groups: cyclic anhydrides, dicarboxylic or multivalent, optionally activated or derivatized, carboxylic acids, compounds with two or more reactive halogens or compounds with at least one reactive halogen atom and at least one carboxyl group; [0169] 2. for linking units that comprise carboxyl groups or derivatives thereof: compounds with at least two similar or different groups such as amino, substituted amino, hydroxyl, -NHNH2 or substituted forms thereof, other known groups for the purpose (activators may be used);
[0170] 3. for linking an amino group and a carboxyl group: for example amino acids or their activated or protected forms or derivatives; [0171] 4. for linking a formyl group or a keto group to another group: a compound comprising e.g. at least one -N-NH2 or -0-NH2 or =N-NH2 group or their like;
[0172] 5. for linking several amino-comprising units: polycarboxylic substances such as EDTA, DTPA or polycarboxylic acids, or anhydrides, esters or acyl halides thereof;
[0173] 6. for linking a substance comprising an amino group to a substance comprising either a formyl group or a carboxyl group: hydrazinocarboxylic acids or their like, preferably so that the hydrazino moiety or the carboxyl group is protected or activated, such as 4-(FMOC-hydrazino)benzoic acid;
[0174] 7. for linking an organic structure to a metal ion: substances that can be coupled to the organic structure (e.g. by virtue of their COOH groups or their NH2 groups) or that are integral parts of it, and that in addition comprise a polycarboxylic part, for example an EDTA- or DTPA-like structure, peptides comprising several histidines or their like, peptides comprising several cysteines or other moieties comprising an -SH group each, or other chelating agents that comprise functional groups that can be used to link them to the organic structure.
[0175] A large variety of the above substances and of other types of suitable linking agents is known in the art.
[0176] A large number of suitable solubility modifier units are known in the art. Suitable solubility modifier units may comprise, for example: [0177] - for increasing aqueous solubility: Molecules comprising
SO3 0, OSO3 ( ), COOH, COO( ), NH2, NH3 (+), OH, phosphate groups, guanidino or amidino groups or other ionic or ionizable groups or sugar-type structures;
[0178] - for increasing fat solubility or solubility in organic solvents: Units comprising (long) aliphatic branched or non-branched alkyl or alkenyl groups, cyclic non-aromatic groups such as the cyclohexyl group, aromatic rings or steroidal structures.
[0179] One especially preferred aqueous-solubility enhancing unit comprises at least one unit according to Formula I:
[0180] (I) -(CH2)m-0-
[0181] where m is an integer of value 1 to 4;
[0182] or at least one unit according to Formula II:
[0183] (II) -(A)s-Y
[0184] where (A)s is a spacer group wherein each A is independently CR1R2, [0185] each Ri and R2 is independently selected from the group of hydrogen, hydroxyl, Ci-3 alkyl and Ci-3 hydroxyalkyl,
[0186] s is an integer of value 0 to 5, and
[0187] Y is selected from COOH, CONH2, NH2 and guanyl;
[0188] or at least one unit according to Formula III: [0189] (A) q_γ
— CR3—
[0190] where (A)q is a spacer group wherein each A is independently CRiR2, [0191] q is an integer of value 1 to 5,
[0192] each R1, R2 and R3 is independently selected from the group of hydro- gen, hydroxyl, C1-3 alkyl and C1-3 hydroxyalkyl, and
[0193] Y is selected from from the group of COOH, CONH2, NH2 and guanyl.
[0194] Useful aqueous solubility enhancing units may comprise at least one, preferably at least three, more preferably at least six and most preferably at least nine units according to Formula I, or at least one unit according to Formula II, or they may comprise at least one and more preferably at least four units according to Formula III.
[0195] Specific examples of targeting agents comprising aqueous- solubility enhancing units are further described in the examples. Such targeting agents have valuable characteristics and excellent properties for diagnostic and therapeutic uses. [0196] A large number of units known in the art can be used as stabilizer units, e.g. bulky structures (such as tert-butyl groups, naphthyl and adamantyl and related radicals etc.) for increasing steric hindrance, and D- amino acids and other unnatural amino acids (including beta-amino acids, omega-amino acids, amino acids with very large side chains etc.) for prevent- ing or hindering enzymatic hydrolysis.
[0197] Units comprising positive, negative or both types of charges can be used as charge modifier units, as can also structures that are converted or can be converted into units with positive, negative or both types of charges. [0198] Spacer units may be very important, and the need to use such units depends on the other components of the structure (e.g. the type of biologically active agents used, and their mechanisms of action) and the synthetic procedures used.
[0199] Suitable spacer units may include for example long aliphatic chains or sugar-type structures (to avoid too high lipophilicity), or large rings. Suitable compounds are available in the art. One preferred group of spacer units are omega-amino acids with long chains. Such compounds can also be used (simultaneously) as linker units between an amino-comprising unit and a carboxyl-comprising unit. Many such compounds are commercially available, both as such and in the forms of various protected derivatives.
[0200] Units that are susceptible to hydrolysis (either spontaneous chemical hydrolysis or enzymatic hydrolysis by the body's own enzymes or enzymes administered to the patient) may be very advantageous in cases where it is desired that the effector units are liberated from the targeting agents e.g. for internalization, intra- or extracellular DNA or receptor binding. Suitable units for this purpose include, for example, structures comprising one or more
ester or acetal functionality. Various proteases may be used for the purposes mentioned. Many groups used for making pro-drugs may be suitable for the purpose of increasing or causing hydrolysis, lytic reactions or other decomposition processes. [0201] The effector units, the targeting units and the optional units according to the present invention may simultaneously serve more than one function. Thus, for example, a targeting unit may simultaneously be an effector unit or comprise several effector units; a spacer unit may simultaneously be a linker unit or a charge modifier unit or both; a stabilizer unit may be an effector unit with properties different from those of another effector unit, and so on. An effector unit may, for example, have several similar or even completely different functions.
[0202] In one preferred embodiment of the invention, the tumor targeting agents comprise more than one different effector units. In that case, the effector units may be, for example, diagnostic and therapeutic units. Thus, for ex-ample, it is preferred to use, for boron neutron capture therapy, such agents whose effector units, in addition to comprising boron atoms, also can be detected or quantified in the patient in vivo after administration of the agent, in order to be able to ascertain that the agent has accumulated adequately in the tumor to be treated, or to optimize the timing of the neutron treatment, and so on. This goal may be achieved e.g. by using such a targeting agents according to the invention that comprise an effector unit comprising boron atoms (preferably isotope-enriched boron) and groups detectable e.g. by PET, SPECT or NMRI. Likewise, the presence of more than one type of therapeutically useful effector units may also be preferred. In addition, the targeting units and targeting agents may, if desired, be used in combination with one or more "classical" or other tumor therapeutic modalities such as surgery, chemotherapy, other targeting modalities, radiotherapy, immunotherapy etc.
Preparation of targeting units and agents according to the present inven- tion
[0203] The targeting units according to the present invention are preferably synthetic peptides. Peptides can be synthesized by a large variety of well-known techniques, such as solid-phase methods (FMOC-, BOC-, and other protection schemes, various resin types), solution methods (FMOC, BOC and other variants) and combinations of these. Automated apparatuses/ devices for the purpose are available commercially, as are also routine synthesis
and purification services. All of these approaches are very well known to those skilled in the art.
[0204] As known in the art, it is often advisable, important and/or necessary to use one or more protecting groups, a large variety of which are known in the art, such as FMOC, BOC, and trityl groups and other protecting groups mentioned in the Examples. Protecting groups are often used for protecting amino, carboxyl, hydroxyl, guanyl and -SH groups, and for any reactive groups/functions.
[0205] As those skilled in the art well know, activation often involves carboxyl function activation and/or activation of amino groups.
[0206] Protection may also be orthogonal and/or semi/quasi/pseudo- orthogonal. Protecting and activating groups, substances and their uses are exemplified in the Examples and are described in the references cited herein, and are also described in a large number of books and other sources of information commonly known in the art.
[0207] Resins for solid-phase synthesis are also well known in the art, and are described in the Examples and in the above-cited references.
[0208] Cyclic peptides are usually especially stable in biological milieu, and are thus preferred. Cyclic structures according to the present inven- tion may be synthesized by methods based on the use of orthogonally protected amino acids, as described in e.g., International Patent Publication WO 2004/031218, incorporated herein by reference.
[0209] The targeting units and agents according to the present invention may also be prepared as fusion proteins or by other suitable recombi- nant DNA methods known in the art. Such an approach for preparing the peptides according to the present invention is preferred especially when the effector units and/or other optional units are peptides or proteins. One example of a useful protein effector unit is glutathione-S-transferase (GST).
Advantages of the targeting units and targeting agents of the invention [0210] There are acknowledged problems related to peptides intended for diagnostic or therapeutic use. One of these problems stems from the length of the sequence: The longer it grows, the more difficult the synthesis of the desired product becomes, especially if there are other synthetic problems such as the presence of difficult residues that require protection- deprotection or cause side reactions.
[0211] As compared to known peptides that contain long and difficult-to-make sequences with problematic amino acid residues, the peptides of the present invention are clearly superior. The targeting units of this invention can be synthesized easily and reliably. An advantage as compared to many prior art peptides is that the targeting units and motifs of this invention do not need to comprise the problematic basic amino acids lysine and histidine, both of which may cause serious side-reactions in peptide synthesis, and, due to which the yield of the desired product might be lowered radically or even the product might be impossible to obtain in adequate amounts or with adequate quality.
[0212] Because of their smaller size and thus drastically less steps in the synthesis, the peptides of the present invention are much easier and cheaper to produce than most targeting peptides of the prior art.
[0213] As histidine is not needed in the products of the present invention, the risk of racemization is of no concern. It is a great advantage not only for the economic synthesis of the products of the present invention but also for the purification and analysis and quality control that any racemization of histidine is outside consideration. It also makes any administration to humans and animals safer and more straightforward. [0214] Because of the smaller size of the targeting units, overall costs are drastically reduced and better products can be obtained and in greater amounts, due to easier and more reliable purification. Furthermore, the reliability of the purification is much better, giving less concern of toxic remainders and of fatal or otherwise serious side effects in therapeutic and diagnostic applications.
[0215] The targeting units of the present invention are also highly advantageous due to their specificity, non-toxicity and non-immunogenicity.
[0216] In the solid phase synthesis of targeting agents according to the present invention, the effector units and optional additional units may be linked to the targeting peptide when it is still connected to the resin, without the risk that the removal of the protecting groups will cause destruction of the effector or optional units. Similar advantages apply to solution syntheses.
[0217] Another important advantage of the present invention and the products, methods and uses according to it is the highly selective and po- tent targeting of the products.
[0218] As compared to targeted therapy using antibodies or antibody fragments, the products and methods of in the present invention are highly advantageous because of several reasons. Potential immunological and related risks are obvious in the case of large biomolecules. Allergic reactions are of great concern with such products, in contrast to small synthetic molecules such as the targeting agents, units and motifs of the present invention.
[0219] As compared to targeting antibodies or antibody fragments, the products and methods described in the present invention are highly advantageous because their structure can be easily modified if needed or desired. Specific amino acids such as histidine, and threonine can be omitted, if desired, and very few functional groups are necessary. On the other hand, it is possible, without disturbing the targeting effect, to include various different structural units, to obtain specific desired properties that are of special value in specific applications.
Use of the targeting agents according to the present invention
[0220] The targeting units and targeting agents according to the present invention are useful in cancer diagnostics and therapy, as they selectively tar-get to tumors, especially to colon tumors in vivo, as shown in the Examples. The effector unit may be chosen according to the desired effect, de- tection or therapy. The desired effect may also be achieved by including the effector in the targeting unit as such. For use in radionuclide therapy the targeting unit itself may be e.g., radioactively labeled.
[0221] The present invention also relates to diagnostic compositions comprising an effective amount of at least one targeting agent according to the present invention. A diagnostically effective amount of the targeting agents according to the present invention may range from 1 femtomol to 10 mmols, depending for example on the effector unit of choice. In addition to the targeting agent, a diagnostic composition according to the present invention may, optionally, comprise carriers, solvents, vehicles, suspending agents, labeling agents and other additives commonly used in diagnostic compositions. Such diagnostic compositions are useful in diagnosing tumors, tumor cells and metastasis, especially tumors of the colon, more specifically colon primary tumors and metastases, in animals as well as in human subjects.
[0222] A diagnostic composition according to the present invention may be formulated as a liquid, gel or solid formulation or as an inhalation formulation, etc., preferably as an aqueous liquid, containing a targeting agent
according to the present invention in a concentration ranging from about 1 x 10"10 mg/l mg/l to 25 x 104 mg/l. The compositions may further comprise stabilizing agents, detergents, such as polysorbates, as well as other additives. The concentrations of these components may vary significantly depending on the formulation used. The diagnostic compositions may be used in vivo or in vitro.
[0223] The targeting agents and targeting units according to the present invention are useful in veterinary and human therapy.
[0224] The present invention also includes the use of the targeting agents and targeting units for the manufacture of pharmaceutical compositions for the treatment of cancer.
[0225] The present invention also relates to pharmaceutical compositions comprising a therapeutically effective amount of at least one targeting agent according to the present invention. The pharmaceutical compositions may be used to treat, prevent or ameliorate cancer diseases, by administering a therapeutically effective dose of the pharmaceutical composition comprising targeting agents or targeting units according to the present invention or therapeutically acceptable salts, esters or other derivatives thereof. The compositions may also include different combinations of targeting agents and targeting units together with labeling agents, imaging agents, drugs and other additives. [0226] A therapeutically effective amount of a targeting agent according to the present invention may vary depending on the formulation of the pharmaceutical composition. Preferably, a pharmaceutical composition according to the present invention may comprise a targeting agent in a concentration varying from about 0.00001 mg/l to 250 g/l, more preferably about 0.001 mg/l to 50 g/l, most preferably 0.01 mg/l to 20 g/l.
[0227] A pharmaceutical composition according to the present invention is useful for administration of a targeting agent according to the present invention. Pharmaceutical compositions suitable for per oral use, for intravenous or local injection, or infusion, or inhalation are particularly preferred. The pharmaceutical corn-positions may be used in vivo or ex vivo.
[0228] The preparations may be lyophilized and reconstituted before ad-ministration or may be stored for example as a solutions, suspensions, suspension-solutions etc. ready for administration or in any form or shape in general, including powders, concentrates, frozen liquids, and any other types. They may also consist of separate entities to be mixed and, possibly, otherwise handled and/or treated etc. before use. Liquid formulations provide the
advantage that they can be administered without reconstitution. The pH of the solution product is in the range of about 1 to about 12, preferably close to physiological pH. The osmolality of the solution can be adjusted to a preferred value using for example sodium chloride and/or sugars, polyols and/or amino acids and/or similar components. The compositions may further comprise pharmaceutically acceptable excipients and/or stabilizers, such as albumin, sugars and various polyols, as well as any acceptable additives, or other active ingredients such as chemotherapeutic agents.
[0229] The present invention also relates to methods for treating cancer, especially solid tumors by administering to an animal subject, including a human patient, in need of such treatment a therapeutically efficient amount of a pharmaceutical composition according to the present invention.
[0230] Therapeutic doses may be determined empirically by testing the targeting agents and targeting units in available in vitro or in vivo test sys- terns. Suitable therapeutically effective dosage may then be estimated from these experiments.
[0231] For oral administration it is important that the targeting units and targeting agents are stable and adequately absorbed from the intestinal tract. [0232] The pharmaceutical compositions according to the present invention may be administered systemically, non-systemically, locally or topically, par-enterally as well as non-parenterally, e.g. subcutaneously, intravenously, in-tramuscularly, per orally, intranasally, by pulmonary aerosol or powder, by injection or infusion into a specific organ or region, buccally, intracrani- cally or intraperitoneally etc.
[0233] Amounts and regimens for the administration of the tumor targeting agents according to the present invention can be determined readily by those with ordinary skill in the clinical art of treating cancer. Generally, the dosage will vary depending upon considerations such as: type of targeting agent employed; age; health; medical conditions being treated; kind of concurrent treatment, if any; frequency of treatment and the nature of the effect desired; gender; duration of the symptoms; and, counterindications, if any, and other variables to be adjusted by the individual physician. Preferred doses for ad-ministration to human patients of targeting units or agents according to the present invention may vary from about 1 x 10"9 mg to about 40 mg per kg of body weight as a bolus or repeatedly, e.g., as daily doses.
[0234] The targeting units and targeting agents and pharmaceutical corn-positions of the present invention may also be used as targeting devices for delivery of DNA or RNA or structural and functional analogues thereof, such as phosphorothioates, or peptide nucleic acids (PNA) into tumors and their metastases or to isolated cells and organs in vitro; i.e. as tools for gene therapy both in vivo and in vitro. In such cases the targeting agents or targeting units may be parts of viral capsids or envelopes, of liposomes or other "containers" of DNA/RNA or related substances, or may be directly coupled to the DNA/RNA or other molecules mentioned above. An especially preferred embodiment of the present invention is a targeting agent comprising a TU as an amino acid chain or its structural or functional analogue, and an EU as a PNA or its analogue, linked together via a peptide bond, as one contiguous molecule. Such a targeting agent may be used for intracellular delivery of small interfering RNA (siRNA; in this case "siPNA") for gene product-specific inhibi- tion (silencing) of gene expression.
[0235] The targeting units and agents according to the present invention may also be modified to improve stability, e.g. lengthen the biological half-life thereof by increasing the retention or stability of the targeting unit in the desired environment such as mammalian circulation. Such properties are achieved by standard pharmaceutical formulation chemistry tools and include introduction of non-hydrolysable bonds, glycosylation, pegulation as well as mixing with pharmaceutically acceptable diluents, adjuvants, carriers or vehicles well know to a person skilled in the art. The targeting units may also be chemically modified to decrease in vivo proteolytic digestion thereof by meth- ods known in the art.
[0236] The present invention also includes kits and components of kits for diagnosing, detecting or analyzing cancer or cancer cells in vivo and in vitro. Such kits comprise at least one targeting agent or targeting unit of this invention together with diagnostic entities enabling detection. The kit may comprise for example a targeting agent or a targeting unit coupled to a unit for detection by e.g. immunological methods, radiation or enzymatic methods or other methods known in the art.
[0237] Further, the targeting units and agents of this invention as well as the targeting motifs and sequences can be used as lead compounds to design peptidomimetics for any of the purposes described above.
[0238] Yet further, the targeting units and agents as well as the targeting motifs and sequences of the present invention, as such or as coupled to other materials, can be used for the isolation, purification and identification of the cells, molecules and related biological targets. [0239] The following examples are given to further illustrate preferred embodiments of the present invention, but are not intended to limit the scope of the invention. It will be obvious to a person skilled in the art, as the technology advances, that the inventive concept can be implemented in various ways. The invention and its embodiments are not limited to the examples described above but may vary within the scope of the claims.
Examples
Example 1
General screening method for bio-panning of patient samples
[0240] Phage display library. Standard procedures according to Smith and Scott (ibid.) were used. Phage display library used for screening of clinical samples was cloned in fUSE5 vector and was of the cyclic structure CX7C. The E.coli strain K91 kan was used as host for phage amplification.
[0241] Phage display on clinical tumor samples. Tissue samples were surgically removed from lung metastases of colorectal cancer patients. Part of the sample was taken for pathological examination, rest was placed in ice cold DMEM-PI (Dulbecco's medium containing protease inhibitors Pl; 10 mM PMSF (Phenyl-methyl-sulphonyl-fluoride), Aprotinin (10 mg/ml) Leupeptin (10 mg/ml)). Tissue samples were minced with a razor blade in a small cell culture plate in 1 ml of DMEM containing protease inhibitors. The samples were transferred to an eppendorf tube and washed with 1 ml DMEM-PI.
[0242] Samples were centrifuged at 5000 rpm for 4 min and were then incubated with 1010 transducing units of phage in 1 ml DMEM-PI at 250C for 15 min. After this the samples were washed three times with DMEM-PI containing 1% BSA (bovine serum albumin). [0243] 1 ml K91kan bacteria, OD600: 1-1.5, in LB containing 100 μg/ml kanamycin (kan) were infected with the washed pellet containing selectively attached phage particles at 250C for 25 min. After infection volume was increased to 5 ml with LB containing 100 μg/ml kan.
[0244] Then infected bacteria were plated on LB agar plates con- taining 40 μg/ml tetracycline (tet) as follows: Three parallel plates of three dilu-
tions (1 :250, 1 :2500, 1 :25000) and the rest of the above K91 kan culture in 300 μl aliquots. The plates were incubated overnight at +370C.
[0245] The following day colonies were picked from the LBtet plates into 96-well micro-plates for sequencing of the phage DNA. Extra clones were also stored at -2O0C for later analysis.
[0246] After picking colonies for sequencing the remaining bacterial colonies were pooled from the plates in 150 ml LB (100μg/ml kan, 20 μg/ml tet) for further growth. The culture was grown at 370C for 1-1.5h.
[0247] Then the bacteria were pelleted at 5000 rpm for 15 min. The supernatant containing amplified phages was precipitated by adding PEG to 0.04 g/ml and NaCI to 0.03 g/ml. The phages were shaken overnight at +40C on ice. After this the phages were pelleted by centrifugation at 10 000 rpm for 20 min at +40C. The resulting pellet was re-suspended in TBS and then re- precipitated for 1 h at +40C on ice by addition of PEG / NaCI as described above. Then the phages were pelleted at 14 000 rpm for 20 min at +40C on ice. Finally, the pellet was re-suspended in 1 ml of TBS containing 0.02% NaN3 and stored at +40C. For the next rounds of bio-panning of clinical samples the titre of the TBS phage stock was determined as described above.
[0248] To achieve selective enrichment of tumor targeting peptides, phage stocks prepared as described above were used three rounds of bio- panning of clinical samples.
[0249] Identification of enrichment of peptides. To determine the number of sequence of selectively enriched peptides, DNA sequencing was performed on 20 to 48 colonies, representing individual phage clones, from the first round of bio-panning onwards.
[0250] First colony PCR was performed to produce DNA for sequencing: Bacterial colonies in the wells of 96-well plate were suspended to30 μl TBS buffer and 5 μl of this were taken to PCR reaction. Next, PCR-Mix was made -PCR-Mix for one reaction is: 0.1 ml 10 mM dNTP's, 5.0 μl of template, 0.7 μl of F1 -forward primer (15 μM), 0.7 μl F1 -reverse primer (15 μM), 4 μl 10x Dynazyme buffer, 0.5 μl of Dynazyme polymerase (=1 U) and 29 μl of dH2O giving a final volume of 40ml. The setting for the PCR program used was 960C for 5 min followed by a cycle of three steps 1 ) 920C for 30 seconds, 2) 6O0C for 30 seconds and 3) 720C for 1 minute. This cycle of three steps was repeated 35 times. The sequences of the primers used in PCR amplification were 5'-
gCAAgCTgATAAACCgATACAATTAAAgg- 3' for F1-F and 5'-gCCC TCA TAg TTA gCg TAA CgA TC- 3' for F1-R.
[0251] Prior to sequencing amplification of DNA insert of the phage clones was verified by electrophoresis. Sequencing was performed with an ALF automated DNA sequencer (AmershamPharmacia Biotech) using the F1 - F and F1 -R primers described above.
[0252] Peptides selectively binding to lung tumors are the following: CYGFVWGEC and CYGFLWGQC. The enriched peptide sequences were collected from ex vivo panning round three.
Example 2
Preparation of synthetic peptides
[0253] All peptide syntheses were carried out manually or by using an automated synthesis instrument (either Applied Biosystems 433A or Advanced Chem Tech 396DC). The method was solid phase peptide synthesis based on N-FMOC protection and HBTU/HOBt/DIPEA activation. The synthesis resins employed were Rink amide MBHA resin, cysteamine-2-chlorotrityl resin, 1 ,2-diaminoethane trityl resin or preloaded FMOC-amino acid Wang resin. In automated syntheses the standard operating procedures and reagents recommended by the manufacturers were employed. [0254] The major reagents in these syntheses were from Applied
Biosystems or from Novabiochem: Fmoc-Cys(Trt)-OH (for 'C), Fmoc-Tyr(tBu)- OH (for 1Y'), Fmoc-Gly-OH (for 'G'), Fmoc-Phe-OH (for 'F), Fmoc-Val-OH (for V), Fmoc-Trp(tBoc)-OH (for 'W), Fmoc-Glu(OtBu)-OH (for 'E'), Fmoc-D-Ala- OH (for 'a') and Fmoc-Glu(O-2-Ph-i-Pr)-OH (for lactam-bridged 1E1, i.e. for 1E*1; the use of the asterisks herein is for indicating the amino acids connected by a lactam bridge).
[0255] The spacer unit reagent Fmoc-11-amino-3,6,9-undecanoic acid (for 'Teg') was purchased from University of Kuopio, Finland, and had been prepared as described previously (Boumrah, Deradji et al., Tetrahedron, 1997, 56: 6977-6992). The spacer unit reagent Fmoc-12-amino-4,7,10- trioxadodecanoic acid (for TEGC) was purchased from NeoMPS.
[0256] Linker 2-aminoethanethiol was produced via the cleavage of the cysteamine resin. Linker 1 ,2-diamino ethane was produced via the cleavage of the diamino ethane resin.
[0257] The thiol-reactive labeling reagent, the europium(lll) chelate of p-iodoacetamidobenzyl-DTPA was prepared from 2-(4-Aminobenzyl)- diethylenetriaminepenta (f-butyl acetate) purchased from Macrocyclics, Dallas,
Texas. This DTPA-Eu reagent was coupled with sulfhydryl bearing peptide compound according to Perkin Elmer's recommended procedure (PerkinElmer
Wallac Ltd., Turku, Finland).
[0258] The following abbreviations are used herein:
[0259] 'Ac' denotes: CH3C(O) i.e. acetyl (not actinium).
[0260] 'ADGA' denotes: Ala-Asp-Gly-Ala. [0261] 'AMB-DTPA-Eu' denotes:
[0262] Eu3+-chelate of (p-((2- aminoethylmercapto)acetamido)benzyl)diethylenetri-amine- N,N,N',N",N"- pentaacetic acid coupled via primary amino group (at the aminoethyl group).
[0263] 'amide' denotes: NH2 group connected to carbonyl (e.g. at the C- terminus of a peptide).
[0264] 'CYGFVWGEC denotes: Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys.
[0265] 'Ac-aYGFVWGEE' denotes: CH3C(O)-(D-Ala)-Tyr-Gly-Phe-Val-Trp-Gly-
GIu-GIu.
[0266] 'a*YGFVWGEE*' denotes: (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*; lactam bridge between amino terminus of D-AIa* and the side chain COOH of
GIuVDTPA' denotes: diethylenetriamine-N,N,N',N",N"-pentaacetic acid.
[0267] 'DTPA-Eu' denotes: Eu3+-chelate of DTPA.
[0268] 'EAT denotes: 2-Aminoethanethiol, also called ethyleneaminothiol, i.e.
NHCH2CH2SH. [0269] Teg' denotes: NH-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2-C(O).
[0270] Teg3' denotes: Teg-Teg-Teg, i.e. (NH-CH2CH2-O-CH2CH2-O-CH2CH2-
O-CH2-C(O))3.
[0271] TEGC denotes: NH-CH2CH2-O-CH2CH2-O-CH2CH2-O-CH2CH2-C(O).
List of reagents: [0272] Fmoc-Cys(Trt)-OH, CAS No. 103213-32-7, Novabiochem
Cat. No. 04-12-1018, Molecular Weight 585.7 g/mol.
[0273] Fmoc-Tyr(tBu)-OH, CAS No. 71989-38-3, Novabiochem Cat. No. 04-12-1037, Molecular Weight 459,6 g/mol.
[0274] Fmoc-Gly-OH , CAS No. 29022-11-5, Novabiochem Cat. No. 04-12-1001 , Molecular Weight: 297.3 g/mol.
[0275] Fmoc-Phe-OH, CAS No. 35661^0-6, Novabiochem Cat. No. 04-12-1030, Molecular Weight 387.4 g/mol.
[0276] Fmoc-Val-OH, CAS No. 68858-20-8, Novabiochem Cat. No. 04-12-1039, Molecular Weight 339.4 g/mol. [0277] Fmoc-Trp(tBoc)-OH, CAS No. 143824-78-6, Novabiochem
Cat. No. 04-12-1103, Molecular Weight 526.6 g/mol.
[0278] FmOC-GIu(OtBu)-OH, CAS No. 71989-18-9, Novabiochem Cat. No. 04-12-1020, Molecular Weight 425.5 g/mol.
[0279] Fmoc-D-Ala-OH, CAS No. 79990-15-1 , Novabiochem Cat. No. 04-13-1006, Molecular Weight 311.3 g/mol.
[0280] Fmoc-Gln(Trt)-OH, CAS No. 132327-80-1 , Novabiochem Cat. No. 04-12-1090, Molecular Weight 610.7 g/mol.
[0281] Fmoc-Leu-OH, CAS No. 35661-60-0, Novabiochem Cat. No. 04-12-1025, Molecular Weight 353.4 g/mol. [0282] Fmoc-Glu(O-2-Ph-i-Pr)-OH, Novabiochem Cat. No. 04-12-
1199, Molecular Weight 487.5 g/mol.
[0283] Fmoc-12-amino-4,7,10-trioxadodecanoic acid, NeoMPS Cat. No. FA19203, Molecular Weight 443.5 g/mol.
[0284] Cysteamine-2-chlorotrityl Resin, Novabiochem 01-64-0107, subst.: 1.33 mmol/g.
[0285] Rink amide MBHA Resin, Novabiochem 01-64-0107, subst.: 1 ,33 mmol/g.
[0286] 1 ,2-Diaminoethanetrityl resin, Novabiochem 01-64-0081 , subst.: 1 ,2 mmol/g. [0287] Fmoc-Glu(OtBu)-Wang resin, Novabiochem 04-12-2052, subst.: 0.62 mmol/g.
[0288] Fmoc-Ala-OH, CAS No. 35661-39-3, Novabiochem Cat. No. 04-12-1006, Molecular Weight 311.3 g/mol.
[0289] Fmoc-Asp(OtBu)-OH, CAS No. 71989-14-5, PerSeptive Bio- systems Cat. No. GEN9110211 , Molecular Weight 411.5 g/mol.
General procedures for peptide synthesis: manual solid phase syntheses. Mass spectral measurements.
[0290] All manual synthetic procedures were carried out in a seal- able glass funnel equipped with a sintered glass filter disc of porosity grade between 2 and 4, a polypropene or phenolic plastic screw cap on top (for sealing), and two PTFE key stopcocks: one beneath the filter disc (for draining)
and one at sloping angle on the shoulder of the screw-capped neck (for argon gas inlet).
[0291] The funnel was loaded with the appropriate solid phase synthesis resin and solutions for each treatment, shaken effectively with the aid of a "wrist movement" bottle shaker for an appropriate period of time, followed by filtration effected with a moderate argon gas pressure.
[0292] The general procedure of one cycle of synthesis (= the addition of one amino acid unit) was as follows:
[0293] The appropriate synthesis resin loaded with approximately 0.25 mmol of FMOC-peptide (= peptide whose amino-terminal amino group was protected with the 9-fluorenylmethyloxycarbonyl group) consisting of one or more amino acid units having recommended protecting groups; approximately 0.5 g of resin (0.5 mmol/g) was treated in the way described below, each treatment step comprising shaking for one to two minutes with 10 ml of the solution or solvent indicated and filtration if not mentioned otherwise.
[0294] 1DCM1 means shaking with dichloromethane, and 1DMF1 means shaking with N,N-dimethylformamide (DMF may be replaced by NMP, i.e., N-methylpyrrolidinone).
[0295] The steps of the treatment were: 1. DCM, shaking for 10-20 min;
2. DMF;
3. 20% (by volume) piperidine in DMF for 5 min;
4. 20% (by volume) piperidine in DMF for 10 min;
5. to 7. DMF; 8. to 10. DCM;
11. DMF;
12. DMF solution of 0.75 mmol of activated amino acid (preparation described below), shaking for 2 hours;
13. to 15. DMF; 16. to 18. DCM.
[0296] After the last treatment (18) argon gas was led through the resin for approximately 15 min and the resin was stored under argon (in the sealed reaction funnel if the synthesis was to continue with further units).
[0297] Activation of the 9-fluorenylmethyloxycarbonyl-N-protected amino acid (FMOC-amino acid) to be added to the amino acid or peptide chain on the resin was carried out, using the reagents listed below, in a separate
vessel prior to treatment step no. 12. Thus, the FMOC-amino acid (0.75 mmol) was dissolved in approximately 3 ml of DMF, treated for 1 min with a solution of 0.75 mmol of HBTU dissolved in 1.5 ml of a 0.5 M solution of HOBt in DMF, and then immediately treated with 1.07 ml of a 1.4 M DIPEA solution in DMF for 5 min; exceptionally 2, 4, 6-tri methyl pyridine was used instead of DIPEA in the case of the activation of FMOC-Cys(Trt)-OH.
[0298] The activation reagents used for activation of the FMOC- amino acid were as follows:
[0299] HBTU = 2-(1 H-benzotriazol-1-yl)-1 ,1 ,3,3- tetramethyluronium hexafluorophosphate, CAS No. [94790-37-1], Applied Bio- systems Cat. No. 401091 , molecular weight: 379.3 g/mol;
[030O] HOBt = 1-Hydroxybenzotriazole, CAS No. 2592-
95-2, molecular weight 135.12 g/mol, Acros Organics Cat. No. 169161000;
[030I] DIPEA = N,N-Diisopropylethylamine, CAS No. 7087-68-5, molecular weight 129.24 g/mol, Acros Organics Cat. No. 115221000.
[0302] The procedure described above is repeated in several cycles using different FMOC-amino acids, containing suitable protecting groups, to produce a "resin-bound" peptide (i.e., resinous source of an appropriate pep- tide). The procedure provides also a way to connect certain linker units, for instance FMOC-Teg (i.e., Fmoc-11-amino-3,6,9-undecanoyl moiety), to the resin-bound peptide. Also the very first unit (at the C-terminal end of the sequence) can be connected to Rink amide resin or to cysteamine resin by means of this general coupling method described above; in the case of cys- teamine resin the initial treatment with piperidine (steps 3 to 11 ) is not necessary at the first cycle. When a lactam-bridged cyclic compound was needed, the first cycle was carried out with 0.25 mmol of activated reagent in step 12 above (instead of usual 0.75 mmol) followed by resin capping between steps 12 and 13 by means of acetylation for 30 min using reagent mixture: 2 ml of acetic anhydride and 1 ml of 2,4,6-trimethylpyridine mixed in 4 ml of DMF.
[0303] When N-terminally acetylated product was needed the procedure above was carried out with the exception of acetic anhydride instead of the activated FMOC-amino acid at step 12 using reagent mixture: 2 ml of acetic anhydride and 1 ml of 2,4,6-trimethylpyridine mixed in 4 ml of DMF. Then the resin was washed with DMF and DCM before the cleavage process described below.
[0304] When lactam-bridged cyclic compounds were needed (lactam bridge between the N-terminus of D-AIa and side chain of γ-2-phenyl- isopropylester protected GIu) the procedure above was carried out with the exception of additional deprotection treatment (removal of the O-2-Ph-i-Pr pro- tection of the side chain of GIu) of the resin after step 10 by shaking with four portions of 2% TFA (0.2 ml) solution in DCM (9.7 ml) containing 1% of triiso- propylsilane (0.1 ml), each for two minutes followed by filtration. Then the resin was washed with 0.2 M DIPEA in DMF followed by washing steps 8-11. Next the resin was shaken for 5 hours with 0.75 mmol of the activation reagent PyAOP (i.e. 7-azabenzotriazol-1-yloxytris(pyrrolidino)phosphoniumhexafluoro- phosphate, Applied Biosystems, CAS No. 156311-83-0, Cat. No. GEN076533, molecular weight 521.4 g/mol) in 5 ml of DMF containing 1.5 mmol of DIPEA followed by final washings according to steps 13-18. Therefore this coupling was intramolecular without any FMOC-amino acid added in step 12. Then the resin was washed with DMF and DCM before the cleavage process described below.
[0305] After removal of the protecting FMOC group of the last amino acid of the peptide via steps 1. to 10., and acetylation according to the process described above or lactam bridge formation according to the process described above, the resin was washed with DCM, dried at argon flow and treated with three portions of the cleavage reagent mixture described below (each about 10 ml), each for one hour. The treatments were carried out under argon atmosphere in the way described above. After three hours from the beginning of the treatment the TFA solutions obtained by filtration were concen- trated under reduced pressure using a rotary evaporator and were recharged with argon.
[0306] Cleavage from the resin was carried out using the following reagent mixture:
[0307] trifluoroacetic acid (TFA) 92.5 vol-%; water 5.0 vol-%; ethanedithiol 2.5 vol-%.
[0308] The cleavage mixture described above also simultaneously removed the following protecting groups: Tert-butoxycarbonyl (Boc) as used for protection of side chain of tryptophan, tert-butyl ester (OtBu)/(tBu) as used for protection of side chain carboxyl group or glutamic acid of hydroxyl group of tyrosine, trityl (Trt) as used for protection of side chain of cysteine.
[0309] When cystine bridged cyclic compounds were needed (disulfide bond between the side chains of cysteine amino acids), the crude peptide, after releasing from the resin according to the protocol described above, was dissolved in 0.05 M ammonium acetate solution at peptide concentration 0.01 M and it was allowed to stand at room temperature over night (air oxidation).
[0310] Purification was performed by reversed phase high- performance liquid chromatographic (HPLC) method using a "Waters 600" pump apparatus with a C-18 type column of particle size 10 micrometers, and a linear eluent gradient whose composition was changed during 30 minutes from 99.9% water/0.1% TFA to 99.9% acetonitrile/0.1% TFA; in some instances (indicated below) the eluent was buffered by 0.05 M ammonium acetate instead of 0.1% TFA. The dimensions of the HPLC columns were 25 cm x 21.2 mm (Supelco cat. no. 567212-U) and 15 cm x 10 mm (Supelco cat. no. 567208-U). Detection was based on absorbance at 218 nm and was carried out using a "Waters 2487" instrument. The fraction indicated by right mass spectrum was collected as product; to enhance purification the eluent composition limits were adjusted to achieve applicable gradient.
[0311] Compounds synthesized this way are constructed from "right to left" in the conventionally (also in this text) presented sequence, i.e. starting from the C-terminal end of the peptide chain.
Mass spectral method employed:
[0312] Matrix Assisted Laser Desorption Ionization - Time of Flight (MALDI -TOF).
Type of the instrument: [0313] Bruker Ultraflex MALDI TOF/TOF mass spectrometer.
Supplier of the instrument:
[0314] Bruker Daltonik GmbH, [0315] Bremen, [0316] Germany.
Maldi-tof positive ion reflector mode:
[0317] External standards: Angiotensin II, angiotensin II, substance P, bombesin, ACTH(I -17) ACTH(18-39), somatostatin 28 and bradykinin 1-7.
[0318] Matrix: alpha-cyano^-hydroxycinnamic acid (2mg/ml solution in aqueous 60% acetonitrile containing 0.1% of trifluoroacetic acid, or acetone only for acid sensitive samples).
Maldi-tof negative ion reflector mode: [0319] External standards: cholecystokinin and glucagon or [GIuI]- fibrinogen peptide B.
[0320] Matrix: alpha-cyano^-hydroxycinnamic acid (saturated solution in acetone).
Sample preparation: [0321] The specimen was mixed at a 10-100 picomol/microliter concentration with the matrix solution as described and dried onto the target.
[0322] Ionization by "shooting" in vacuo by nitrogen laser at wavelength 337 nm. The Voltage of the probe plate was 19 kV in positive ion reflector mode and -19 kV in the negative ion reflector mode.
General remarks about the spectra (concerning positive ion mode only):
[0323] In all cases the M+1 (i.e., the one proton adduct) signal with its typical fine structure based on isotope satellites was clearly predominant. In almost all cases, the M+1 signal pattern was accompanied by a similar but markedly weaker band of peaks at M+23 (Na+ adduct). In addition to the bands at M+1 and M+23, also bands at M+39 (K+ adduct) or M+56 (Fe+ adduct) could be observed in many cases.
[0324] The molecular mass values reported within synthesis examples correspond to the most abundant isotopes of each element, i.e., the 'exact masses'.
Synthesis of targeting agent HP202
[0325] The synthesis of ADGA-CYGFVWGEC-Teg3-amide, i.e. Ala-Asp-Gly-Ala-Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys-Teg-Teg-Teg-NH2, that has solubility-enhancing units and is cyclic by virtue of the disulfide bond between the two cysteines (Cys), was carried out using an Applied Biosystems 433A peptide synthesis instrument and based on Rink amide MBHA Resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-11-amino-3,6,9-undecanoic acid i.e. Fmoc-Teg-OH that was used in the regular manner). After release from the resin, the crude peptide
was cyclized according to the air oxidation protocol described above and purified by RP-HPLC.
[0326] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+1 : 1943.81 Da; M+Na: 1965.81 Da. [0327] Calculated isotopic M: 1942.83.
Synthesis of targeting agent HP203
[0328] The synthesis of ADGA-CYG FLWGQC-Teg3-amide, i.e. Ala-Asp-Gly-Ala-Cys-Tyr-Gly-Phe-Leu-Trp-Gly-Gln-Cys-Teg-Teg-Teg-NH2, that has solubility-enhancing units and is cyclic by virtue of disulfide bond be- tween the two cysteines (Cys), was carried out using an Applied Biosystems 433A peptide synthesis instrument and based on Rink amide MBHA Resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-11-amino-3,6,9-undecanoic acid i.e. Fmoc-Teg-OH that was used in the regular manner). After release from the resin, the crude peptide was cyclized according to the air oxidation protocol described above and purified by RP-HPLC.
[0329] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+Na: 1976.64 Da.
[0330] Calculated isotopic M: 1953.86.
Synthesis of control peptide HP204
[0331] The synthesis of ADGA-CWEGGLYFC-Teg3-amide, i.e. Ala-Asp-Gly-Ala-Cys-Trp-Glu-Gly-Gly-Leu-Tyr-Phe-Cys-Teg-Teg-Teg-NH2, that has a solubility-enhancing units at the C-terminus and is cyclic by virtue of disulfide bond between the two cysteines (Cys), was carried out using an Ap- plied Biosystems 433A peptide synthesis instrument and based on Rink amide MBHA Resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-11-amino-3,6,9-undecanoic acid i.e. Fmoc-Teg- OH that was used in the regular manner). After release from the resin, the crude peptide was cyclized according to the air oxidation protocol described above and purified by RP-HPLC.
[0332] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+Na: 1979.7 Da.
[0333] Calculated isotopic M: 1956.8.
Synthesis of targeting agent KK12
[0334] The synthesis of Ac— CYGFVWGEC-(TEGC-GIU)2- NHCH2CH2NH2 i.e.
Acetyl-Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys-(TEGC-Glu)2-NH-CH2CH2-NH2, cyclic by virtue of a cystine bridge between the two cysteines (Cys), and comprising solubility-enhancing units, was carried out manually according to the general protocol described above, based on 1 ,2-Diaminoethanetrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-TEGC-OH that was used in the regular manner). The N-terminus was acetylated according to the general protocol described above and the compound was cleaved off the resin, as described above, and cyclized in 0.05 M ammonium bicarbonate solution exposed by air at room temperature over night, and then purified by RP-HPLC.
[0335] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+1 : 1809.85 Da, M+Na: 1831.68 Da, M+K: 1847.65 Da.
[0336] Calculated isotopic M: 1808.8 Da.
Synthesis of europium-labeled targeting agent MJ069
[0337] The synthesis of cystine-bridged targeting agent Acetyl- CYGFVWGEC-(TEGC-Glu)2-NHCH2CH2NHC(S)-p-NH-Benzyl-DTPA-Eu comprising a europium chelating effector unit, a solubility-enhancing spacer unit and a targeting unit CYGFVWGEC, i.e.
Cys-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Cys, cyclic by virtue of the disulfide bond between the cysteines (Cys), was performed as follows: 2.5 mol equivalents (0.00363 mmol) of ITC-DTPA (p-SCN-Benzyl-DTPA, Macrocyclics, Dallas Texas, MW: 649.92 g/mol) was dissolved in 0.33 ml of 0.05 M aqueous Na- HCO3. Then 1 molar equivalent (0.00145 mmol) of peptide KK22, described above, in 0.2 ml of aqueous NaHCO3, was added to the ITC-DTPA solution and pH was adjusted to 9 with aqueous NaOH. After gentle stirring overnight, at room temperature and protected from light, 3 mol equivalents (0.00436 mmol) of EuCI3 x 6H2O, in 50 μL of H2O, was added to the reaction mixture. Then, after gentle stirring for 4 h at room temperature, the mixture was dissolved in 100 μL of 1 M NaHCO3.
[0338] The compound was purified by RP-HPLC at water- acetonitrile eluent gradient buffered by 0.05 M ammonium acetate, and the
desired product was identified by MALDI-TOF mass spectrometry: Observed positive ions M+1 : 2497.80 Da, M+Na: 2521.80 Da, M+K: 2537.77 Da. [0339] Calculated isotopic M: 2498.814 Da.
Synthesis of control peptide HP238 [0340] The synthesis of a linear control peptide Ac-aWEYGVGFE-
(TEGC-GIu)2-EAT, i.e.
Acetyl-(D-Ala)-Trp-Glu-Tyr-Gly-Val-Gly-Phe-Glu-(TEGC-Glu)2-EAT comprising a sulfhydryl bearing linker unit via a solubility-enhancing spacer unit at the C- terminus of the peptide sequence, was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including unusual Fmoc-TEGC-OH that was used in the regular manner). The N-terminus was acetylated according to the general protocol described above and after release from the resin the crude peptide was purified by RP-HPLC.
[0341] The identification of the product was based on MALDI-TOF mass spectrum: Observed negative ion M-1 : 1820.44 Da. [0342] Calculated isotopic M: 1821.8 Da.
Synthesis of targeting agent MJ012 [0343] The synthesis of linear targeting agent Ac-aYGFVWGEE-
(Teg-Glu)2-EAT, i.e.
Acetyl-(D-Ala)-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu-(Teg-Glu)2-EAT comprising targeting unit aYGFVWGEE and sulfhydryl bearing linker agent via solubility- enhancing spacer units at the C-terminus of the targeting unit was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner). The N-terminus was acetylated according to the general protocol described above and after release from the resin the crude peptide was purified by RP-HPLC.
[0344] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+Na: 1816.77 Da; M+K: 1832.75. [0345] Calculated isotopic M: 1793.77Da.
Synthesis of targeting agent MJ080
[0346] The synthesis of lactam-bridged targeting agent a*YGFVWGEE*-Teg-Glu, i.e. (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*-Teg- GIu, cyclic by virtue of a lactam bridge between the N-terminus and the side- chain of E* (glutamic acid) and bearing a solubility-enhancing unit at the C- terminus of the targeting unit, was carried out manually according to the general protocol described above and was based on Fmoc-Glu(OtBu)-Wang resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner). The lactam bridge was prepared according to the general protocol described above and the peptide was purified by RP-HPLC.
[0347] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+Na: 1371.60 Da, M+ Na: 1396.59 Da, M+K: 1409.56 Da. [0348] Calculated isotopic M: 1370.60 Da-
Synthesis of targeting agent MJ013
[0349] The synthesis of lactam-bridged targeting agent a*YGFVWGEE*-(Teg-Glu)2-EAT, i.e. (D-Ala)*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*-(Teg-Glu)2-EAT (lactam bridge be- tween N-terminus of a* and side chain COOH group of E*) comprising the targeting unit a*YGFVWGEE* and a sulfhydryl bearing linker agent via solubility- enhancing spacer units at the C-terminus of the targeting unit, was carried out manually according to the general protocol described above and was based on cysteamine-2-chlorotrityl resin and solid phase Fmoc-chemistry and regular protected amino acid reagents (including Fmoc-Teg-OH that was used in the regular manner). The lactam bridge was prepared according to the general protocol described above and the peptide was purified by RP-HPLC.
[0350] The identification of the product was based on MALDI-TOF mass spectrum: Observed positive ion M+Na: 1756,73 Da; M+K: 1772,71 Da. [0351] Calculated isotopic M: 1733,75 Da.
Preparation of europium labeling agent Eu-DTPA-IAA
[0352] The Synthesis of Eu-DTPA-IAA i.e. Eu3+-chelate of (p- iodoacetamidobenzyl)diethylenetriamine-N,N,N',N",N"-pentaacetic acid was performed in three steps. The synthesis was started from (t-BuO)5DTPA-Bz- NH2 purchased from Macrocyclics, Dallas, Texas (0.300 mmol), which was
allowed to react with iodoacetic anhydride (0.330 mmol) and triethylamine (0.315 mmol) in dichloromethane (6 ml) at room temperature for 2 hours. The crude product was purified by flash chromatography in silica gel column eluted by 30% ethyl acetate in hexane. Then the flash-purified t-BuO-protected DTPA-IAA was deprotected by excess of neat TFA at room temperature over night and, without purification, labeled with europium (2 mol equivalent of aqueous EuCI3 X H2O) in ammonium acetate buffer (3 mol equivalent) at room temperature over night. This final Eu-DTPA-IAA compound was purified by RP-HPLC at water-acetonitrile eluent gradient buffered by 0.05 M ammonium acetate and the desired product was identified by MALDI-TOF mass spectrometry. Calculated M: 816.00 Da; obtained positive ion M+H: 816.96 Da.
Synthesis of europium-labeled targeting agent MJ017
[0353] The synthesis of linear targeting agent Ac-aYGFVWGEE- (Teg-Glu)2-AMB-DTPA-Eu, i.e. Acetyl-D-Ala-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu-(Teg-Glu)2-NHCH2CH2-S-
CH2C(O)-p-aminobenzyl-DTPA-Eu comprising targeting unit aYGFVWGEE and a europium-bearing DTPA chelate coupled via a thioether bond (included in 1AMB1 linkage) and solubility-enhancing spacer units at the C-terminus of the targeting unit, was carried out in aq NaHCO3.at pH 8.5. The peptide (MJ012, 1 eq) was dissolved in 0.05 M NaHCO3 and the Eu3+-chelate of (p- iodoacetamidobenzyl)diethylenetriamine-N,N,N',N",N"-penta-acetic acid (Eu- DTPA-IAA, 2 eq) in 0.05 NaHCO3 was added to the peptide solution. After this, pH was adjusted to 8.5, the solution was protected from light and allowed to stay overnight at 370C The DTPA-Eu labeled peptide was purified by RP- HPLC at water-acetonitrile eluent gradient buffered by 0.05 M ammonium acetate.
[0354] The identification of the product was based on MALDI-TOF mass spectrum: Observed negative ion M-1 : 2480.68 Da. [0355] Calculated isotopic M: 2481.86 Da.
Synthesis of europium-labeled targeting agent MJ018
[0356] The synthesis of lactam-bridged targeting agent a*YGFVWGEE*-(Teg-E)2-AMB-DTPA-Eu, i.e.
D-Ala*-Tyr-Gly-Phe-Val-Trp-Gly-Glu-Glu*-(Teg-Glu)2-NHCH2CH2-S-CH2C(O)- p-aminobenzyl-DTPA-Eu (lactam bridge between N-terminus of a* and the side chain COOH group of E*) comprising targeting unit a*YGFVWGEE* and a
europium-bearing DTPA chelate coupled via a thioether bond (included in 1AMB1 linkage) and solubility-enhancing spacer units at the C-terminus of the targeting unit, was carried out in aq NaHCθ3.at pH 8.5. The peptide (MJ013, 1 eq) was dissolved in 0.05 M NaHCO3 and the Eu3+-chelate of (p- iodoacetamidobenzyl)diethylenetriamine-N,N,N',N",N"-penta-acetic acid (Eu- DTPA-IAA, 2-3 eq) in 0.05 NaHCO3 was added to the peptide solution. After pH was adjusted to 8.5, the solution was protected from light and allowed to stay overnight at 370C The DTPA-Eu labeled peptide was purified by RP- HPLC at water-acetonitrile eluent gradient buffered by 0.05 M ammonium ace- tate.
[0357] The identification of the product was based on MALDI-TOF mass spectrum: Observed negative ion M-1 : 2420.67 Da.
[0358] Calculated isotopic M: 2421.84 Da.
Example 3 Selective binding of colorectal cancer cells to immobilized targeting agents
[0359] In these examples the following cell lines and culture conditions were used, where not otherwise indicated:
[0360] The human colorectal cancer HCT-15 cell line (ATCC: CCL- 225), called herein also "HCT-15", was cultured in RPMI 1640 medium with 2 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10 mM HEPES, and 1.0 mM sodium pyruvate, 1% penicillin/streptomycin, 10% fetal bovine serum.
[0361] The human colon adenocarcinoma cell line LoVo (ATCC:CCL-229), called herein "LoVo", was cultured in Ham's F-12 medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, 1.5 g/L sodium bicarbonate and 10% fetal bovine serum.
[0362] The colorectal cancer cell line HCT-15-LM1 was developed as follows. The cell culture was started with cancer cells from lung metastases which had developed after injection of human colorectal cancer HCT-15 cells into the bloodstream of a mouse. The inoculation procedure was then repeated with HCT-15-LM1 cells leading to the establishment of another metastatic cell line, HCT-15-LM2.
[0363] The mouse fibroblast line NIH3T3, called herein also "NIH3T3", has been described previously by Koga et al. in Gann, 1979, 70:
585-591. The cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
[0364] The mouse vascular endothelial cell line SVEC4-10, called herein also "SVEC4-10", has been described previously by O'Connell et al. in J. Immunol., 1990, 144: 521-525. The cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum.
[0365] The human melanoma cell line C8161 has been described previously by Welch et al. in Int. J. Cancer, 1991 , 47: 227-237. A more metas- tatic cell line C8161T, called herein also "C8161T", was developed by culturing cells from a subcutaneous melanoma tumor developed after inoculation of C8161 melanoma cells on the flank of a nude mouse. The cell line was cultured in DMEM medium adjusted to contain 2 mM L-glutamine, 1% penicillin/streptomycin, and 10% fetal bovine serum. [0366] The human oral squamous cell carcinoma line HSC-3, called herein "HSC-3" (JCRB Cell Bank 0623, National Institute of Health Sciences, Japan) was cultivated in 1 :1 DMEM and Ham's F 12 medium containing 10% FBS, 1% penicillin/streptomycin, L-glutamate and sodium pyruvate and 0.4 ng/ml hydrocortisone. [0367] Preparation of plates for assays. Wells of Reacti-Bind
Maleimide activated clear strip plate (Pierce, Prod#. 15150) were coated with targeting agents of this invention at a concentration of 30 μg/ml. The incubation was carried out of overnight at 2O0C. The binding buffer containing unbound peptide was removed from the wells. [0368] The wells were blocked with blocking buffer (0.5% BSA,
0.05% Tween20 in phosphate buffer saline (PBS). PBS was prepared as follows: 40 g of NaCI, 1 g of KCI, 7g of Na2HPO4 x 2H2O and 1 g of KH2PO4 were dissolved in 1000 ml of deionized H2O. Blank wells as controls were prepared by treating empty wells with blocking buffer. The plates were incubated 1 hour 30min at 2O0C. After incubation the plate was washed three times with PBS, pH 7.4.
[0369] Cell binding assay. 75000 cells in volume of 150 μl of medium were added into coated wells and were incubated for 30 minutes at 370C. After cell binding, the wells were washed with PBS for 30 minutes. Detection of targeting agent bound cells was based on the MTT assay (described in detail in Example 6, Cytotoxicity). 10 μl of MTT reagent and 90 μl of medium were
added to the wells. The plate was incubated for three hours at +370C. After the incubation, 100 μl of lysis buffer was added to the wells and let to incubated o/n 370C. On following day the absorbance of plate was measured at 560nm with ELISA-reader (ThermoLabsystems, Multiskan EX). [0370] The colon cancer cell lines, HCT-15 and HCT-15-LM1 , HSC-
3 oral cancer cell line and C8161T melanoma cell line and control cell lines NIH-3T3 and SVEC4-10 and targeting agents MJ012 and MJ013 (described in Example 2) were used in the cell binding assays.
[0371] The results of the cell binding assay showing the selective binding of cancer cell lines to the targeting agents are shown in Figure 1. The colon cancer cell lines HCT-15 (A), HCT-15-LM1 (B), tongue carcinoma HSC-3 (C) and melanoma cell line C8161T (D), bind selectively to the immobilized targeting agents MJ012 (Figure 1A) and MJ013 (Figure 1 B), whereas the control cell lines, mouse fibroblast cell line NIH3T3 (E) and murine endothelial cell line SVEC4-10 (F) show significantly less binding. The results are shown as measured absorbance at 560 nm.
Example 4
Accumulation of targeting CYGFLWGQC-phage in primary tumors and lung metastases in mice [0372] In this example the biodistribution of the targeting phage displaying peptide sequence CYGFLWGQC on the surface is shown for primary tumors of colon cancer and also for lung metastases in mice after iv. injection of HCT-15-LM1 colon cancer cells and metastase development. It is shown that the tested targeting peptide displaying phage according to the present inven- tion selectively targets to colon cancer tumors and lung metastases with high tumor/muscle ratio.
[0373] For production of experimental tumors 1 x 106 cells of HCT- 15-LM 1 line (described in Example 3) were injected subcutaneously into both flanks of athymic-nu nude mice strain (Harlan Laboratories). The tumors from six mice were harvested when they had reached a weight of about 0.4 g.
[0374] To produce lung metastases, 6 x 106 cells of HCT-15-LM1 cell line were injected into the bloodstream of two mice. The animals were weighed twice a week to monitor the weight loss indicating possible metastase development.
[0375] Tumor-bearing mice were anesthetized by 0.02 ml/g body weight of Avertin [10 g 2,2,2-tribromoethanol (Fluka) in 10 ml 2-methyl-2- butanol (Sigma Aldrich)] intraperitoneal^ (i.p.). To determine the accumulation of the targeting phage, 109 transducing units of CYGFLWGQC-peptide display- ing phage were injected to the tail vein of the mouse. After 15 minutes circulation time the animals were perfused through heart with 20-60 ml DMEM. Tumors and control organs were removed and washed with DMEM+PI before they were homogenized. After this the samples were washed three times with DMEM-PI containing 1% BSA (bovine serum albumin). [0376] 0,5 ml K91kan bacteria, OD600 (optical density of 600nm)
1-1.5, in LB (Lurian broth) containing 100ug/ml kanamycin (kan) were infected with the pellet containing phage particles binding to the tissues. After infection volume was increased to 5 ml with LB containing 100ug/ml kan. 100, 10, 1 and 0.1 μl from the solution of infected bacteria were plated on LB agar plates con- taining 40μg/ml tetracycline (tet). The plates were incubated overnight at +370C. Next day the colonies were counted and the results were analyzed.
[0377] The number of colonies / 1 g tissue showed the following tumor versus muscle phage binding ratios, ni is the number of tumors and n2 is the number of mice. Primary tumor: muscle 23,8:1 ni=6
Metastase: muscle 39,4:1 n2=2
Example 5
Targeting peptide biodistribution
[0378] In this example biodistribution of the targeting agents MJ017 and MJ018 (described in Example 2) is shown for primary tumors of HTC-15 and lung metastases of HCT-15-LM1. It is shown that the tested targeting agents according to the present invention selectively target to primary tumors in vivo as well as lung metastases but not to normal tissues or organs.
[0379] For production of experimental tumors 22.5 x 106 cells of HCT-15 line (described in Example 3) were injected subcutaneously into both flanks of athymic-nu nude mice strain (Harlan Laboratories). Tumors were harvested when they had reached a weight of about 0.1 g. Tumor-bearing mice were anesthetized by 0.02 ml/g body weight of Avertin [10 g 2,2,2- tribromoethanol (Fluka) in 10 ml 2-methyl-2-butanol (Sigma Aldrich)] intraperi- toneally (i.p.).
[0380] To determine the biodistribution pattern of the targeting agents MJ017 and MJ018, 4 nmol of MJ017-Eu and MJ018-Eu targeting agent was injected into the tail vein of athymic nude mice in a volume of 200 μl in physiological saline solution (Baxter). Targeting agent was allowed to circulate for 15 min. Mice were then perfused through the heart with 60 ml of physiological saline. Organs and tissues, including tumors were collected and weighed.
[0381] For determination of the Eu content of the tumors and control organs, 0.1-0.2 g of tissue was transferred into lysis buffer (20 mM Tris-HCI, 150 mM NaCI, 1% Nonident P40, pH7,5) and homogenized. Eu-content was analyzed from tissue lysates prepared into the Enhancement solution (Perkin Elmer Wallac Ltd., Turku, Finland) and transferred to DELFIA Micro titration strip plates (Perkin Elmer Wallac Ltd, Turku, Finland). Time-resolved fluorescence was measured after incubation with a Wallac 1420 VICTOR3™ V plate reader using a D615nm filter.
[0382] The comparison of the amount of europium detected in the mouse tissues showed that the MJ017-Eu and MJ018-Eu targeting agents accumulated strongly and selectively in HTC-15 tumors and HCT-15-LM1 lung metastases compared to normal tissue, except for the kidney showing high signal due to excretion of the agent via these routes.
[0383] The observed high tumor-to-muscle ratio further proves the highly selective binding of MJ017-Eu and MJ018-Eu to HTC-15 tumors shown in Figure 2. A= tumor, B=heart, C= lung, D=liver, E=spleen, F= small intestine and G= brain. [0384] The ratio of lung metastase Eu-content to-muscle Eu-content of targeting agent MJ017 was 4.1.
[0385] Thus, the used targeting agent shows highly selective tumor and metastase targeting properties.
Example 6 Cytotoxicity assay with CYGFLWGQC -peptide
[0386] In this assay LoVo cell line (described in example 3) was exposed to two different concentrations (5 μg/ml and 138 μg/ml) of targeting unit HP203 (described in Example2) for three days to test the toxicity of the peptides. The measurement of cell viability was done with MTT (Thiazolyl blue, Sigma M-5655) tetrazolium salt. MTT is cleaved to water-insoluble formazan
dye by the "succinate-tetrazolium reductase" system, which is active only in viable cells. After formazan was solubilized by 10% SDS-0, 01 M HCI, it was quantified in an ELISA spectrometer (ThermoLabsystems Multiscan EX) at 560 nm. CuSAO2 [trans-bis(salicylaldoximato)copper(ll)] 7.5 μg/ml was used as a positive control for 100% toxicity.
[0387] Procedure. Cells were trypsin ized from the cell culture dish (0 9 cm) with 1 ml of TE for 1-5 minutes and moved to a 50 ml Falcon tube. After this the volume was increased to 20 ml of cell line specific medium and cells were transferred to a Burker chamber and diluted in medium to a concen- tration of 2500-3500 cells/100 μl depending on cell line. Two or three 96-well micro plates, 24 h, 48h and 72h were prepared as follows: the first column of the 96-well plate was filled with 100 μl medium/well (w/o cells), and the rest of the columns needed for the experiment with 100 μl of the cell solution so that each well contains 2500-3000 cells. After this the cells were let to attach over night in a cell culture incubator.
[0388] Next day 40 μl of medium was removed from all wells except from the ones with only medium and one column with cells. Then 40 μl of HP203 targeting unit in appropriate medium were added to the wells in two concentrations, so that final concentrations were 5 μg/ml and 138 μg/ml, and the volume of the wells was raised back to 100 μl. Similarly, 40 μl of reference substance Cu(SAO)2 were added to all the wells in one column so that the final concentration was 7.5 μg/ml. The plates were incubated in an incubator for 24 h, 48 h or 72 h. The next day the cell morphology was analyzed with a microscope. After this 10 μl of MTT reagent 5 mg/ml in PBS were added to all wells on the plate and the plate was incubated for 3 h at 370C. Finally, 100 μl of 10% SDS in 0.01 M HCI were added to all the wells and the microplate was incubated over night at 370C.
[0389] The next day, the MTT assay described above was performed. The viable count (v.c.) was calculated as: [0390] Average toxicated cell absorbance - Average DMEM absorbance = Viable count
[0391 ] Average living cell absorbance - Average DMEM absorbance
[0392] HP203 targeting unit was found non-toxic for the tested cell line whereas CuSAO2 7.5 μg/ml, used as a positive control, showed 100% cell killing. An example of the results is shown as viable count vs. time in Figure 3
where A= Cu(SAO)2, B= DMSO, C= 138 μg/ml HP203 and D= 5 μg/ml HP203.
Example 7
In vivo toxicity study [0393] 1 mg of targeting unit HP203 (described in Example 2) was injected i.v. into the tail vein of three Athymic nude mice in a volume of 100 μl of sterile physiological saline. The behavior of mice was observed during 30 min right after injection and during 15 min on the following day (comparison to non-injected mouse). Injection of targeting unit HP203 did not have any toxic effect on mice.
Example 8
In vivo tumor reduction
[0394] This example is provided to show that targeting units MJ017 and MJ018 (described in Example 2) when coupled to cytotoxic substances can be used as therapeutic agents for the treatment of colon cancer.
[0395] Production of experimental colon cancer tumors is described in Example 3. Mice bearing colon cancer tumors on their flanks are divided into two groups: Control animals receiving a standard dose of a cytotoxic substance administrated intravenously, and the test animals receiving an equal amount of said cytotoxic substance coupled to targeting unit MJ017 or MJ018. Body weight loss, indicating toxicity and tumor growth delay indicating antitumor activity are followed. Weight and tumor size are measured every third day for four weeks. The experiment is terminated before the final endpoint if the body weight of the animal is reduced by 30% from the baseline. [0396] Net body weight loss is calculated as:
[0397] initial weight - lowest weight
[0398] X 100 %
[0399] initial weight
[0400] Mean tumor volume (mm3) is calculated according the formula with measurements using calipers:
[0401 ] (length x height x width x π) /6
[0402] By comparing the results between the mice in the test and the control groups it can be shown that targeting units MJ017 and MJ018 cou-
pled to cytotoxic substance can reduce body weight loss and tumor growth in mice and thus show therapeutic activity.
Claims
[0403] 1. A targeting unit having a peptide sequence:
[0404] Cy- Y - G - F - X- W - G - Z - Cyy [0405] or a pharmaceutically or physiologically or diagnostically acceptable salt thereof, wherein, Y is tyrosine or a structural or functional analogue thereof; G is glycine or a structural or functional analogue thereof; F is phenylalanine or a structural or functional analogue thereof; X is alanine, valine, leucine, or isoleucine or a structural or functional analogue thereof; W is tryptophan or a structural or functional analogue thereof; Z is glutamine or glutamic acid, or a structural or functional analogue thereof; and Cy and Cyy are optional entities forming a cyclic structure; said unit selectively targeting tumors.
[0406] 2. The targeting unit according to claim 1 , wherein said tu- mor is a colon cancer tumor.
[0407] 3. The targeting unit according to claim 2, wherein said tumor is a metastasis originating from the colon.
[0408] 4. The targeting unit according to claim 3, wherein said tumor is a lung metastasis. [0409] 5. The targeting unit according to any one of claims 1 to 4, wherein the peptide is linear.
[0410] 6. The targeting unit according to claim 5 selected from the group consisting of YGFVWGE (SEQ ID NO. 1 ), YGFVWGQ (SEQ ID NO.
2),
YGFLWGQ (SEQ ID NO.
3), YGFLWGE (SEQ ID NO.
4), YGFAWGQ (SEQ ID NO.
5), YGFAWGE (SEQ ID NO.
6), YGFIWGQ (SEQ ID NO.
7), YGFIWGE
(SEQ ID NO. 8), aYGFVWGEE (SEQ ID NO. 17), aYGFVWGQE (SEQ ID NO.
18), aYGFLWGQE (SEQ ID NO. 19), aYGFLWGEE (SEQ ID NO. 20), aYGFAW-GQE (SEQ ID NO. 21 ), aYGFAWGEE (SEQ ID NO. 22), aYGFIWGQE (SEQ ID NO. 23) and aYGFIWGEE (SEQ ID NO. 24). [0411] 7. The targeting unit according to any one of claims 1 to 4, wherein the peptide is cyclic or forms part of a cyclic structure.
[0412] 8. The targeting unit according to claim 7, wherein the cyclic structure is a lactam.
[0413] 9. The targeting unit according to claim 8, wherein Cy is se- lected from the group consisting of glutamic acid, aspartic acid and structural or functional analogues thereof when Cyy is selected from the group consisting
of lysine, ornithine and structural or functional analogues thereof; or Cy is selected from the group consisting of lysine, ornithine, structural or functional analogues thereof and an N-terminal D-amino acid when Cyy is selected from the group consisting of glutamic acid, aspartic acid and structural or functional analogues thereof.
[0414] 10. The targeting unit according to claim 9 wherein Cy is D- alanine and Cyy is glutamic acid.
[0415] 11. The targeting unit according to claim 10 selected from the group consisting of aYGFVWGEE (SEQ ID NO. 17), aYGFVWGQE (SEQ ID NO. 18), aYGFLWGQE (SEQ ID NO. 19), aYGFLWGEE (SEQ ID NO. 20), aYGFAWGQE (SEQ ID NO. 21 ), aYGFAWGEE (SEQ ID NO. 22), aYGFIWGQE (SEQ ID NO. 23) and aYGFIWGEE (SEQ ID NO. 24).
[0416] 12. The targeting unit according to claim 7, wherein the cyclic structure is formed through a disulphide bond. [0417] 13. The targeting unit according to claim 12, wherein Cy and
Cyy are cysteine or a structural or functional analogue thereof.
[0418] 14. The targeting unit according to claim 13 selected from the group consisting of CYGFVWGEC (SEQ ID NO. 9), CYGFVWGQC (SEQ
ID NO. 10), CYGFLWGQC (SEQ ID NO. 11), CYGFLWGEC (SEQ ID NO. 12), CYGFAWGQC (SEQ ID NO. 13), CYGFAWGEC (SEQ ID NO. 14),
CYGFIWGQC (SEQ ID NO. 15) and CYGFIWGEC (SEQ ID NO. 16).
[0419] 15. A tumor targeting agent comprising at least one targeting unit of any one of claims 1 to 14, directly or indirectly coupled to at least one effector unit. [0420] 16. The tumor targeting agent according to claim 15, wherein the effector unit is a therapeutic substance, a directly or indirectly detectable substance, or a substance having binding ability.
[0421] 17. The tumor targeting agent according to claim 16, wherein the detectable substance comprises a chelator, a complexed metal, an en- riched isotope, radioactive material, a paramagnetic substance, an affinity label, a fluorescent label, a luminescent label, a PET-active substance or a SPECT-active substance.
[0422] 18. The tumor targeting agent according to claim 16, wherein the therapeutic substance is selected from the group consisting of cytotoxic, cytostatic, immunomodulating and radiation emitting substances.
[0423] 19. The tumor targeting agent according to any one of claims 15 to 18, further comprising at least one optional unit.
[0424] 20. The tumor targeting agent according to claim 19, wherein said optional unit is an aqueous-solubility enhancing unit. [0425] 21. The tumor targeting agent according to claim 20, wherein said aqueous-solubility enhancing unit comprises at least one unit according to Formula I:
[0426] (I) -(CH2)m-O-
[0427] where m is an integer of value 1 to 4; [0428] or at least one unit according to Formula II:
[0429] (II) -(A)s-Y
[0430] where (A)s is a spacer group wherein each A is independently CR1R2, [0431] each Ri and R2 is independently selected from the group of hydrogen, hydroxyl, Ci-3alkyl and Ci-3 hydroxyalkyl, [0432] s is an integer of value 0 to 5, and
[0433] Y is selected from the group of COOH, CONH2, NH2 and guanyl; [0434] or at least one unit according to Formula III:
[0435] (A) q-Y
-CR3-
[0436] where (A)q is a spacer group wherein each A is independently CRiR2, [0437] q is an integer of value 1 to 5,
[0438] R-I, R2 and R3 are independently hydrogen, hydroxyl, Ci-3 alkyl or Ci-3 hydroxyalkyl, and [0439] Y is selected from COOH, CONH2, NH2 and guanyl.
[0440] 22. A diagnostic or pharmaceutical composition comprising at least one targeting unit according to any one of claims 1 to 14, or at least one targeting agent according to any one of claims 15 to 21.
[0441] 23. A targeting unit according to any one of claims 1 to 14, or a targeting agent according to any one of claims 15 to 21 for use in therapy.
[0442] 24. A targeting unit according to any one of claims 1 to 14, or a targeting agent according to any one of claims 15 to 21 for use in diagnostics.
[0443] 25. Use of a targeting unit according to any one of claims 1 to 14, or a targeting agent according to any one of claims 15 to 21 for the preparation of a medicament for the treatment of cancer or cancer related diseases.
[0444] 26. The use according to claim 25, wherein said cancer or cancer related disease is a solid tumor or its metastases. [0445] 27. The use according to claim 26, wherein said solid tumor is selected from the group consisting of colon cancer, colorectal cancer and their lung metastases.
[0446] 28. Use of a targeting unit according to any one of claims 1 to 14, or a targeting agent according to any one of claims 15 to 21 , for the preparation of a diagnostic composition for the diagnosis of cancer or cancer related diseases.
[0447] 29. A method for treating cancer or cancer related diseases, comprising providing to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 22. [0448] 30. The method according to claim 29, wherein said subject is a human.
[0449] 31. The method according to any one of claims 29 - 30, wherein said cancer or cancer related disease is selected from the group consisting of colon cancer, colorectal cancer and their metastases. [0450] 32. A method for diagnosis of cancer or cancer related diseases, comprising providing to a subject in need thereof a diagnostically suitable amount of a diagnostic composition according to claim 22.
[0451] 33. The method according to claim 32, wherein said subject is a human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI20065210A FI20065210A0 (en) | 2006-03-31 | 2006-03-31 | Diagnostic and therapeutic agents |
FI20065210 | 2006-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007113385A1 true WO2007113385A1 (en) | 2007-10-11 |
Family
ID=36192055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FI2007/050176 WO2007113385A1 (en) | 2006-03-31 | 2007-03-30 | Diagnostic and therapeutic agents |
Country Status (2)
Country | Link |
---|---|
FI (1) | FI20065210A0 (en) |
WO (1) | WO2007113385A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001057069A2 (en) * | 2000-02-02 | 2001-08-09 | Transgene S.A. | Targeting peptides |
WO2003086284A2 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
US20040029182A1 (en) * | 1993-10-26 | 2004-02-12 | Waldman Scott A. | ST receptor binding compounds and methods of using the same |
-
2006
- 2006-03-31 FI FI20065210A patent/FI20065210A0/en not_active Application Discontinuation
-
2007
- 2007-03-30 WO PCT/FI2007/050176 patent/WO2007113385A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040029182A1 (en) * | 1993-10-26 | 2004-02-12 | Waldman Scott A. | ST receptor binding compounds and methods of using the same |
WO2001057069A2 (en) * | 2000-02-02 | 2001-08-09 | Transgene S.A. | Targeting peptides |
WO2003086284A2 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
Non-Patent Citations (1)
Title |
---|
KELLY K. ET AL.: "Detection of Invasive Colon Cancer Using a Novel, Targeted, Library-Derived Fluorescent Peptide", CANCER RESEARCH, vol. 64, September 2004 (2004-09-01), pages 6247 - 6251 * |
Also Published As
Publication number | Publication date |
---|---|
FI20065210A0 (en) | 2006-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090180958A1 (en) | Diagnostic and therapeutic agents | |
KR100879702B1 (en) | Peptide-Based Compounds | |
EP1991562A2 (en) | Cancer imaging and treatment | |
US20120244070A1 (en) | Fibronectin targeting contrast agent | |
EP3710068A1 (en) | A double-labeled probe for molecular imaging and use thereof | |
US20070258899A1 (en) | Diagnostic and therapeutic agents | |
JP2006524183A (en) | New peptide | |
WO2007113385A1 (en) | Diagnostic and therapeutic agents | |
US20060275213A1 (en) | Tumor targeting agents and uses thereof | |
Ucar et al. | A new radio-theranostic agent candidate: Synthesis and analysis of (ADH-1) c-EDTA conjugate | |
EP1549667A1 (en) | Tumor targeting agents and uses thereof | |
WO2024046469A1 (en) | Cyclic peptide and preparation method therefor, and complex comprising same and use thereof | |
WO2004031220A1 (en) | Tumor targeting agents and uses thereof | |
US20060263294A1 (en) | Tumor targeting agents and uses thereof | |
CA3008052C (en) | Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes | |
WO2014116144A2 (en) | Cyclic octapeptide, radiopharmaceutical agent based thereon and method for using a radiopharmaceutical agent to produce medicinal (pharmaceutical) agents for the treatment of neoplasms which express somatostatin receptors | |
MX2011002937A (en) | Bicyclic therapeutic and contrast agents. | |
Baishya et al. | MedChemComm | |
CN101184769A (en) | Diagnostic and therapeutic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07730663 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07730663 Country of ref document: EP Kind code of ref document: A1 |